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Abstract 
Annually, 11,500 men in the UK die of prostate cancer (PCa). PCa tumours are 
initially dependent upon androgen receptor (AR) signalling and androgen 
deprivation therapy (ADT) is highly effective in restricting tumour growth. 
However, ADT resistance and progression to castrate-resistant prostate cancer 
(CRPC) is inevitable, usually occurring within three years. CRPC is considerably 
more aggressive, and metastatic CRPC remains incurable. One mechanism of 
ADT resistance is neuroendocrine differentiation (NED). NED is common in PCa 
tumours treated with ADT (30% of cases) and is associated with poorer survival. 
Prevalence of NED is rising and can be induced by other therapeutics including 
radiotherapy and chemotherapeutics. However, the precise molecular events 
underlying NED remain poorly understood. Therefore, an in-depth molecular 
investigation of NED was conducted using an in vitro system. 
 
The first objective was to establish a robust, in vitro model of ADT-induced NED 
using the PCa cell line, LNCaP. Extensive molecular analysis by qRT-PCR, 
Western blotting and confocal microscopy revealed the transcription factor, 
human achaete-scute homolog-1 (hASH1) as a potential key driver of NED. 
hASH1 localisation shifted from exclusively cytoplasmic to nuclear upon 
acquisition of NED morphology, concurrent with increased expression of the 
clinical biomarker neuron specific enolase (NSE) and decreased expression of 
prostate-specific antigen (PSA). 
 
Next, the effects of intermittent (I)ADT on the NED pathway were investigated. 
AD arrest resulted in reacquisition of epithelial morphology and resurgence of 
PSA expression. Interestingly, hASH1 was retained in the nucleus alongside NSE 
upregulation, indicating emergence of a potential ‘hybrid’ phenotype. After a 
second AD cycle, cells regained NED morphology and maintained hASH1 
nuclear localisation. As hASH1 drives the development of GABAergic neurons 
and GABA has previously been implicated in PCa growth and invasion, a 
comprehensive characterisation of GABA receptor subunit expression in PCa 
cells was undertaken. Differential expression between androgen-sensitive and 
androgen resistant cells was discovered and indicated PCa GABAergic signalling 
may be modulated by androgen availability. 
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 1 
1. Introduction 
1.1 Prostate Cancer Epidemiology 
Prostate cancer is the second most common cancer in men and the second most 
common cause of cancer-related death in men in the UK (Nelson et al., 2014). 
Each year, 11,500 men die from prostate cancer in the UK alone. The incidence 
of prostate cancer continues to rise, in part due to better detection techniques 
and increasing adoption of serum prostate specific antigen (PSA) tests to 
diagnose prostate cancer. UK population ageing also contributes to increased 
incidence of prostate cancer, with age remaining the biggest risk factor for all 
cancers (Jahn, Giovannucci, & Stampfer, 2015).  
 
In addition, it must be considered that at autopsy, 80% of men aged 80 years or 
older displayed sub-clinical signs (non-symptomatic and unlikely to be 
diagnosed) of prostate cancer. Importantly, 50% of 50-year-old men also display 
sub-clinical prostate cancer. In addition, 36% of Caucasians and 51% of African-
Americans aged 70-79 had prostate cancer tumours discovered upon autopsy 
(Jahn et al., 2015). Therefore, it is likely that even with advances in prostate 
cancer care, incidence is likely to continue to rise in the foreseeable future. The 
vast majority (>85%) of prostate cancer patients are diagnosed over the age of 
65 and the average age of prostate cancer sufferers is between 70-75 years old 
(Cancer Research UK statistics). For men diagnosed with locally confined 
disease, radical prostatectomy is often curative. However, in many cases the 
disease recurs, often due to occult metastases, which can be difficult to detect 
using current imaging techniques due to their strong bone tropism (Bill-Axelson 
et al., 2014). In addition, many patients only experience serious symptoms after 
the disease has spread beyond the prostate gland, rendering radical 
prostatectomy ineffective.  
 
The seminal work of Charles Huggins, first identified that almost all prostate 
cancers are initially dependent upon androgen for their growth and survival 
(Huggins, 1941). Androgen deprivation therapy (ADT) triggers regression of 
prostate tumours, however, resistance to ADT usually develops within 3 years 
and is termed castrate-resistant prostate cancer (CRPC) (Karantanos, Corn, & 
  
2 
 
Thompson, 2013). Once CRPC has become metastatic, no curative therapeutic 
options currently exist and patients usually succumb to the disease within 18 
months. Gaining a greater understanding of the mechanisms facilitating 
progression to CRPC is vital to the identification of novel therapeutic strategies 
and targets.  
 
1.1.1 Endogenous and Exogenous Risk Factors 
Analysis of data from several large scale studies has shown family history to be 
highly informative on the relative risk of developing prostate cancer second only 
to PSA screening (Madersbacher et al., 2011). Males with a father or brother with 
prostate cancer display a 2-fold increased likelihood of developing the disease 
with the risk increasing substantially for every additional first degree family 
member with prostate cancer (Steinberg et al., 1990). As with all cancer types, 
risk increases dramatically with age and current European Urologic Association 
guidelines suggest that PSA screening should begin between age 40 and 45 
(Glass, Cary & Cooperberg, 2013; Heidenreich et al., 2013).  The incidence of 
prostate cancer is also correlated to race, with black populations at the highest 
risk and often presenting at earlier ages with higher grade disease (Glass, Cary 
& Cooperberg 2013). Caucasian individuals have the second highest risk, whilst 
Asian populations make up the lowest risk group. Germ-line mutations to either 
BRCA1 or BRCA2 also confers a 3-fold higher risk of developing prostate cancer 
and are associated with more aggressive forms of the disease (Castro et al., 
2013). 
 
In addition to endogenous risk factors, exogenous factors such as the western 
diet and obesity have been linked to prostate cancer development. 
Westernisation of diet in Japan appears to have influenced a gradual increase in 
prostate cancer diagnoses (Gathirua-Mwangi & Zhang, 2014; Satoh et al., 2014). 
Tobacco consumption is associated with increased prostate cancer-specific 
morbidity, as well as increased rate of disease recurrence, however this risk 
returns to that of non-smokers after 10 years of abstention (Kenfield et al., 2011). 
Perhaps the greatest exogenous risk factor is chronic inflammation of the prostate 
gland (prostatitis), caused by infection (Palapattu et al., 2005). 
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1.1.2 Androgen Steroidogenesis 
In males, testosterone is synthesised in the testes and the adrenal glands, with 
the testes comprising 95% of androgen production (Mooradian et al., 1987). 
Conversion of testosterone to DHT, which is a considerably more potent agonist 
of the AR, can occur in the prostate, liver, brain and skin. The production of 
androgens first requires the conversion of cholesterol into progestogens which 
are then further modified into androgen precursors and finally to testosterone 
(Marks, 2004). Cholesterol side-chain cleavage enzyme CYP11A1 converts 
cholesterol into pregnenolone, a pre-cursor to a wide range of steroids including 
mineralocorticoids, glucocorticoids, estrogens and androgens. The outputs of 
steroidogenesis are tightly regulated by the activity of specific enzymes for each 
group of steroids, 17-HSD and 5-reductase (androgens), aromatase 
(estrogens) 11-hydroxylase (glucocorticoids and aldosterone synthase 
(mineralocorticoids) (Miller & Auchus, 2011). For androgen synthesis, 
pregnenolone is either converted directly to 17-hydroxy pregnenolone, or first 
converted to progesterone by 3-HSD before being converted to 17--
hydroxyprogesterone by 17-hydroxylase. These are then converted by 17,20 
lyase to dehydroepiandrosterone or androstenedione respectively. At this stage, 
androstenedione can be directly converted to testosterone by 17-HSD, whereas 
dehydroepiandrosterone must first be converted to androstenediol by 17-HSD 
and then into testosterone by 3-HSD. Once testosterone has been synthesised, 
its conversion to DHT is performed by the 5-reductase enzyme (Chang et al., 
2013). 
 
1.1.3 Anti-androgen therapeutic targets and total androgen blockade 
Anti-androgens are able to disrupt androgen receptor signalling through either 
direct targeting of the AR or by inhibiting the production of AR ligands. In the 
treatment of prostate cancer, two most frequently used AR antagonists are 
bicalutamide and enzalutamide (Hoffman-Censits & Kelly, 2013). In order to 
inhibit the production of androgens, both from the testes and the adrenal cortex, 
the CYP17A1 inhibitor abiraterone acetate can be used (Koninckx et al., 2019).  
Combining both of these approaches results in total androgen blockade, which 
can be effective against resistance mechanisms to each approach (Arora et al., 
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2013). For example, where treatment with enzalutamide has resulted in 
increased androgen production or where AR becomes overexpressed, 
hypersensitive or promiscuous to other ligands to adapt to the low androgen 
availability caused by abiraterone treatment (Attard et al., 2014). In addition, 5-
reductase inhibitors such as finasteride have been investigated as a potential 
preventative treatment for prostate cancer. The recent Prostate Cancer 
Prevention Trial (PCPT) found finasteride to be effective in this role (Unger et al., 
2018), although its use remains controversial as it could lead to underdiagnoses 
by significantly decreasing PSA production. This risk was highlighted in the PCPT 
study which found although risk of developing PC fell 25%, in the men that did 
develop PCa there was a 68% increase in the likelihood of this being a high grade 
Gleason score 7-10 tumour (Unger et al., 2018). 
 
1.1.4 Prostate Anatomy and Physiology  
Although there has been considerable debate over differing models of prostate 
anatomy, it has become generally recognised that McNeal’s ‘zonal’ description 
(McNeal, 1968) remains more accurate and clinically relevant than the Tissell and 
Salandar ‘lobular’ model (Myers, 2000; Tisell & Salander, 1975). 
 
 
Figure 1.1 Diagram displaying the zonal model of prostate anatomy. 
Adapted from (De Marzo et al., 2007).  
 
75%
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The human prostate is comprised of 3 major zones, the peripheral zone, the 
central zone and the transition zone. Of these zones, it is the peripheral zone that 
is the most common site of carcinogenesis, the transition zone which is the 
primary location for benign hyperplasia and the central zone that is the most 
resistant to disease (McNeal, 1968). Despite the physiological differences 
between the different zones of the prostate, it should be noted that other factors 
are more statistically significant for prognosis than location alone (Cohen et al., 
2008). 
 
The peripheral zone (the largest zone of the prostate) surrounds the distal urethra 
and approximately 75% of tumours arise from this zone (Shen & Abate-Shen, 
2010). Due to its positioning, the peripheral zone is easily screened for potential 
carcinoma via a digital rectal examination (DRE) making early diagnosis 
considerably easier than other zones. However, early stage tumour growth in this 
zone rarely impinges on the function of the urethra. This means that without a 
medical diagnostic procedure such as DRE or a PSA test, a patient is unlikely to 
present clinically until the disease has progressed further (Myers, 2000; Verma 
et al., 2014).  
 
The Central zone surrounds the ejaculatory ducts. A study of 2,494 tumours 
found that only 2.5% of tumours originated in the central zone. Although rare, a 
tumour in the central zone is usually considerably more aggressive with a higher 
likelihood for metastasis given the close proximity to the seminal vesicles and 
ejaculatory ducts allowing invasive cells to leave the prostate gland. A 
compounding factor in the poor prognosis of central zone prostate tumours is that 
the central zone is often avoided during prostate gland biopsy, often preventing 
early diagnosis and treatment (Cohen et al., 2008). 
 
The transition zone surrounds the proximal urethra and accounts for 
approximately 5% of the prostate gland at puberty with 10% of prostate tumours 
arising from this zone. In addition, this zone continues to grow throughout the life 
of the individual and is the site of benign prostate hyperplasia (BPH) (Shen & 
Abate-Shen, 2010). Either malignant or benign growth in this zone of the prostate 
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is highly likely to cause obstruction of the urethra and associated symptoms (Lee 
& Kuo, 2017). 
 
1.1.5 Androgen Dependent Growth of Healthy Prostate 
The androgen receptor (AR) is critical for growth and development of the prostate 
in response to androgens (Gao et al., 2013; Parimi et al., 2014). The primary 
mechanism for activation of AR is through uptake of circulating testosterone into 
the cell, which is then converted by steroid-5α-reductase, α-polypeptide 2 
(SRD5A2) into dihydrotestosterone (DHT). Upon androgen receptor activation, 
heat-shock proteins HSP90 and HSP70 dissociate from the AR causing the AR 
protein to dimerise and translocate into the nucleus (Chang et al., 2011; Foley & 
Mitsiades, 2016). 
 
Androgen receptor signalling is able to control and maintain the differentiation 
and proliferation of prostate tissue via androgen response elements (AREs) in 
the promoter regions of specific genes (Dutt & Gao, 2009). Prostate specific 
antigen (PSA) is known to contain an ARE and is expressed in response to 
androgen receptor signalling (Dutt & Gao, 2009; Kim & Coetzee, 2004). Prostate 
cancer tumours are initially dependent upon androgens for their growth and 
express PSA, which has been utilised as a biomarker of prostate cancer growth 
(Feldman & Feldman, 2001; Gudmundsson et al., 2010).  
 
It is also important to consider that AR signalling can occur in a non-genomic 
fashion. In this pathway, binding of androgens to the AR can result in increased 
cell proliferation and survival through direct activation of the mitogen-activated 
protein kinase (MAPK) and protein kinase B (AKT) pathways (Leung & Sadar, 
2017; Migliaccio et al., 2000; Zarif et al., 2015) facilitated by the interaction of the 
AR with non-receptor tyrosine kinase Src (Leung & Sadar, 2017; Migliaccio et al., 
2000; Migliaccio et al., 2007). This non-genomic signalling mechanism is active 
at very low androgen concentrations (0.1 nM) up to concentrations that are 
approaching physiological levels (10 nM) (Leung & Sadar, 2017; Unni et al., 
2004).  
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1.1.6 Neuroendocrine cells in benign and malignant prostate tissue  
Neuroendocrine (NE) cells make up >1% of benign prostate tissue (Parimi et al., 
2014) and are able to influence surrounding cells via paracrine secretions and 
dendritic-like extensions to support the growth and development of the gland (Hu 
et al., 2002). NE cells are terminally differentiated, non-proliferating and primarily 
found within the basal compartment of the prostate (Lang, Frame, & Collins, 
2009). NE cells of the prostate are differentiated from epithelial stem cells, as 
opposed to the neural crest which is the source of NE cells in the pituitary and 
adrenal glands (Cox et al.,  1999). Although the functions of NE cells are relatively 
well understood in the development of the prostate, the role of these cells in adult 
prostate tissue is less clear (Cox et al., 1999). 
 
NE cells also contain synaptic vesicles that can secrete neurotransmitters, 
including gamma aminobutyric acid (GABA), glutamate and glycine. These 
secretions are regulated by cAMP, cGMP and calcium (Parimi et al., 2014). In 
addition, NE cells are very challenging to identify via haematoxylin and eosin 
(H&E) staining and immunohistochemistry (IHC) is the preferred method of 
identifying NE cells. To achieve this, there are four commonly utilised clinical 
biomarkers of NE cells, neuron-specific enolase (NSE), synaptophysin (SYP), 
chromogranin A (CgA) and CD56 (Altree-Tacha, Tyrrell, & Li, 2017; Kamiya et 
al., 2003; Kaufmann, Georgi, & Dietel, 1997). NSE is considered a high sensitivity 
marker of neuronal as well as NE cells, however it is not highly specific to only 
these two cell types (Marangos & Schmechel, 1987; Schmechel, Marangos, & 
Brightman, 1978.; Seshi et al.,  1988). Synaptophysin is a marker both of NE cells 
and of neurons that participate in synaptic transmission (Chang et al., 2017; 
Gupta et al., 2013; Zhu et al., 2014). CgA is present in and secreted by NE cells 
(Cox et al., 1999; Danza et al., 2012; Esposito et al., 2015), however it is highly 
unspecific (Gut et al., 2016). CD56 is also considered a highly specific marker for 
primary NEPC (Altree-Tacha et al., 2017; Kaufmann et al., 1997).   
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Despite being non-proliferative themselves, enrichment of the NE cell niche 
during prostate cancer progression is associated with poor prognosis (Yuan, 
Veeramani, & Lin, 2007). These cells are inherently androgen-independent, and 
are resistant to most PCa therapeutics such as ADT, radiotherapy and most 
chemotherapeutics. In addition, previous evidence has demonstrated that the 
epithelial cells surrounding NE cells display increased proliferation, perhaps due 
to paracrine activity of NE cells (Noordzij et al., 1995). 
 
Neuroendocrine prostate cancer (NEPC) arising de novo is extremely rare, 
accounting for less than 2% of malignancies (Shen & Abate-Shen, 2010). It is 
usually diagnosed as carcinoid or small-cell carcinoma due to difficulty in 
identification via haematoxylin and eosin staining (Parimi et al., 2014; Grignon, 
2004). However, following administration of ADT, neuroendocrine differentiation 
(NED) becomes common place and is observed in the majority of advanced 
prostate adenocarcinomas (Terry & Beltran, 2014), evidenced by enrichment of 
neuroendocrine markers (Nouri et al., 2014a; Shen & Abate-Shen, 2010). These 
neuroendocrine-like cells are non-proliferative and genetic analysis suggests that 
they originate via transdifferentiation of adenocarcinoma cells, rather than 
differentiation of pluripotent stem cells (Sauer et al., 2006). Once 
transdifferentiated to a neuroendocrine phenotype, these cells become highly 
treatment resistant and support growth and recurrence of tumours in a paracrine 
manner (Terry & Beltran, 2014; Wu et al., 2014; Chevalier et al., 2002).  
 
1.1.7 Prognostic Factors and diagnostic tools 
The only currently approved prognostic factors for prostate cancer are tumour 
stage, grade and serum PSA (Rapa et al., 2008).  The standard method for many 
decades of assessing the prognosis of PCa is the Gleason grading system 
(Humphrey, 2004) which was last reviewed and updated by the International 
Society of Urological Pathology in 2014 (Epstein et al., 2015). The Gleason 
grading system uses a scale of 2-10 (1 and 2 are not considered malignant) which 
is a composite of the primary and secondary pattern grades. Pathologists analyse 
samples of the biopsied prostate tissue and determines the pattern of the tumour 
from 1 (resembles normal prostate tissue) to 5 (little to no recognisable glands). 
The primary and secondary patterns present in the sample are graded (1-5) and 
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their sum forms the overall Gleason Score (Humphrey, 2004). It should be noted 
that even at the same Gleason score there can be differences in the prognoses 
given since the same score can be attained from different combinations of 
primary and secondary scores. For example, an individual with a primary score 
of 3 and a secondary score of 4 would have a more favourable prognosis than a 
patient with primary score 4 and secondary score 3 as the majority of the latter’s 
tumour is at a higher grade despite both having an overall Gleason score of 7 
(Humphrey, 2004). The latest update to Gleason grading system aimed to 
address this through the addition of grade groups, which lists Gleason 3+4 as 
lower grade than Gleason 4+3 and has been accepted by the World Health 
Organization in 2016 (Berney et al., 2016; Epstein et al., 2015) Gleason scores 
between 3-6 are considered to be low risk and are ideal for active surveillance, 7 
is moderate and scores of 8-10 have the fastest progression (Penney et al., 
2013). A large statistical study of many cohorts found that it was rare for the 
Gleason score of a tumour to change and that the aggressiveness of the tumour 
may be determined early on in its development (Penney et al., 2013).  
 
From a patient’s perspective, it is unlikely that clear symptoms will be experienced 
during the early stages of the disease. Occasionally, difficulty in urination and the 
onset of erectile dysfunction will present alongside tumour growth (Hamilton et 
al., 2006). In addition, patients often initially present due to symptoms of bone 
pain caused by metastases in later stages of the disease (Gater et al., 2011). 
Unfortunately, the non-specificity of these symptoms and their frequent 
occurrence in old age often mean that they are ignored by patients. Therefore, 
accurate and sensitive techniques for the diagnosis of prostate cancer are vital 
to discovering early stage, curable disease. 
 
The primary low invasiveness tests for PCa are the digital rectal exam (DRE) and 
serum PSA concentration, whilst these methods lend themselves very well to a 
convenient, economic and low-risk way to mass screen large populations, these 
methods are not considered to have high specificity for prostate cancer (Verma 
et al., 2014). This method of screening inevitably results in a large amount of 
false-positive diagnoses, leading to many patients undergoing unnecessary and 
invasive biopsies often impacting negatively upon potency and continence. In a 
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cohort of 521 men referred for biopsy in 2011, only 57% were ultimately 
diagnosed with prostate cancer (Verma et al., 2014).  
 
This raises an interesting dilemma, in that current methods of mass screening 
are frequently resulting in unnecessary biopsies, yet if screening based on PSA-
serum and DRE were abandoned, many cases of prostate cancer would be 
detected later and with lower likelihood of survival. Whilst serum PSA remains a 
useful predictor of prostate cancer, it is important that this value be considered in 
the context of several other factors (such as family history and genetic 
disposition) and not as the ‘magic bullet’ as initially hoped (Boccon-Gibod, 2007). 
One approach to improving the accuracy of PSA screening is to test at-risk 
individuals earlier in life and to consider the rise in PSA concentration relative to 
the individual’s basal level, rather than defining a universal threshold 
(Gudmundsson et al., 2010).  
 
1.1.8 Current Treatment Strategies 
Radical prostatectomy involves the removal of the entire prostate gland. Whilst 
radical prostatectomy can be curative for men with prostate confined disease, to 
benefit from this treatment a patient is expected to have a future life expectancy 
greater than 10 years (Bill-Axelson et al., 2014). Radical prostatectomy is the 
preferred option for men with intermediate and high risk disease (Gleason score 
>7 and Stage 2 or higher). A limitation of this treatment is that often men present 
with disease which has already progressed beyond the prostate gland (Bill-
Axelson et al., 2014).  
 
Androgen deprivation therapy (ADT) was first described as an effective treatment 
for prostate cancer by Charles Huggins in 1941. The first method of achieving 
androgen deprivation (AD) was bilateral orchiectomy, the effects of which were 
soon able to be mimicked using GnRH agonists in order to force a downregulation 
of GnRH receptors, making surgical removal of the testes rare in the modern era 
(Perlmutter & Lepor, 2007). It should also be considered that even after 
orchiectomy, small amounts of androgen can be produced from the adrenal 
glands (Chang, Ercole, & Sharifi, 2014; Perlmutter & Lepor, 2007). Evolution of 
GnRH agonists focussed upon increasing their potency by substituting the sixth 
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amino acid of LHRH to achieve downregulation sooner and at lower dosages to 
avoid cardiotoxicity (Perlmutter & Lepor, 2007). The key limitation of GnRH 
agonists is that time to achieve maximal AD is around 30 days, during which 
patients experience the ‘flare’ phenomenon whereby production of testosterone 
dramatically increases in response to the down regulation of GnRH receptors 
resulting in brief but rapid tumour growth which can prove paralytic or even fatal 
in patients which spinal metastasis (Crawford & Hou, 2009; Perlmutter & Lepor, 
2007).  
 
Combined therapy of GnRH agonists with non-steroidal anti-androgens such as 
flutamide and bicalutamide have been approved since 1989 and are able to 
prevent the androgen flare by acting directly on the androgen receptor to prevent 
the binding of testosterone or DHT (Perlmutter & Lepor, 2007). From 2008 GnRH 
agonists have been effectively superseded by novel GnRH antagonists that not 
only achieve maximal AD far sooner, but also do not require the use of an anti-
androgen to prevent the ‘flare’ response (Crawford & Hou, 2009). 
 
The latest additions to ADT therapy abiraterone (Ryan et al., 2015) and 
enzalutamide (Tran et al., 2009) have been demonstrated to extend the time 
frame that ADT can control a tumour via targeting other tissue sources of 
androgen production and blocking androgen receptor nuclear co-localisation 
respectively. Each of these drugs demonstrated a 5-month extension to overall 
survival in Phase III clinical trials (Merseburger et al., 2015; Ryan et al., 2015). 
These pharmacological advances in ADT have undoubtedly contributed to an 
extension of survival for metastatic prostate cancer patients, unfortunately all 
forms of ADT place a strong selective pressure upon prostate tumours to adopt 
a castrate-resistant phenotype, usually occurring within 3 years of treatment 
(Karantanos et al., 2013; Nouri et al., 2014). 
 
Given that a significant proportion of patients with suspected PCa are advanced 
in age and with slow disease progression, a strategy of ‘watchful waiting’ rather 
than immediate treatment is sometimes adopted. Under watchful waiting, patients 
are given no treatment until symptoms begin to develop. If symptoms develop, 
patients receive palliative treatments (Bill-Axelson et al., 2014; Klotz et al., 2010).  
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To avoid unnecessary treatments and their associated negative side-effects, men 
with low-moderate risk disease can be closely monitored via their serum PSA 
level and a series of prostate biopsies, a strategy termed ‘active surveillance’ 
(Klotz et al., 2010). If disease progression is detected, treatment begins 
immediately. For low risk patients, active surveillance has an almost 100% 5-year 
survival rate. The method of delaying treatment also has the additional benefit of 
delaying the onset of resistance to treatments such as ADT (Klotz et al., 2010).  
 
It is well established that PCa tumours treated with ADT often display increased 
NED (Shen et al., 1997; Terry & Beltran, 2014). As such, intermittent (I)ADT has 
long been touted as a solution to delaying the development of CRPC in response 
to ADT (Feldman & Feldman, 2001). The intermittent use of radio and 
chemotherapeutics clinically is well accepted, primarily because poorly tolerated 
toxicity necessitates discontinuous use (Canil & Tannock, 2004; Cash et al., 
2018). Whereas, in the case of ADT, intermittent treatment is proposed to delay 
hormone therapy resistance, improve patient quality of life and reduce financial 
costs (Shore & Crawford, 2010). Indeed, it has been argued that IADT should be 
the standard of care for PCa (Seruga & Tannock, 2008).  However, European 
Association of Urology guidelines  continue to mandate that ADT be constant and 
do not support the use of IADT clinically (Heidenreich et al., 2014).  
 
Clinical trials evaluating IADT have been conducted from as early as 1986. These 
early trials focussed on the quality of life enhancements offered by IADT and were 
very favourable (Klotz et al., 1986). Unfortunately, the small sample size (n=20) 
makes it impossible to draw accurate conclusions on overall survival or disease 
progression. Higher powered studies (n=3040 and n=1386) focussing on overall 
survival, found that IADT was at best non-inferior to constant ADT (cADT) or 
performed considerably worse than cADT (Crook et al., 2012; Hussain et al., 
2013; Mottet et al., 2012). Unfortunately, all of these trials suffer from a lack of 
molecular stratification of these tumours, meaning that it is not possible to infer if 
IADT reduced NED or benefitted/harmed patients with high NED compared to 
cADT. This lack of stratification, to account for tumour heterogeneity, could also 
explain the inconclusive findings of IADT clinical trials to date (Hussain., 2017). 
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Evidently, before more structured clinical trials can investigate the effects of IADT 
on NED, a greater understanding of the molecular drivers of NED is required.  
 
Following the failure of ADT to contain tumour progression to symptomatic CRPC, 
chemotherapeutics become the first line treatment. Until recently, there was very 
little evidence to support the use of chemotherapy before this point, either as an 
adjuvant or neoadjuvant treatment for localised prostate cancer (Canil & 
Tannock, 2004). However, the latest results from the STAMPEDE clinical trial 
demonstrate that starting docetaxel chemotherapy alongside ADT or even before 
ADT can improve survival by an average of 10 months, one of the largest life 
extension margins in the modern era (James et al., 2016, 2017; Vale et al., 2016). 
 
The primary chemotherapeutic strategy used to treat CRPC is docetaxel in 
combination with immuno-suppressant prednisone (Heidenreich et al., 2014; 
James et al., 2016). Docetaxel (approved in 1999) acts by binding to Beta-
Tubulin, resulting in induction of apoptosis.  Docetaxel has succeeded 
mitoxantrone (a topoisomerase II inhibitor approved for use since 1987) as the 
first line of chemotherapeutic treatment for CRPC, providing a modest 2-month 
improvement to overall survival (Petrylak et al., 2004).  
 
For patients where the disease continues to progress after treatment with 
Docetaxel, the final clinical chemotherapeutic option currently available is 
cabazitaxel. Cabazitaxel has been demonstrated to provide a median 
progression free survival increase compared to mitoxantrone but a significant 
increase in grade 3 and 4 adverse effects, most notably neutropenia leaving 
patients at increased risk of infection (Basch et al., 2014).    
 
Despite next generation chemotherapeutics such as docetaxel and cabazitaxel 
becoming available and approved for use in CRPC, the increase in life extension 
has been poor with overall survival still under 2 years. The use of 
chemotherapeutics for metastatic CRPC has to date been an exercise in palliative 
rather than curative care and their use must be carefully weighed against 
potential quality of life impacts on patients (Basch et al., 2014; Canil & Tannock, 
2004; Petrylak et al., 2004). Currently, the only clinically available response to 
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PCa NED is the use of platinum based chemotherapeutics (Aparicio et al., 2013). 
However, these therapeutics, such as cisplatin, do not specifically target 
mechanisms of NED mediated survival and drug resistance. The life extension 
and anti-tumour effects of these platinum based agents is modest, usually 
securing around 8-months life extension  (Aparicio et al., 2013; Hager et al.,  
2016; Vlachostergios & Papandreou, 2015).  
 
Brachytherapy is suitable for men with low-intermediate risk disease and involves 
either the permanent implantation of radioactive beads into the prostate (low dose 
rate) or the insertion of radioactive wires into the prostate for several hours (high 
dose rate). For patients with higher risk disease, brachytherapy is often combined 
with external beam radiotherapy (EBRT), although EBRT can also be used 
independently for all patients or used in conjunction with ADT in patients with 
more advanced disease (Krause et al., 2014; Lu-Yao et al., 2009; von Amsberg 
et al., 2014). 
 
Immunotherapy is a rapidly emerging area of oncological research which can 
broadly be defined as any therapeutic designed to invoke an immune or auto-
immune response (Hammerstrom et al., 2011). There are three main strategies 
for immunotherapy including vaccines, monoclonal antibodies and 
immunomodulatory agents. In 2010 Sipuleucel-T became the first approved 
therapeutic vaccine for CRPC in patients with minimally symptomatic disease 
(Hammerstrom et al., 2011).  Sipuleucel-T is able to induce an auto-immune 
response against prostate tumours via in vitro modification of a patient’s own 
dendritic cells to present prostatic acid phosphatase on their surface (Fernández-
García et al., 2014). 
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1.2 Progression to Castrate-Resistant Prostate Cancer 
Prostate cancer is the second most common cause of cancer-related death in 
males (Karantanos, Corn, & Thompson, 2013). It is initially androgen dependent 
and tumours are responsive to ADT (Mooso et al., 2012). However, long-term AD 
induces prostate cancers to transition to a more aggressive androgen-
independent phenotype, resulting in poor prognosis and limited treatment options 
(Di Lorenzo et al., 2010; Karantanos et al., 2013). These hormone refractory 
tumours, termed castrate-resistant prostate cancer (CRPC) are able to progress 
with serum levels of testosterone below 200ng/L (Gomella, 2009) and are 
incurable once metastasised (Fernández-García et al., 2014). Combined 
treatment with docetaxel and prednisone is the standard of care for metastatic 
CRPC (Fig. 1.2) providing only a modest 18-month life extension (Karantanos et 
al., 2013). 
 
 
Figure 1.2. Progression of prostate cancer to metastatic castrate-resistant 
prostate cancer (mCRPC). 
 
 
1.2.1 Molecular Mechanisms of Castrate Resistant Prostate Cancer 
1.2.1.1 Androgen Receptor  
The androgen receptor (AR) is critical for the growth and development of the 
prostate in response to androgens (Gao et al., 2013). The primary mechanism 
for activation of AR is through the uptake of circulating testosterone which is then 
converted by SRD5A2 into DHT which has five times greater affinity for the AR 
than testosterone. Upon activation by DHT, heat-shock proteins HSP90 and 
HSP70 disassociate causing the AR protein to translocate into the nucleus, form 
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dimers and to influence gene transcription by binding to androgen responsive 
elements (AREs) (Cottard et al., 2013; Niu et al., 2008; Zhu et al., 2013).  
 
Removal of the AR ligands testosterone and dihydrotestosterone via ADT is 
initially effective, however there are a multitude of mechanisms by which AR 
signalling can persist in the AD environment (Feldman & Feldman, 2001). 
Although serum levels of androgen are almost entirely ablated by ADT, aberrant 
androgen receptor (AR) activation via alternative mechanisms or auto/paracrine 
sources of androgen remains an important consideration, hence these cancers 
are more accurately described as castrate-resistant rather than androgen-
independent (Crawford & Petrylak, 2010). Mutations and expression of different 
splice variants of the AR gene can facilitate the circumvention of ADT in several 
ways (Fig. 1.3), including becoming hypersensitive to the remaining androgen, 
promiscuous activation by non-androgen ligands, direct phosphorylation, 
alternative pathways for androgen synthesis or upregulation of various AR 
coactivators (Dehm et al., 2011; Jones et al., 2015; Jones et al., 2017; Kong et 
al., 2015). 
 
1.2.1.2 Hypersensitive Pathway 
Despite ADT, trace levels of serum androgen remain, in response prostate cancer 
cells often become hypersensitive. One of the most common early events 
following ADT treatment is amplification of the AR gene allowing for continued 
AR signalling even at castrate levels of testosterone (Bubendorf et al., 1999; 
Gundem et al., 2015). The presence of excess AR protein may also be achieved 
via an upregulation in transcription or enhanced half-life of the protein due to 
inhibition of its degradation (Katsogiannou et al., 2015). In addition, sensitivity to 
remaining androgen may be heightened due to increase in 5a-reductase enzyme 
activity, thus converting more testosterone to the more potent DHT. (Dutt & Gao, 
2009).  
 
1.2.1.3 Promiscuous Pathway 
Mutations in the AR gene T877A and L701H change the structure of the AR 
protein ligand binding domain, resulting in loss of specificity and facilitating 
promiscuous activation (van de Wijngaart et al., 2010). Of particular interest is 
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mutant AR T877A which was found to be activated by flutamide, an anti-androgen 
routinely used in ADT, with flutamide withdrawal proving beneficial to prognosis 
and resulting in decreased PSA level (Scher & Kelly, 1993). Furthermore, 
androgen receptor splice variant AR-V7 produces a truncated protein lacking the 
ligand binding domain entirely and can bind the AREs in the absence of any 
ligand (Dehm et al., 2011; Jones et al., 2015; Jones et al., 2017; Kong et al., 
2015). 
 
1.2.1.4 Outlaw Pathway & Paracrine Signalling 
The outlaw pathway removes the necessity of an AR ligand entirely. In this 
pathway, the AR is directly phosphorylated by AKT/MAPK (Feldman & Feldman, 
2001) facilitated by upstream deregulation of growth factors such as EGF or Src 
(Ishikura et al., 2010). Therefore, mechanisms allowing for modulation of these 
growth factors may facilitate the outlaw AR mechanism. It has previously been 
demonstrated that Src can directly phosphorylate the AR and drive its 
transcriptional activity in low androgen conditions (Guo et al., 2006; Asim et al., 
2008; Cai et al., 2011). Interestingly, treatment of PCa cell lines LNCaP and PC-
3 with GABA and GABAA receptor agonists has been shown to increase levels of 
phospho-Src and resulted in increased proliferation (Wu et al., 2014). 
Furthermore, elevated phospho-Src was found to be specific to invasive PCa 
cells co-expressing the GABAA receptor α1 subunit (Wu et al., 2014). These 
previous findings would suggest that GABA is a potential mediator of outlaw AR 
signalling.  
 
A potential source of GABA is paracrine signalling from NED PCa cells, which 
have been demonstrated in mouse models, to overexpress the GABA synthesis 
enzyme GAD1 and possess increased levels of GABA compared to normal NE 
cells of the prostate (Hu et al., 2002). LNCaP cells have also been shown to 
secrete GABA vesicles when treated with AR siRNA (Solorzano et al., 2018). In 
addition to its potential direct role as a facilitator of outlaw AR signalling, paracrine 
GABA signalling may also indirectly support AR outlaw pathways by inducing the 
expression of other neuropeptides such as gastrin-releasing peptide (GRP) which 
is linked to increased invasiveness and resistance to chemotherapeutics in PCa 
cell lines (Solorzano et al., 2018; Salido, Vilches & Lopez, 2002; Nagakawa et 
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al., 2008). Treatment of LNCaP cells in low androgen culture conditions with GRP 
has previously been shown to induce expression of AR target genes specifically 
in AR+ PCa cells (Lee et al., 2001). This evidence suggests that the paracrine 
GABA signalling via GABAB receptors effects of NED PCa cells can facilitate a 
version of the outlaw AR mechanism.  
 
1.2.1.5 Endogenous Androgen Synthesis 
Synthesis of dihydrotestosterone (DHT) from testosterone by prostatic cells is 
facilitated by isoenzyme SRD5A (Chang et al., 2011). Isoform SRD5A2 is 
constitutively expressed, however, during CRPC progression SRD5A1 
expression is induced and becomes dominant. SRD5A1 is able to convert 
androstenedione to 5α-androstenedione, allowing for endogenous DHT 
production in the absence of serum testosterone (Chang et al., 2011). This 
pathway is active in six different PCa cell lines as well as primary human tissue 
(Chang et al., 2011) 
 
1.2.1.6 Constitutively active androgen receptor splice variants 
It is important to consider that CRPC is not necessarily androgen receptor 
independent, it is merely independent of AR ligands. Some splice variants of the 
androgen receptor, such as AR-V7 are known to lack the ligand binding domain, 
but retain transcriptional activity (Beltran et al., 2016), making them resistant to 
enzalutamide and abiraterone (Hu et al., 2012). These AR splice variants 
(including AR-V7 and ARV567es) are known to be upregulated by AD and 
crucially, these AR splice variants have unique transcriptional profiles that are 
enriched for cell cycle genes and depleted of genes implicated in cellular 
differentiation (Hu et al., 2012). Therefore, the emergence of AR splice variants 
after application of ADT is a key driver of therapeutic resistance and alters the 
transcriptional landscape of CRPC cells (Jones et al., 2015; Jones et al., 2017; 
Kong et al., 2015).  
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Figure 1.3 Pathways facilitating androgen receptor activation in an 
androgen deprived environment. Adapted from Feldman and Feldman (2001). 
(A) Increased production of androgen receptor (AR) and increased conversion of 
testosterone to DHT results in hypersensitivity to remaining androgen. (B) The 
ligand specificity of the AR is reduced via mutations, allowing for promiscuous 
binding and activation of the AR to non-androgens. (C) The androgen receptor is 
directly phosphorylated by protein kinase B or mitogen- activated protein kinase 
allowing ligand independent activation. (D) Expression of oncogenes, such as 
BCL2, prevents apoptosis due to lack of AR signalling. (E) Prostate cancer stem 
cells and neuroendocrine cells are inherently androgen independent and can 
facilitate downstream activation of growth and survival pathways through 
differentiation and paracrine secretions (Feldman & Feldman, 2001). The drug 
targets of Abiraterone acetate (testosterone synthesis via CYP17A1 inhibition), 
Finasteride (5-reductase inhibitor) and Enzalutamide (AR antagonist) are also 
indicated, as is the proposed mechanism by which PCa NED may utilise the 
outlaw pathway via secretion of neuropeptides such as GABA in a paracrine 
manner, although the receptor by which GABA may mediate upregulation of EGF 
and Src remains unknown (Wu et al., 2014). 
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1.2.2 Tumour Evolution  
The tumour microenvironment places selective pressures upon cancerous cells 
which influences their evolutionary route towards a more aggressive and 
metastatic phenotype (Gundem et al., 2015). Although initially highly effective in 
limiting tumour growth, ADT becomes the prevailing selective pressure upon 
androgen sensitive tumours, driving them to become castrate-resistant (Dago et 
al., 2014; Nouri et al., 2014b; Harris et al., 2009). The chronology of mutations 
facilitating castrate-resistance is variable and multiple mechanisms of CRPC 
progression have been characterised. However, transition to CRPC is 
synonymous with mutations to Phosphatase and tensin homolog (PTEN) and 
TP53 tumour suppressor genes, followed by transient amplification of the 
androgen receptor (AR) and genes facilitating androgen receptor signalling such 
as FOXA1 (Gundem et al., 2015).  
 
Although there are uniting carcinogenic events that appear frequently in prostate 
cancer, it is proposed that both the sub-type of cells these mutations first arise in, 
as well as the specific microenvironment, is key to determining the evolutionary 
course of the tumour and its ultimate phenotype (Tu & Lin, 2012). This high level 
of heterogeneity both between patients and within tumours demonstrates that 
there is no single root pathway of prostate carcinogenesis or castrate resistance, 
but rather a complex relationship between multiple distinct mechanisms 
(Palapattu et al., 2005).  
 
One of the earliest and common events in the natural history of prostate cancer 
is the fusion of the TMPRSS2 and ERG genes, occurring in the majority of 
prostate cancers (Esgueva et al., 2010; Gundem et al., 2015; Yu et al., 2010). 
Transcription of the TMPRSS2 gene is upregulated by androgen receptor 
signalling, whilst ERG is an oncogene that has been demonstrated to increase 
cell invasion in prostate cancer through upregulation of MMP-3 and MMP-9 
(Tomlins et al., 2008; Yu et al., 2010). In addition to its ability to increase the 
aggressiveness of prostate cancer, ERG is a multifunctional repressor of 
androgen receptor signalling, thus TMPRSS2-ERG gene fusion can act to disrupt 
the canonical androgen mediated differentiation of prostate cells. Furthermore, 
TMPRSS2-ERG repression of androgen receptor signalling, may constitute an 
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intracellular selective pressure, driving epigenetic changes facilitating androgen 
independent growth (Katsogiannou et al., 2015; Tomlins et al., 2008; Yu et al., 
2010).  
 
1.2.3 Metastasis and Invasion of Prostate Cancer 
Once metastasised, CRPC becomes incurable, therefore understanding 
mechanisms of metastasis and how these metastases differ from primary 
tumours is a key area of prostate cancer research (Karantanos et al., 2013; Saad 
et al., 2015). Matrix metallopeptidase 9 (MMP-9) is a zinc metalloproteinase 
enzyme which is primarily involved in degradation of extracellular matrix, giving it 
important roles in tissue remodelling, wound healing as well as facilitating the 
invasion of cancer cells in a pathological setting (Nagase & Woessner, 1999). 
Interestingly, evidence shows that GABA(B) receptor activity can promote MMP 
expression in PCa cells (Abdul et al., 2008; Ippolito et al., 2006). Due to the 
potentially destructive activity of MMP’s, they are produced as inactive zymogens 
and their activity is tightly regulated by the binding of tissue inhibitors of 
metalloproteinases (TIMPS) (Ramos-DeSimone et al., 1999; Nagase & 
Woessner, 1999). In the case of MMP-9, the enzyme is produced as pro-MMP-9 
and is inhibited by TIMP-1 (Roderfeld et al., 2009). Activation of pro-MMP-9 and 
the release of TIMP-1 is a two-step process, requiring the activation of MMP-3 by 
plasmin, which then allows for MMP-3 to activate MMP-9 (Christensen & Shastri, 
2015; Ye et al., 1996). However, it should also be considered that MMP-9 has 
been shown to be activatable by other enzymes under different conditions, 
including MMP-2, MMP-7, MMP-10, MMP-13, plasmin, cathepsin G and 
cathepsin K, however MMP-3 remains the most effective activator of MMP-9 
(Christensen & Shastri, 2015). MMP-9 has been strongly associated with 
metastatic and invasive activity in numerous different types of cancer including 
cervical (Kato, Yamashita, & Ishikawa, 2002), colorectal (Baker & Leaper, 2002), 
liver and pancreatic (Nagakawa et al.,  2002). Prostate cancer tumours with 
Gleason scores above 8 had significantly higher MMP-9 mRNA and protein levels 
than those with a Gleason score of 6 or less (p = 0.01) (Cardillo, Di Silverio, & 
Gentile, 2006). In addition, when the prostate cancer cell line LNCaP was 
transfected with a pcDNA6-MMP-9 expression plasmid, invasive activity was 
significantly increased (Aalinkeel et al., 2004). 
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1.2.4 Cancer Stem Cells 
Cancer stem cells (CSCs) have been implicated in a wide range of cancer types 
due to their self-renewal properties, high potential for differentiation and 
resistance to chemotherapeutics (Chen et al., 2013; Hu et al., 2009; Klarmann et 
al., 2009). Although treatments such as ADT, docetaxel and radiotherapy are 
effective against the majority of prostate cancer cells, an underlying sub-
population of CSCs are refractory to treatment and can re-establish the tumour 
mass (Zhang & Waxman, 2010). This is of particular clinical interest in prostate 
cancer where the AD state of the patient creates a strong selective pressure upon 
the CSCs, inducing an androgen independent tumour phenotype (Chen et al., 
2013; Gundem et al., 2015). It is important to distinguish that even within a CSC 
population there is considerable heterogeneity and sub-types (Chen et al., 2013). 
An effective way to characterise these is through analysis of co-expression 
patterns of CSC surface markers such as CD44, CD133, CD166 and 21-
integrin (Mizrak, Brittan, & Alison, 2008; Patrawala et al., 2006; Reyes et al., 
2013; Smith et al., 2012; Tu & Lin, 2012).  
 
The presence and activity of CD44+ CSCs would appear to be a strong evidence 
in support of the lurker cell theory given that they are AR- but are able to 
differentiate into AR+ tumour cells. CD44+ cells were also found to have higher 
rates of proliferation and metastatic ability than CD44- prostate cancer cells and 
appear to co-express several other genes native to stem cells such as Oct-3/4, 
Bmi, beta-catenin and SMO. (Patrawala, et al., 2006) 
 
CD133+ cells have been shown to make up around 5% of the population of 
prostate cancer cell lines and they fit the usual criteria of CSCs in that they are 
able to self-renew, proliferate indefinitely and are able to differentiate (Reyes et 
al., 2013). AC133 is a glycosylated epitope of CD133 and cells with expression 
profile AC133+/CD34+ showed greater proliferation than AC133-/CD34+ cells 
indicating that AC133 is a more specific target for the identification of CD133 stem 
cells. (Mizrak, Brittan, & Alison, 2008). CD166 has been demonstrated to be 
highly expressed in the prostates of developing human fetuses as well as in both 
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human and mouse CRPC cells, making it a likely CSC marker (Smith et al.,  
2012). 
 
1.3 Neuroendocrine Differentiation 
Neuroendocrine differentiated (NED) tumour cells are thought to 
transdifferentiate from adenocarcinoma cells (Fig. 1.4), a theory supported by 
genetic analysis (Sauer et al., 2006). Neuroendocrine-like (NE) cells have been 
implicated in the progression of PCa to CRPC because of the role of NE cells in 
healthy prostate tissue in stimulating the growth of surrounding cells in a 
paracrine manner (Terry & Beltran, 2014). NE-like cells are non-proliferative, 
making them resistant to many chemotherapeutics, and able to resist apoptosis 
by overexpression of survivin (Xing et al., 2001), allowing continued paracrine 
support of regional cancerous cells through expression of proliferative and 
angiogenic growth factors (Chevalier et al., 2002). 
 
Increased NED is closely associated with PCa disease progression whilst under 
the selective pressure of ADT, which can be seen both histologically and in 
increased NED markers such as NSE and CgA in patient serum (Isgro, Bottoni, 
& Scatena, 2015; Kamiya et al., 2003; Rech et al.,  2006). NED is becoming a 
more prevalent issue in prostate cancer treatment, which has coincided with the 
introduction of more potent ADT therapeutics. In addition, the proportion of 
patients experiencing NED is increasing as patients are living longer with prostate 
cancer, giving more time for NED to occur (Bluemn et al., 2017).  
 
Given that ADT is a known inducer of NED both in vitro (Rapa et al., 2013) and 
in vivo (Zhang et al., 2018), that PCa resistance to ADT and progression to CRPC 
is inevitable in patients (Beltran et al., 2011) and that CRPC and mCRPC tumours 
show greatly increased NED with disease progression (Borromeo et al., 2016), it 
is clear that NED may be a core facilitating feature of progression and 
maintenance of CRPC. In this study we aim to investigate how androgen 
deprivation of androgen sensitive PCa cells can trigger NED, the extent to which 
this is reversible and whether there is potential for paracrine (e.g. GABAergic) 
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signalling in PCa NED cells using an in vitro model. Previous studies have 
demonstrated that the androgen sensitive PCa cell line LNCaP is amenable to 
NED in response to a variety of treatments including AD, radiotherapy, 
chemotherapeutics and hypoxia (Bang et al., 1994; Cox et al., 1999; Zhu et al., 
2014; Deng et al., 2011; Farach et al., 2016; Komiya et al., 2009; Rapa et al., 
2008, 2013; Danza et al., 2012; Liang et al., 2014; Lin et al., 2016; Sarkar et al., 
2011; Yadav et al., 2017), making it a practical and robust basis of a model to 
study the effects of AD and intermittent AD in the context of PCa NED. 
 
 
Figure 1.4 The origin and involvement of the NE niche in CRPC progression. 
The cancer stem cell (CSC) niche can contribute to disease recurrence and 
progression through classical tumour reseeding (Chang, 2016). The CSC niche 
has low proliferation and high therapeutic resistance, meaning that after the 
application of therapeutic regimens such as androgen deprivation therapy (ADT), 
CSCs can remain (Lang et al., 2009), these cells can then contribute to disease 
progression by repopulating the tumour with castrate-resistant or androgen-
independent cells (Lang et al., 2009). The less differentiated state of CSCs grants 
increased ability to adapt under the selective pressure of applied therapeutics 
(Chang, 2016; Lang et al., 2009). It is a possibility that the NED niche may also 
be able to fulfil a similar role, by becoming treatment resistant (Hu et al., 2015) 
and later transdifferentiating back into an epithelial PCa  (Shen et al., 1997) or 
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castrate-resistant prostate cancer (CRPC) phenotype. Furthermore, the 
enrichment of the NED niche within tumours could have the potential to exert 
effects upon surrounding PCa and CRPC cells, as well as influencing the 
differentiation of existing CSCs through modulation of the tumour 
microenvironment (Chevalier et al., 2002; Hu et al., 2015; Terry & Beltran, 2014; 
Xing et al., 2001). 
 
1.3.1 Potential interplay between PCa CSCs, epithelial PCa cells and NED 
PCa cells. 
When describing the potential implications of PCa NED it is important to consider 
that within a tumour, the NED niche is also accompanied by the cancer stem cell 
population, androgen sensitive epithelial PCa cells and potentially CRPC cells. 
Although NED PCa cells are known to have a slower proliferative rate than 
epithelial PCa cells (Grigore et al., 2015) the effects that these NED cells may 
have upon the other subpopulations of PCa cells via paracrine signalling may 
contribute to the poorer outcomes observed clinically in tumours with high NED 
(Komiya et al., 2013). The precise mechanisms of interplay between the NED 
niche and other PCa tumour subpopulations remains poorly understood. 
However, the ability of NED PCa cells to secrete neuropeptides and growth 
factors is well established including NSE, chromogranin-A, bombesin and 
synaptophysin which are clinically utilised NED markers. Recently, the possibility 
that NED PCa cells could be secreting or be sensitive to GABA has been a 
growing area of research interest (Ippolito & Piwnica-Worms, 2014; Wu et al., 
2014).  In addition, several other secreted factors of NED PCa cells have been 
reported in the literature including: adrenocorticotrophic hormone, antidiuretic 
hormone, α-human chorionic gonadotrophin, calcitonin, cholecystokinin, 
glucagon, parathyroid hormone-related protein,  serotonin, somatostatin and 
thyroid-stimulating hormone (Bok and Small, 2002; Cussenot et al,. 1998, 
Abrahamsson., 1999; Ather et al., 2000).  
 
Considering the plethora of secreted paracrine factors produced by NED PCa 
cells, it is possible that this modification of the tumour microenvironment could 
influence the activity and differentiation of PCa CSCs into proliferative PCa or 
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CRPC cells (Fig 1.4). Such mechanisms could enhance the ability of the PCa 
CSC niche to contribute to tumour reseeding, therapeutic resistance and disease 
recurrence under ADT. For example, NED PCa cells have been linked to the 
activation of EGFR pathway in surrounding cells (Wu et al., 2014) and this is a 
key driver of CSC self-renewal (Rybak et al., 2013; Conteduca et al., 2014). The 
ability of PCa CSCs to facilitate tumour recurrence by differentiation into resistant 
and proliferative phenotypes is well established (Chang, 2016; Lang et al., 2009). 
 
The ability of PCa cells to undergo NED as a resistance mechanism to ADT, 
radiotherapy and several chemotherapeutics could provide a similar ‘resevoir’ of 
highly resistant cells that are the able to return to a proliferative epithelial 
phenotype similar to the CSC niche (Deng et al., 2011; Hu et al., 2015; Wang et 
al., 2018; Yadav et al., 2017). This studies proposed pathway for PCa NED is 
described in section 1.3.4. In addition, the secreted factors of the NED 
subpopulation are thought to facilitate the growth and survival of PCa epithelial 
cells in low androgen conditions (Ippolito et al., 2006; Ippolito & Piwnica-Worms, 
2014; Komiya et al., 2009; Wu et al., 2014).  
 
1.3.2 Known inducing factors of NED 
NED has been demonstrated to be inducible in LNCaP cells by a variety of stimuli, 
including cAMP (Bang et al., 1994; Cox et al., 1999), IL-6 (Zhu et al., 2014), 
ionising radiation (Deng et al., 2011), ADT (Farach et al., 2016; Komiya et al., 
2009; Rapa et al., 2008, 2013), hypoxia (Danza et al., 2012; Liang et al., 2014; 
Lin et al., 2016), chemotherapeutics such as docetaxel (Sarkar et al., 2011) and 
most recently, tyrosine-kinase inhibitors such as dovitinib (Yadav et al., 2017). 
Importantly, there are no existing therapeutics which directly target NED PCa 
cells or the NED process. Evidently, the wide range of endogenous and 
therapeutic stimuli that can induce PCa NED is of concern clinically and highlights 
a need to better understand NED as a mechanism of therapeutic resistance and 
progression to CRPC. Interestingly, the morphological features induced by all of 
these stimuli and the increased expression of a core set of NED biomarkers 
(NSE, CgA and synaptophysin) appear to be present in all these types of NED 
induction. There are also some known molecular drivers of NED that appear to 
be shared across at least two inducing factors, for example the reduction in RE-
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1 silencing transcription factor (REST) expression (the canonical repressor of 
neurogenesis) has previously been implicated in both IL-6 and hypoxia mediated 
PCa NED (Liang et al., 2014; Zhu et al., 2014). However, considering PCa NED 
research has only recently increased in volume and that this research is 
fragmented between studies investigating a wide array of different inducing 
factors, each with their own models, it remains unclear which components of the 
PCa NED pathway are shared or required. In contrast, study of lung cancer NED 
has progressed relatively rapidly, partly due to NED being a feature mainly 
observed in small cell lung cancer (SCLC) (Meder, et al., 2016).  The molecular 
mechanisms by which these known inducers can trigger NED can be distinct. For 
example IL-6 is implicated in activation of PI3K and STAT3 pathways (Deeble et 
al., 2001). Meanwhile, cAMP induction of NED is thought to arise from activation 
of the PKA/CREB signalling pathway (Cox et al., 1999). Furthermore, a recent 
study demonstrated that canonical neurogenesis promoter human achaete-scute 
homolog-1 (hASH1) is essential for NED in SCLC in both human SCLC cell lines 
and in a mouse model (Borromeo et al., 2016) 
 
1.3.3 Previously developed models of ADT induced NED 
The focus of this project is to investigate AD as an inducing factor of PCa NED, 
which required the development and characterisation of a model of ADT induced 
NED using androgen-sensitive LNCaP cells. Several models are previously 
published in the literature and can broadly be categorised into two branches; 
models which utilise current ADT therapeutics to target the AR directly and ones 
in which androgens are depleted from the cell culture media. This can be 
achieved through charcoal-stripping the fetal bovine serum (CS-FBS), which 
preferentially, but not specifically, removes hormones from the media and/or by 
reducing the overall concentration of FBS in the media, typically from 10% to 5%, 
which uniformly decreases all factors within the FBS (Farach et al., 2016; Komiya 
et al., 2009; Rapa et al., 2008, 2013).  
 
The vast majority of existing ADT induced NED models for PCa utilise the LNCaP 
cell line, however LuCaP cells are occasionally used as an in vivo xenograft 
model (Xiaotun Zhang et al., 2015). Models using charcoal-stripping and 
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reduction of FBS in the cell culture media usually use either 10% (Rapa et al., 
2013; Shen et al., 1997), 5% (Yuan et al., 2006) or 0% (Juarranz et al., 2001; 
Martín-Orozco et al., 2007) CS-FBS. Under these conditions, LNCaP cells have 
been cultured for up to 4 days in 0% FBS, up to 9 days using 5% CS-FBS and 15 
days with 10% CS-FBS (Juarranz et al., 2001; Martín-Orozco et al., 2007; Rapa 
et al., 2013; Yuan et al., 2006). Some studies have also directly used ADT 
therapeutics to create models of NED using LNCaP cells (Bishop et al., 2017). 
 
1.3.4 This studies proposed pathway of AD-induced NED 
Notch1 is selectively expressed in the basal epithelial cells of the adult prostate 
where it regulates and maintains cell differentiation and is highly expressed in 
prostate progenitor cells during development (Belandia et al., 2005; Wang et al., 
2004). One function of the Notch1 signalling cascade is the negative regulation 
of hASH1 (a promoter of neurogenesis) through upregulation of bHLH 
transcriptional repressor genes Hes1 and Hey1(Axelson, 2004; Ishibashi et al., 
1995). PTOV1 acts as a negative regulator of Notch1 signalling by interacting 
with the Notch repressor complex, thus facilitating increased expression of 
hASH1 leading to NED. This mechanism is further evidenced by the co-
localisation of PTOV1 with NED marker chromogranin-A (Alaña et al., 2014) and 
the correlation between AD and increased hASH1 expression (Rapa et al., 2008) 
 
Notch signalling via Hey1 also acts as a repressor of AR signalling in the absence 
of testosterone, therefore loss of Notch signalling may allow continued 
expression of androgen responsive genes even in an AD state (Belandia et al., 
2005). Patients with PCa showed a complete lack of Hey1 localised in the nucleus 
whereas those with benign prostate hyperplasia retained Hey1 in the nucleus 
(Belandia et al., 2005). These findings suggest that abnormalities in Notch1 
signalling and the resulting exclusion of Hey1 from the nucleus could contribute 
to androgen independence. This hypothesis was supported by a previous study 
demonstrating the tumour suppressive qualities of Notch and Hey1 in the prostate 
and that PTOV1 may be responsible for the breakdown of Notch signalling during 
PCa progression (Alaña et al., 2014). In order to prevent activation of pro-neural 
development pathways in non-neuronal tissues, and to preserve the adult neural 
stem cell pool, REST recruits corepressors CoREST and mSin3a to the 
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chromatin for prevent the expression of target genes including hASH1 (Gao et 
al., 2011). Therefore, a reduction in REST expression or activity is likely 
necessary to allow for hASH1 mediated NED and has been previously found to 
be essential for hypoxia-induced NED of PCa (Lin et al., 2016). 
 
1.3.5 hASH1 mediated canonical neurogenesis 
Transcription factor hASH1 is critical to neuroblast differentiation and helps to 
maintain lateral inhibition by increasing the expression of Delta-like ligands. 
Although originally discovered in drosophila studies, the mechanism of hASH1 
mediated neurogenesis has been found to be conserved in all animals (Henke et 
al., 2009; Nelson et al., 2009) and is particularly important in the development of 
GABAergic neurons (Guillemot & Hassan, 2017; Casarosa, Fode & Guillemot, 
1999).  hASH1 is expressed in neuronal pre-cursor cells of both the central (CNS) 
and peripheral nervous system (PNS). Gain and loss of function experiments 
have demonstrated that hASH1 is required for neurogenesis and able to 
independently drive neurogenesis (Bertrand et al., 2002; Wilkinson et al., 2013). 
Knock down of hASH1 in mouse models in vivo results in a lethal phenotype due 
to improper formation of the CNS and PNS (Axelson et al., 2004). The ability for 
hASH1 to induce neurogenesis has also been demonstrated in fibroblasts, 
pericytes and astrocytes (Raposo et al., 2015; Vierbuchen et al., 2010). hASH1 
is able to drive deployment of neuronal transcriptional programs by binding to its 
putative consensus site ‘CAGCTGC’, where hASH1 targets gene pathways 
responsible for neurotransmitter biosynthesis, notch signalling regulation, axon 
guidance, regulation of cell cycle and cell fate commitment and cell projection 
morphogenesis amongst others as assessed by ChIP-chip and Gene Ontology 
analysis results (Castro et al., 2011).  
 
1.3.6 hASH1 ability to act as a pioneer factor in neurogenesis and cancer 
The powerful ability of hASH1 to trigger neurogenesis both in neural precursor 
and non-neuronal cells relies on its ability to act as a pioneer factor and facilitate 
the accessibility of closed chromatin (Raposo et al., 2015). The pioneer factor 
activity of hASH1 is likely the reason that it is a required factor for neurogenesis, 
as it allows subsequent transcription factors to access chromatin and drive 
expression of their target genes (Raposo et al., 2015; Zaret & Carroll, 2011). 
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Furthermore, the chromatin remodelling and genome wide transcriptional activity 
of pioneer factors such as hASH1 make them a strong candidate for roles in NED 
of PCa cells and hASH1 has been strongly implicated in NED of small cell lung 
cancer (SCLC) (Borromeo et al., 2016). Importantly, hASH1 is unique in its ability 
to trigger neuronal differentiation in non-neuronal tissues (Guillemot & Hassan, 
2017).  
 
hASH1 activity in cancer has been most thoroughly studied in neuroblastoma 
(NB) (Gillotin, Davies & Philpott, 2018; Wylie et al., 2015). During canonical 
neurogenesis, hASH1 is expressed transiently, increasing in expression in non-
proliferating differentiating cells until neurogenesis is complete and then receding 
as cells re-enter the cell cycle (Raposo et al., 2015). However, in the NB setting, 
hASH1 expression fails to decrease and remains high even in proliferating NB 
cells (Wylie et al., 2015), it is thought that the phosphorylated hASH1 is able to 
maintain NB cells in a proliferative state, potentially through interactions with N-
MYC (Wylie et al., 2015). Therefore, hASH1’s role in NB is converse to its 
reported role in non-neuronal cancers such as SCLC and PCa. In the NB setting 
high hASH1 expression prevents the final stage of differentiation, maintaining the 
plasticity of NB precursor cells, whereas in SCLC and PCa hASH1 could 
effectively ‘de-differentiate’ epithelial cancer cells, driving NED and increased 
plasticity by contributing to further repression of notch signalling (Somasundaram 
et al., 2005). 
 
1.3.7 hASH1 activity in SCLC 
In addition to neuroblastoma, hASH1 has also been extensively studied in the 
context of SCLC NED and has been identified as a potential therapeutic target 
(Augustyn et al., 2014; Borromeo et al., 2016; Demelash et al., 2012; Nishikawa 
et al., 2011; Osada et al., 2008, 2005). Recent studies have demonstrated that 
hASH1 is the only required and sufficient factor to induce SCLC NED and that 
the target genes of hASH1 in SCLC include several GABAergic pathway genes 
including GAD2 which synthesizes GABA and GABAA receptor subunit GABRB3 
(Borromeo et al., 2016). In addition, it is known that hASH1 drives expression of 
Delta-like ligands and research into hASH1 activity in SCLC has led to the 
development of rovalpituzumab, a DLL3 inhibitor which is currently in phase III 
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clinical trials (ClinicalTrials.Gov; NCT03033511). This previous literature provides 
a strong basis that hASH1 is able to induce NED in non-neuronal tissue cancer 
types and further demonstrates the pioneer factor activity of hASH1 facilitating 
NED in already differentiated cells making hASH1 a logical candidate for driving 
PCa NED as well.  
 
1.3.8 hASH1 in PCa  
Previous studies examining PCa NED have demonstrated that transduction of 
hASH1 is associated with increased expression of NED markers chromogranin-
A and synaptophysin (Rapa et al., 2013). Furthermore, hASH1 staining has 
previously been found in the nuclei of human PCa samples co-expressing 
chromogranin-A (Rapa et al., 2008). However, no studies have previously 
examined the response of hASH1 localisation to androgen deprivation and 
whether these responses are persistent or reversible during intermittent 
androgen deprivation or whether hASH1 triggers a GABAergic phenotype.  
 
1.4 Gamma aminobutyric acid is implicated in increased growth and 
aggression of prostate cancer 
Although originally thought to only be present in the central and peripheral 
nervous system, it is now well established and accepted that both GABAA and 
GABAB receptors are present and functional in many healthy non-neuronal 
tissues, albeit in much lower abundance (Takehara et al., 2007; Hedblom & 
Kirkness 1997; Tyagi et al., 2007). Therefore, and perhaps unsurprisingly, 
GABARs have also been detected in multiple cancer types including PCa where 
a previous study detected GABAARs in 95% of prostate cancer specimens by 
immunohistochemistry (Abdul, McCray & Hoosein, 2007). Whilst much is still 
unknown about their oncogenic activity, activation of both the GABAA and GABAB 
receptors in cancer has been demonstrated to modulate growth, invasion and 
metastasis of cancer cells (Young & Bordey, 2009; Bugan et al., 2016; Wu et al., 
2014). Given that hASH1 has previously been associated with increased prostate 
cancer NED (Rapa et al., 2008; Rapa et al., 2013) and that hASH1 is known to 
drive the differentiation of GABAergic neurons (Guillemot & Hassan, 2017; 
Casarosa, Fode & Guillemot, 1999), this has led to investigations into the 
potential activity of GABA and GABARs in PCa NED. 
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Presence of NE-like cells in prostate cancers and enrichment of this cell niche via 
ADT induced transdifferentiation has prompted researchers to analyse the 
gamma aminobutyric acid (GABA) axis as a possible novel mechanism of 
castrate resistance (Ippolito & Piwnica-Worms, 2014; Nouri et al., 2014; Wu et 
al., 2014). Recent studies have demonstrated that GAD1, a gene encoding 
GAD67 enzyme, critical for production of GABA, is upregulated in CPRC (Ippolito 
& Piwnica-Worms, 2014). Furthermore, it has also been demonstrated that 
treatment of prostate cancer cells with GABA upregulated transcription of 
epidermal growth factor and resulted in increased activation of EGFR and Src 
(Wu et al., 2014), which would implicate GABA as potentially modulating PCa 
growth via the outlaw pathway (Figure 1.3).  
 
GABA production is dependent upon GAD65 and GAD67 encoded by the GAD2 
and GAD1 genes respectively (Hu, et al., 2002). Expression of the mouse variant 
of hASH1, mASH1, is known to induce production of GAD67 in mice (Fode, et 
al., 2000) and hASH1 is also known to drive the development of GABAergic 
neurons (Castro et al., 2011; Peltopuro et al., 2010; Wang et al., 2017). 
Immunohistochemistry analysis of PCa previously found that the expression of 
hASH1 correlated with NE differentiation and that hASH1 expression was co-
localised with NE marker chromogranin-A (Hu, et al., 2002).  
 
Activation of GABAA receptors (GABAARs) by GABA has been demonstrated to 
result in activation of the EGFR and Src in both LNCaP and PC-3 PCa cell lines. 
These pathways are strongly associated with tumour growth, therefore, it is 
suggested that transdifferentiation of PCa cells to NE-like cells can provide PCa 
tumours with an androgen independent pathway for growth and survival via the 
paracrine signalling of NE transdifferentiated cells (Wu, et al., 2014). In addition, 
activation of the GABAA receptor has been demonstrated to increase the growth 
of four PCa cell lines, whilst the same study found GABAB receptor agonism had 
no effect on growth (Abdul, McCray & Hoosein, 2007). Meanwhile, activation of 
the GABAB receptor has been demonstrated to increase the invasive abilities of 
PCa cells through upregulation of MMP-9, an effect which was not observed after 
treatment with GABAA receptor agonists (Azuma et al., 2003). This suggests that 
the oncogenic activity of GABARs in PCa is potentially synergistic, with GABAAR 
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activation implicated in increased growth and GABABR with invasive potential. 
Finally, GABA has previously been shown to increase androgen production in rat 
testicular tissue (Ritta, Campos, & Calandra, 1987). It is already established that 
prostate cancer tumours are capable of producing DHT from androgen 
precursors (Chang, Ercole, & Sharifi, 2014; Chang et al., 2011) and this might be 
a mechanism of ADT resistance. 
 
1.4.1 Structure and function of GABAA and GABAB receptors 
There are two classes of GABARs, the ionotropic GABA type A receptors 
(GABAARs) and the metabotropic type B receptors (GABABRs). The GABAAR 
family also includes the GABA type C (GABACRs), however, these are generally 
confined to the retina (Lukasiewicz, 1996; Qian, 1995) and are not considered in 
this study. The structure and function of GABAARs and GABABRs is very different, 
GABAARs are ligand-gated ion channels, whereas GABABRs are G-protein 
coupled receptors. As such, GABAARs usually mediate rapid responses to the 
endogenous ligand GABA (Barnard et al., 1998), whilst GABABRs mediate slower 
responses to GABA (Bowery et al., 2002). Although, it should be noted that some 
GABAARs can mediate slow responses, which is believed to be mediated by the 
5 subunit (Zarnowska et al., 2009). 
 
1.4.2 GABAA Receptors 
The structure of the GABAAR is considerably more complex than that of the 
GABABR, with the full crystal structure only recently resolved (Miller & Aricescu, 
2014). Therefore, when studying GABAAR subunits, especially in novel contexts 
such as PCa and NED PCa, all subunits must be considered. In a physiological 
setting, a GABAAR usually comprises two , two  and one other subunit 
(generally a  subunit) (Sigel & Steinmann, 2012). The  receptors are 
generally synaptic, where they mediate phasic transmission,  receptors are 
mainly extrasynaptic where they mediate tonic inhibition (Dixon et al., 2014; 
Serwanski et al., 2006; Zheleznova et al., 2009). The most common combination 
of subunit is 1, 2 and 2 (Whiting, McKernan, & Wafford, 1995), which is usually 
arranged 2212 around the central pore of the receptor (Baumann et al., 
2002; Baur et al., 2006; Tretter et al., 1997). in addition to  1-6,  1-3 and 1-3 
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there are also the , ,  and   subunits, which can substitute for the  subunit 
with various effects upon the receptors activity and pharmacology (Jacob et al., 
2008; Montori et al., 2012). Also of interest, is that five 3 subunits have the ability 
to form functional GABAARs, independently of other subunits (Miller & Aricescu, 
2014).  GABA binds to GABAARs at the interface of the  and  subunits and 
activation occurs when two GABA molecules bind simultaneously (Puthenkalam 
et al., 2016). Upon GABA binding, a conformational switch forms, which opens 
the ion channel resulting in Cl- ion flow into the cell causing membrane 
hyperpolarisation and thereby inhibiting neurotransmitter release (Miller & Smart, 
2010).  
 
The GABAAR subtype has thus far shown to be of particular importance in the 
progression of CRPC as its activation has many downstream proliferative and 
mitogenic effects including upregulation of EGF and activation of Src which 
activates both the MAPK and STAT pathways (Wu et al., 2014). When studying 
the effects of GABAAR activation, the specific agonist muscimol is frequently 
utilised in the literature (Johnston, 2014).  
 
1.4.3 GABAB Receptors 
In comparison to GABAA receptors which can be formed from 16 different 
subunits, GABAB receptors are heterodimers composed of just 2 subunits 
(Bormann, 2000), GABAB1 and GABAB2. The GABAB1 subunit also has two 
isoforms, GABAB1a and GABAB1b encoded by the GABBR1 gene, although the 
effects of each isoform appear to be indistinguishable (Gassmann & Bettler, 
2012). GABABRs, like GABAARs, are also typically inhibitory to neurotransmitter 
release (Benarroch, 2012; Hill & Bowery, 1981). The GABAB1 subunit contains an 
arginine-rich endoplasmic reticulum-retention signal, which is obstructed when 
bound to GABAB2, ensuring that only these heterodimers are able to leave the 
endoplasmic reticulum and reach the cell surface (Gassmann & Bettler, 2012). 
The GABAB1 subunit contains the GABA binding site, whilst the GABAB2 subunit 
is responsible for activation of the G protein (Gassmann & Bettler, 2012). Binding 
of GABA to GABABRs results in the closure of the Venus fly trap domain (VFTD) 
of GABAB1, causing it to interact with the VFTD of GABAB2, resulting in activation 
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of the G protein (Gassmann & Bettler, 2012). Synthetic selective GABABR agonist 
baclofen is employed ubiquitously in the previous literature examining the effects 
of GABABR activation (Hill & Bowery, 1981). 
 
 
Figure 1.5 Structural diagram illustrating the composition of a typical 
GABAAR and GABABR. (A) GABAARs are heteropentameric and can be formed 
from 16 unique subunits. The endogenous ligand GABA binds at the interface of 
 and  subunits and activation of the receptor requires the simultaneous binding 
of two GABA molecules. Upon activation, the central pore of the receptor opens 
and allows the influx of Cl- ions. Many clinically important pharmacological agents 
also bind to GABAARs, including benzodiazepines (BZs on image). (B) GABABRs 
are obligate heterodimers of just two subunits (GABAB1 and GABAB2), the 
GABAB1 subunit comprises the GABA binding site and is retained in the 
endoplasmic reticulum until bound to the GABAB2 subunit, which is responsible 
for the activation of the G protein. GABABRs are indirectly coupled to K+ ion 
channels and when activated they open K+ ion channels and decrease influx of 
Ca2+ ions (Olsen & DeLorey, 1999). Image of GABAAR adapted from  (Jacob, 
Moss, & Jurd, 2008) and image of GABABR adapted from  (Benarroch, 2012). 
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1.4.4 CCC regulation of GABAA receptor activity 
The chloride gradient across the cell membrane is a key determinate of whether 
GABAAR activity is inhibitory or excitatory. Therefore, the activity of cation-
chloride co-transporters (CCCs) ultimately influences the effects of GABAAR 
signalling.   
 
Despite GABA’s role as the most prevalent inhibitory neurotransmitter in the 
human central nervous system, when neuronal chloride concentration is high, the 
activation of GABAA receptors by GABA and other clinically-important ligands can 
act in an excitatory rather than inhibitory manner (Li & Xu, 2008). This process is 
determined by the chloride gradient of the cell and this is regulated by CCC 
transport proteins (Kahle et al., 2008; Li & Xu, 2008).  
 
 
Figure 1.6 The expression and activity of CCCs determines the activity of 
GABAARs. (A) Na–K–2Cl cotransporter NKCC1 is the predominantly 
expressed CCC during neonatal neuronal development and usually has high 
activity, whilst KCC2 expression and activity is very low during development, 
therefore the [Cl−]i is high meaning that activation of the GABAAR and therefore 
opening of the CCCs results in chloride efflux, causing neuronal excitation via 
depolarization (Li & Xu, 2008; Succol et al., 2012). (B) In mature neurons, 
KCC2 expression and activity increases whilst NKCC1 decreases (Hartmann 
& Nothwang, 2014; Li & Xu, 2008). This results in a lower [Cl−], therefore, 
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activation of the GABAA receptor results  hyperpolarization (neuronal inhibition) 
due to chloride influx, adapted from Kahle et al., (2008). Also important to note 
is that the composition of the GABAAR subunits can be influenced by the chloride 
gradient, therefore, certain subunit assemblies can be indicative of excitatory or 
inhibitory activity (Succol et al., 2012). 
 
The chloride gradient of cells and the nature of GABAA receptor activity is 
primarily governed by CCCs. These can be categorised into Na+-K+-2Cl- co-
transporters (NKCC1-2) and K+-Cl- co- transporters (KCC1-4). The Cl- 
concentration in neonatal cells is known to be higher (by 20-40 mM) than in adult 
neurons, a shift which determines whether GABA receptor activation in inhibitory 
(adult neurons, lower Cl- concentration) or excitatory (immature neurons, higher 
Cl- concentration) (Ben-Ari, 2002). NKCCs typically raise the neuronal [Cl-]i by Cl- 
influx, whilst KCCs mediate Cl- efflux and lower neuronal [Cl-]i (Ben-Ari, 2002). 
Thus, NKCC1 is upregulated during early CNS development, whilst KCC2 is 
responsible for the shift from excitatory to inhibitory action of GABA receptors and 
is a useful biomarker of mature neurons (Li & Xu, 2008), however NKCC1 is 
ubiquitous and not a specific neuronal marker (Ben-Ari, 2002; Li & Xu, 2008). 
 
1.4.5 GABA Metabolism in cancer 
In addition to its effects mediated through GABAA and GABAB receptors, some 
studies have proposed that metabolism of GABA could also be a pro-oncogenic 
pathway facilitating PCa NED and CRPC (Ippolito et al., 2006; Ippolito et al 2014), 
a theory which has been previously demonstrated in other cancer types including 
breast cancer brain metastases (Neman et al 2014) and gastric cancer (Matuszek 
et al., 2001). In addition, the prostate tissue is known to have one of the highest 
levels of GABA-T expression outside of the CNS (DepMap, Broad Institute), an 
enzyme that alongside SSADH can convert GABA into succinate and therefore 
input into the TCA cycle (Ippolito et al., 2006). 
 
1.4.6 Previous GABAAR and GABABR studies in prostate cancer 
GABARs have been found in a variety of tissue types and implicated in a 
multitude of disease states, including PCa (Nouri et al., 2014; Wu et al., 2014). 
Glutamate decarboxylase 1 (GAD1) which encodes the GAD67 enzyme, critical 
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for GABA synthesis and is upregulated in CPRC (Ippolito & Piwnica-Worms, 
2014). Furthermore, treatment of PCa cells with GABA (10 nM) upregulated 
transcription of epidermal growth factor (EGF) and resulted in increased 
activation of epidermal growth factor receptor (EGFR) and Src (a non-receptor 
tyrosine kinase which transduces signals from the EGFR) (Wu et al., 2014). 
Activation of EGFR and Src is closely associated with increased proliferation, 
treatment of LNCaP and PC-3 cells with 10 nM GABA significantly increased 
growth (Wu et al., 2014). A possible mechanism for the initiation of EGFR and 
Src signalling is activation of the GABAAR. Both androgen sensitive and 
insensitive cell lines (LNCaP and PC-3, respectively) show increased EGFR and 
Src expression when treated with GABA and other GABAAR specific agonists 
(Wu, et al., 2014). Recently, 3-diol (a metabolite of dihydrotestosterone (DHT)) 
was found to mediate increased EGF expression and growth in PC-3 cells in a 
GABAAR dependent manner, independent of androgen receptor (AR) (Xia et al., 
2018). Furthermore, selective activation of GABAB receptor using baclofen, 
increased the migration of PC-3 PCa cells (Xia et al., 2017).  
 
GABA production is dependent upon GAD65 and GAD67 encoded by the GAD2 
and GAD1 genes respectively (Hu, et al., 2002).  Previously, mASH1 expression 
has been found to induce production of GAD67 in mice (Fode, et al., 2000). 
Expression of the human ortholog of mASH1, hASH1, correlates with NED and 
hASH1 expression is co-localised with NE marker chromogranin-A (Hu, et al., 
2002). hASH1 expression is regulated via the highly conserved Notch signalling 
pathway (Sriuranpong et al., 2002), which is also critical to the development of 
the prostate and maintenance of prostate epithelial cell fate (Wang et al., 2006), 
which in turn is dependent upon androgens (He et al., 2018). Therefore, it is 
possible that ADT is a mechanism of notch signalling disruption, increasing cell 
fate plasticity and facilitating expression of hASH1 to drive a NE-like 
transcriptional program. Therefore, it is suggested that transdifferentiation of PCa 
cells to NE-like cells can provide PCa tumours with an androgen-independent 
pathway for growth and survival via the paracrine signalling of NE 
transdifferentiated cells (Wu, et al., 2014).  
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It has previously been shown that GABAR subunit expression changes during 
cellular differentiation and during development, which can result in altered 
sensitivity to GABA and pharmacological agents (Neelands, Zhang, & 
Macdonald, 1999.; Succol et al., 2012), therefore, investigating the changes in 
GABAR subunit expression during NED and throughout IAD could help to 
elucidate the function of GABARs in these cells. Finally, gabapentinoids such as 
gabapentin are increasingly prescribed off label for management of PCa related 
pain. Gabapentin is a known ligand of the 2-2 subunit of voltage-gated calcium 
channels (VGCCs) (Warnier et al., 2015; Zvejniece et al., 2015) and is proposed 
to have an indirect effect upon levels of GABA through altering GABA secretion, 
uptake and metabolism (Lanneau et al., 2001) 
 
1.5 Summary 
In summary, prostate cancer is a highly dichotomous disease which originates as 
a slow growing and often indolent malignancy that can be effectively controlled 
using ADT and curative surgical therapy is common (Bill-Axelson et al., 2014). 
However, for patients whose disease progresses under ADT to CRPC, the 
disease becomes more aggressive with high metastatic potential (Katsogiannou 
et al., 2015). Once metastasised, CRPC remains incurable and current treatment 
strategies only offer modest extension to life (Karantanos et al., 2013). The 
tumour evolutionary paths that can lead to CRPC are varied and complex 
(Feldman & Feldman, 2001; Gundem et al., 2015), however, NED appears to be 
enriched among CRPC patient tumours (Bluemn et al., 2017) and is known to be 
directly inducible by almost all clinically used therapies, including ADT, 
radiotherapy and chemotherapeutics (Deng et al., 2011; Hu et al., 2015a; Wang 
et al., 2018; Yadav et al., 2017). NED is also increasing in prevalence, both due 
to the enhanced efficacy and potency of ADT drugs and the increasing life-span 
of PCa patients (Bluemn et al., 2017).  
 
Research into the mechanisms of ADT induced NED in PCa are critical to 
addressing an unmet clinical need. Currently, there are no targeted therapeutics 
to combat PCa NED, as such, it is vitally important that research identifying key 
components of the NED pathway are identified to facilitate the acquisition of novel 
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therapeutic targets. Finally, the ability to specifically target NED has the potential 
to increase the value of all existing therapeutic options, potentially extending the 
efficacy of ADT and delaying the necessity to apply chemotherapeutics to 
patients. Therefore, the primary goal of this study is to develop and characterise 
an in vitro model of PCa NED to study AD and intermittent AD to investigate the 
hypothesised NED pathway and potentially identify key drivers of the NED 
process. 
 
1.6 Hypothesis and aims 
The current literature, discussed in this chapter, highlights the challenges posed 
by NED of prostate cancer. Chief among which are the induction of NED by a 
variety of current therapeutic strategies, the high therapeutic resistance of PCa 
NED cells and potential for these NED cells to support the survival and growth of 
PCa tumours through paracrine activity. Although the correlation between NED 
and poorer clinical outcome is well established (Grigore et al., 2015), the 
mechanisms by which NED contributes to this effect is largely unknown at a 
molecular level. The reversibility of PCa NED and the effects of intermittent AD 
have never previously been studied, particularly in regard to the molecular drivers 
of NED.  Based upon the core hypothesis that NED is deleterious to the prognosis 
of prostate cancer, the aim of this study was to use a LNCaP based in vitro model 
to investigate the molecular drivers of prostate cancer NED in response to AD  
and identify mechanisms by which NED could contribute to poor outcome. 
Therefore, three projects were undertaken within this study to achieve these 
aims. 
 
1. Characterisation of NED cells and identification of an AD-induced NED 
pathway 
A model of AD-induced NED was established and extensively characterised. This 
allowed for the study of PCa NED morphology and the underlying molecular 
pathways driving NED.  
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2. An investigation into the effects of reintroduction of androgen on gene 
expression and cell morphology and a preliminary investigation into 
Intermittent AD. 
To investigate the morphological and molecular reversibility of PCa NED, a model 
of intermittent ADT was developed and used to study the morphological and 
molecular changes caused by AD cessation and a second period of AD.  
 
3. Investigation of the potential role of GABA receptors in PCa and NED PCa 
cells. 
An assessment of GABAAR and GABABR subunit expression in PCa cell lines 
was performed and the effects of AD and IAD on subunit expression was 
investigated. Finally, the effects of applying GABAergic compounds to these cells 
was also investigated.  
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2. Materials and Methods 
2.1 Cell culture techniques 
2.1.1 Cell lines 
The human androgen-sensitive prostate cancer cell line LNCaP was purchased 
from American Type Culture Collection (ATCC) (CRL-1740). The adherent 
human castrate-resistant prostate cancer cell lines DU-145 and PC-3 were a 
generous gift from Professor Jim Ross at the University of Edinburgh, UK (Tissue 
Injury and Repair Group, Edinburgh Medical School). LNCaP cells were issued 
with STR genotype validation from ATCC. All cell lines were regularly assessed 
for expression of characteristic markers (AR, PSA), consistent morphology and 
growth rate and were subjected to mycoplasma testing. 
 
2.1.2 Cell culture conditions 
LNCaP, DU-145 and PC-3 cells were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium containing 10% (v/v) heat-inactivated foetal bovine serum 
(FBS, Gibco, UK), 2 mM L-glutamine and 100 units/mL (v/v) penicillin and 100 
g/mL streptomycin (Gibco, UK) (complete medium). Cells were grown in T75 
tissue culture flasks (Corning, UK) containing 12 mL of complete medium unless 
otherwise stated. Cells were cultured at 37 °C in a humidified incubator at an 
atmospheric pressure of 5 % (v/v) CO2. The presence of mycoplasma 
contamination was routinely assessed using the Venor®GeM Classic 
Mycoplasma PCR Detection Kit (Cambio, UK). 
 
2.1.3 Passaging cell lines  
Cells were passaged at approximately 80% confluence. Cells were passaged by 
removing culture medium, washing with 10 mL 1 x phosphate buffered saline 
(PBS) and incubation with 2 mL 0.1 % (v/v) trypsin (Gibco, UK) in 0.9% (w/v) 
NaCl (Baxter, UK) for 2 minutes in a humidified incubator at 37 °C. Cells were 
observed by light microscopy (10 x magnification) to ensure dissociation from the 
tissue culture flask before the addition of 8 mL complete medium to deactivate 
the trypsin. Cells were transferred to 15 mL falcon tubes (total volume 10 mL) 
and centrifuged at 148 RCF for 5 minutes in a Universal 320R centrifuge (Hettich, 
Germany). The resultant cell pellet was resuspended in fresh medium and cells 
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were sub-cultured into sterile T75 tissue culture flasks at a ratio of 1:6 for LNCaP 
and 1:10 for DU-145 and PC-3 as per ATCC recommendations. All cell lines used 
for experiments were between passage 8 and 25 (number of times sub-cultured 
since acquisition).  
 
2.1.4 Counting cells 
Cells were trypsinised as previously described in section 2.1.3 and cell pellets 
were resuspended in 10 mL complete medium. A 10 L aliquot of cell suspension 
was pipetted into each chamber of a haemocytometer covered by a glass 
coverslip. Cells were visualised under light microscopy at 10 x magnification and 
cells residing in the middle square of the haemocytometer grid were counted. The 
mean count across both haemocytometer chambers was representative of 1x104 
cells per millilitre and was used to calculate the total number of cells in the 10 mL 
suspension.  
 
2.1.5 Cryopreservation of cell lines 
Cryopreservation solution contained dimethylsulfoxide (DMSO; Sigma, UK) and 
foetal bovine serum (FBS; Gibco, UK) at 1:4 ratio. Cells at 80% confluency were 
trypsinised (see section 2.1.2) and centrifuged at 148 RCF for 5 minutes in a 
Universal 320R centrifuge (Hettich, Germany) to collect the cell pellet. Media was 
removed and the pellet was resuspended in 1 mL complete medium and 1 mL of 
cryopreservation solution was added and mixed by gentle pipetting. Cells were 
transferred in 500 L aliquots into 1.2 mL cryotubes and placed into a Mr Frosty 
(Nalgene) freezing container filled with isopropanol, and stored at -80 °C. For long 
term storage cells were transferred to storage in vapour phase liquid nitrogen.  
 
2.1.6 Reviving cells from liquid nitrogen storage 
Cells were thawed by addition of 1 mL warmed complete medium (37 °C) and 
gently resuspended by pipetting. Cell suspensions were transferred to a 15 mL 
falcon tube and the volume was adjusted to 10 mL with warmed medium. Cells 
were centrifuged at 148 RCF for 5 minutes in a Universal 320R centrifuge 
(Hettich, Germany) and cell pellets were resuspended in fresh complete medium 
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and transferred into a single T75 tissue culture flask. Cells were incubated at 37 
°C until confluent. 
 
2.1.7 Androgen deprivation of prostate cancer cells 
AD was simulated using charcoal-stripped FBS (CS-FBS) in RPMI 1640 medium. 
LNCaP cells were seeded at 1×106 cells in 10 mL of medium in T75 flasks. Cells 
were also seeded into 12-well plates at a density of 2×104 cells in 1 mL medium.  
Cells were grown to approximately 50 % confluence over 48 hours. To simulate 
AD, culture medium was removed and cells were washed with 10 mL sterile 
saline before addition of phenol-red free RPMI 1640 medium supplemented with 
10 % (v/v) heat inactivated CS-FBS, 2 mM L-glutamine, 100 units/mL (v/v) 
penicillin and 100 g/mL streptomycin (CS-Complete Medium). Cells were 
cultured for a further 5-15 days depending on the experiment and culture medium 
was replaced every 3 days, for each timepoint in AD conditions a matched control 
flask was also seeded and cultured in normal media containing 10% FBS and 
harvested at the same timepoint as its matched AD flask. LNCaP cells grown in 
AD conditions were not passaged as this was not necessary, due to extremely 
low growth rate in AD conditions. LNCaP cells grown in control conditions and 
DU-145 and PC-3 cells grown in all conditions were passaged when approaching 
90% confluency. The full media controls were seeded at lower densities to 
minimise the need to passage, when approaching confluence, the cells were split 
at ratios that would ensure they would be at similar confluence to the cells grown 
in CS-FBS. Furthermore, cells were never passaged within 72 hours of being 
harvested to minimise effects of cell stress on gene and protein expression. 
 
2.1.8 Synthetic androgen treatment 
R1881 (Sigma, UK) is a synthetic androgen and considered as the gold standard 
AR agonist, R1881 has extremely high affinity for the AR, R1881 has also been 
shown to bind to progesterone and glucocorticoid receptor (Ho-Kim et al., 1981; 
Singh et al., 2000). Stock concentrations were prepared at 10 M in DMSO. Cells 
were seeded at 1x106 in 10 mL of medium in T75 flasks and cultured in the 
presence of 1 nM or 10 nM R1881 or 0.01 % (v/v) DMSO vehicle control (matched 
flasks for each timepoint) for 5, 10 and 15 days to observe the effect of R1881. 
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Cells were also cultured for 15 days in androgen-deprived culture conditions, then 
treated with R1881 or DMSO vehicle control for a further 15 days. For extended 
incubations (>3 days), culture medium containing R1881 or vehicle control was 
replaced every 3 days. When cells became confluent, they were passaged into 
medium containing R1881 by trypsinisation as described in section 2.1.3.  
 
2.1.9 Muscimol, baclofen and gabapentin drug treatments 
Muscimol is a potent selective agonist of the GABAA receptor (Frolund et al., 
2002), whilst baclofen is a potent selective agonist of the GABAB receptor 
(Woodward et al., 1993). Gabapentin is a gabapentinoid which binds to the 
alpha2delta subunits of voltage-gated calcium channels, where it acts as an 
antagonist, but does not bind directly to either GABAA or GABAB receptors (Gale 
and Houghton., 2011; Calandre et al., 2016). Stock concentrations of muscimol, 
baclofen (Sigma, UK) and gabapentin (GBP) (Tocris, UK) were prepared at 100 
mM in ethanol. Cells were seeded at 1x106 in 10 mL of medium in T75 flasks, 
allowed to reach 50% confluence and then cultured 15 days in AD conditions with 
varying concentrations of muscimol (1, 10 or 100 M) or baclofen (10, 100, 500 
M) added for the final 48 hours. For GBP experiments, cells were cultured in 
complete media to 50% confluence, then treated with GBP (2, 20, 166 M) for 48 
hours. 
 
2.1.10 Harvesting cells 
Cells were harvested on ice. The culture medium was removed and cells were 
washed once with 10 mL ice-cold PBS. PBS was removed and 5 mL ice-cold 
PBS was added to the T75 flask. Adherent cells were dislodged from the flask 
surface using a rubber cell scraper (Corning, UK) and transferred into 15 mL 
falcon tubes before centrifugation at 148 RCF at 4 °C for 5 minutes in a Universal 
320R refrigerated centrifuge (Hettich, Germany). Cell pellets were then 
resuspended in 1 mL ice-cold PBS and transferred to microfuge tubes and 
centrifuged at 835 RCF at 4 °C for 5 minutes in a 5415R refrigerated centrifuge 
(Eppendorf, Germany). The supernatant was aspirated and the cell pellets were 
stored at -80 °C for future experiments.   
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2.1.11 Alamar blue cell viability assay 
To assess cell viability, cells were seeded at a density of 1x103 cells per well in 
96-well plates in 100 L complete culture medium and cultured at 37 °C. After 24 
hours, medium was removed and replaced with 100 L fresh medium containing 
drug treatments at the indicated concentrations. After a further 48 hours, 10 L 
of Alamar Blue 10 x solution was added to each well and incubated for a further 
24 hours at 37 °C protected from light. As a control, wells containing only Alamar 
blue and media were included in addition to wells containing only Alamar blue, 
media and cells as an untreated control. Media containing 2% v/v Triton-X 
(Sigma, UK) was used as a positive control for cell death. Plates were analysed 
by measuring the absorbance at 570 nm and a reference measurement at 600 
nm using an LT-5000MS plate reader and Manta software (LabTech, UK). The 
raw data was processed by subtracting the absorbance of Alamar blue and media 
only from all readings. The control untreated cells were taken to be 100% viable 
and all other readings were expressed as a percentage of this.  
 
2.2 RNA Isolation 
2.2.1 Preparation of nuclease-free water 
Nuclease-free water was prepared by treating distilled water with 
diethylpyrocarbonate (DEPC) (Sigma, UK). DEPC was added to distilled water at 
a final concentration of 0.1 %, mixed and incubated overnight at room 
temperature. The solution was autoclaved for 1 hour at 121 °C and 15 psi in order 
to deactivate the DEPC and allowed to cool to room temperature before use. 
 
2.2.2 RNA isolation 
Total RNA was extracted from cell pellets using TRIsure (Bioline, UK) according 
to manufacturer’s protocol. RNA was extracted from cell pellets, which had been 
stored at -80 °C as previously described in section 2.1.7. TRIsure reagent (1 mL) 
was added to cell pellets and cell membrane disruption was aided by pipetting. 
Samples were incubated for 5 minutes at room temperature before 200 L 
chloroform was added. Samples were shaken vigorously by hand for 15 seconds 
before a further 3-minute incubation at room temperature to allow for phase 
separation. Samples were centrifuged at 13000 RCF for 15 minutes at 4 °C in a 
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5415R refrigerated centrifuge (Eppendorf, Germany). The upper transparent 
phase containing RNA was transferred to a sterile microfuge tube and 
precipitated by the addition of 500 L ice-cold isopropanol (Sigma, UK). The 
mixture was incubated on ice for 30 minutes before samples were centrifuged at 
13000 RCF for 10 minutes at 4 °C in a 5415R refrigerated centrifuge (Eppendorf, 
Germany) to form a pellet. RNA pellets were washed using 1 mL 75% (v/v) 
molecular grade ethanol (Sigma, UK) and gently vortexed before centrifugation 
at 9000 RCF for 5 minutes at 4 °C in a 5415R refrigerated centrifuge (Eppendorf, 
Germany). The supernatant was removed by pipetting and RNA pellets were 
allowed to air dry for 10 minutes at room temperature. RNA pellets were 
resuspended in 20 L DEPC-treated water and stored at -80 °C.  
 
2.2.3 Quantification of RNA by spectrophotometry (Nanodrop 2000) 
Extracted RNA was first analysed via spectrophotometry using NanoDrop 2000 
(Thermo Fisher Scientific, UK) prior to microfluidic analysis to ensure samples 
assessed were within the optimal range of the Bioanalyzer 2100 (Agilent, UK) 
instrument (20-500 ng / L).  DEPC-treated water (1 L) was used as a calibration 
‘blank’ before 1 L RNA in DEPC-treated water was analysed via assessing 
absorbance at 260 nm. The absorbance at wavelengths 260/280 was used as an 
indication of RNA purity, with a ratio of 2.00 considered pure (Gallagher & 
Desjardins, 2006). 
 
2.2.4 Quantification of RNA by microfluidic analysis (Bioanalyser 2100) 
Extracted RNA was also quantified and the RNA integrity assessed by 
microfluidic analysis using a Bioanalyser 2100 (Agilent Technologies, UK). The 
100 bp RNA 6000 NanoLadder was first prepared by heat denaturing at 70 °C for 
2 minutes then cooled on ice. The Nano gel matrix was prepared by filtering 550 
L of the gel through a spin filter column via centrifugation at 1500 RCF at room 
temperature for 10 minutes in a 5415R centrifuge (Eppendorf, Germany). 
Aliquots of 65 L of filtered gel were transferred to fresh microfuge tubes, stored 
at 4 °C and used within a maximum of 4 weeks. In order to prepare the gel for 
the chip, dye was added. RNA 6000 Nano dye concentrate was brought to room 
temperature, vortexed for 10 seconds and pulse centrifuged for 5 seconds in a 
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5415R centrifuge (Eppendorf, Germany) before 1 L of the dye was added to a 
65 L aliquot of gel. Gel-Dye matrix was vortexed and then centrifuged at 13000 
RCF for 10 minutes at room temperature in a 5415R centrifuge (Eppendorf, 
Germany).  
 
RNA samples were diluted to the optimal range (20-500 ng/L) with DEPC-
treated H2O. RNA 6000 Nano chips (Agilent Technologies, UK) were prepared 
by pipetting 9 L gel-dye mix into the well marked ‘G’. The gel was dispersed 
through the chip via gentle pressure using the chip priming station and the 
plunger was depressed for 30 seconds to achieve this. Next, 9 L of the gel-dye 
mix was pipetted into the other 2 wells marked ‘G’ and 5 L of RNA 6000 Nano 
marker was loaded into the sample and ladder wells on the chip. RNA samples 
(1 L) were added to each sample well and 1 L of RNA ladder was added to the 
appropriate ladder well on the chip. The prepared chip was then vortexed for 60 
seconds at 2400 RPM using an IKA vortex mixer (Agilent, UK) and analysed via 
Bioanalyzer 2100, using Agilent 2100 Expert software, generating microfluidic gel 
images, electropherograms and RNA integrity numbers (RIN). Samples with RIN 
>9 were used in quantitative reverse transcription-polymerase chain reactions 
(qRT-PCRs) (Bustin et al., 2009). 
 
2.2.5 Reverse transcription of RNA / cDNA synthesis 
Total RNA (2 μg) was reverse transcribed using the NanoScript 2 RT Premix kit 
(PrimerDesign, UK). Reactions were prepared containing 2 μg RNA in a final 
volume of 20 L containing 1x RT Premix (including dNTPs, random octamers, 
and oligo dT) in 0.2 mL thin-walled reaction tubes. RNA was reverse transcribed 
at 42 °C for 20 minutes before the enzyme was heat inactivated at 72 °C for 10 
minutes, using a programmed thermocycler (Applied Biosystems, UK). It was 
assumed that all reactions had 100% efficiency i.e. created 2 g (c)DNA. The 
resultant complimentary (c)DNA was diluted to 5 ng/L using DEPC-treated H2O 
before use in qRT-PCRs or stored at -20 °C for future use. Control reactions for 
qRT-PCR experiments were prepared by substituting RNA samples with an equal 
volume of DEPC-treated water in the reverse transcription reactions (no template 
control). 
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2.3 Quantification of gene expression 
2.3.1 Oligonucleotide design and preparation 
Oligonucleotides targeting genes of interest were designed to span exon 
boundaries to avoid genomic DNA amplification. They also had annealing 
temperature between 58-60 °C, 18-25 bp in length, 40-60 % guanine and cytosine 
content and amplicon sizes between 100-200 bp. Annealing temperatures were 
calculated using OligoCalc (Justbio, http://www.justbio.com/index. 
php?page=oligocalc) (Kibbe, 2007) and in silico analysis of oligonucleotide 
specificity was performed using the nucleotide basic local alignment search tool 
(BLAST; https://blast.ncbi.nlm.nih.gov) hosted by the National Centre for 
Biotechnology Information (NCBI; Altschul et al., 1990). Alignments of transcript 
variants were performed using MultAlin (Corpet, 1988) 
(http://multalin.toulouse.inra.fr/multalin/) and where possible oligonucleotides 
were designed to target all known splice variants. For AR, oligonucleotides used 
in this study target transcript variants 1 and 2.  The oligonucleotides used in this 
study are shown in Table 2.1 and 2.2.   
 
Validation of qPCR primers involved rigorous in silico and empirical testing both 
during the design of oligonucleotides and after data acquisition. Oligonucleotide 
sequences were screened using NCBI Primer Blast tool in order to confirm that 
only the target gene would be targeted (Ye et al., 2012), any oligonucleotides 
which had any off-target matches were redesigned to be target specific. Where 
possible, oligonucleotides were designed to target all known splice variants of the 
target gene, with the exception of AR for which only variants 1 and 2 were 
targeted (NM_000044.4 and NM_001011645.3, respectively). Initial testing and 
validation of oligonucleotides was performed in qPCR reactions using positive 
control cDNA, for example cDNA derived from human brain for GABA and 
neuronal related genes and LNCaP cells for androgen pathway genes. The 
majority of oligonucleotides were initially tested using end-point PCR where 
production of a PCR product at the expected amplicon size and absence of 
additional products or observable primer dimers on the gel was determined. After 
qPCR reactions had generated melt curves showing a single clear product, the 
melt temperature of this melt curve was cross-referenced with the in silico 
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predicted melt temperature for that gene product using the uMelt tool (Dwight et 
al., 2011). Oligonucleotides which had been validated were then used in 
experiments, where positive and non-RT and water only controls were run 
alongside test samples. The melt curves of test samples were then compared to 
those of positive controls to ensure that the gene product peak was overlapping 
with the positive control. Oligonucleotides targeting GABA receptor subunits and 
CCCs were designed by Dr Amy V. Poole but were still subjected to the same 
extensive validation by Joseph E. Sutton. 
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Table 2.1: Oligonucleotides used in this study for qRT-PCR analysis, 
relevant accession numbers are provided 
Target 
gene 
Accession 
number 
Oligo 
orientation 
Sequence 5’ – 3’ 
AR NM_000044.4 
Forward CACTGCTACTCTTCAGCATTATTCC 
Reverse ATGCAGCTCTCTCGCAATAGG 
GAD1 NM_000817.2 
Forward AACGTACGATACCTGGTGCG 
Reverse TTCTTGGAGGATTGCCTCTCC 
GAD2 NM_000818.2 
 
Forward AAGGTGGCTCCAGTGATTAAAGC 
Reverse AAGTCAATGTCTTGGTGAGTTGCC 
ASCL1 NM_004316.3 
Forward AAGCAGGGTGATCGCACAAC 
Reverse ATGCCTCGCTTAGTTGGCG 
MMP-9 NM_004994.2 
Forward GCACGACGTCTTCCAGTACC 
Reverse CAGGATGTCATAGGTCACGTAGC 
NSE NM_001975.2 
Forward TATCCTGTGGTCTCCATTGAGG 
Reverse TTGCACGCTTGGATGGCTTC 
PSA NM_001648.2 
Forward ATTGAACCAGAGGAGTTCTTGAC 
Reverse AGCACACAGCATGAACTTGGTC 
PTOV1 NM_017432.4 
Forward AACCTGGAGACCGACCAGTG 
Reverse TCTCTGTTGGTGAAGTGGAACTG 
REST NM_005612.4 
Forward ATATGCGTACTCATTCAGGTGAG 
Reverse AATTGAACTGCCGTGGGTTCAC 
SYN NM_003179.2 
Forward TGTAGTCTGGTCAGTGAAGCC 
Reverse ACTCAAGACTGGGCACCTAG 
CD44  
NM_000610.3 
Forward TTGAATATAACCTGCCGCTTTGC 
Reverse CCTTCTATGAACCCATACCTGC 
CD166 NM_001627.3 
Forward TTCTGCCTCTTGATCTCCGC 
Reverse AGCCATCGGGCTTTTCATATTTC 
ITGA2 NM_002203.3 
Forward ACCAGCTGCTCAAGAACAACC 
Reverse CTACATCGCAGGCAACAGAC 
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Table 2.2: List of oligonucleotides used in this study for CCCs, GABAA and 
GABAB receptor subunit expression. GABRA = alpha, GABRB = beta, GABRG 
= gamma, GABRD = delta, GABRT = theta, GABRP = pi, GABBR = GABAB 
Receptor. 
Target 
gene 
Accession 
number 
Oligo 
orientatio
n 
Sequence 5’ – 3’ 
GABRA1 NM_000806.5 
Forward ATCTTCAGCAAAGGAGCACG 
Reverse AAAGACAGTCAGACAGACCTG 
GABRA2 NM_000807.2 
Forward AGCCCATCGCTCCACGCTCTC 
Reverse AGCAGGAATGCATGTTGTAAGATG 
GABRA3 NM_000808 
Forward TTGGGAAGGCAAGAAGGTGC 
Reverse CAACCTGGCCAAGGACACT 
GABRA4 NM_000809 
Forward TGCGGAGTGTCCCATGAGA 
Reverse CTAAGCTGGAAGACTCCTTCG 
GABRA5 NM_000810 
Forward TGAAATTTGGCAGCTATGCGTAC 
Reverse TGTATTCGCCTGTGCTGGTG 
GABRA6 NM_000811 
Forward CAGGACATAATCTAAGACCACAAAC 
Reverse TGCCTCAAGTCAGTCAGTAATCCAATAG 
GABRB1 NM_000812.3 
Forward ATGGTCTGTTGTGCACACAGCAC 
Reverse TCGTGAGCACTTCCGAGCC 
GABRB2 NM_021911.2 
Forward TGATAATGCAGTAACAGGAGTAACG 
Reverse ACGCAATAGACGATGTTGAAGAAG 
GABRB3 NM_000814 
Forward GTCTCGAGGAATGTTGTCTCCG 
Reverse AAGGACACCCACGACAGAATC 
GABRG1 NM_173536.3 
Forward CATGGATGAACATTCCTGTCCAC 
Reverse CTCACACGATCTCTGGGGATTA 
GABRG2 NM_198904.2 
Forward ACAGGAAGCTCAGTCTACTCG 
Reverse GCCAGAAATCTGATGATGACTATGA 
GABRG3 NM_033223.4 
Forward TCCTCAAGATGGATTCCTGAGC 
Reverse CCTGTGTCTATGAGTGTCTGGAT 
GABRD NM_000815.4 
Forward TGTCTCTAGGCATCACCACG 
Reverse TTCTGCTTCTTCCTGTAGTCG 
 
  
  
53 
 
Table 2.2 Continued 
Target 
gene 
Accession 
number 
Oligo 
orientation 
Sequence 5’ – 3’ 
GABRE NM_004961.3 
Forward TTCTGAATGGCAATGTGGTGAGCC 
Reverse TTGATACGAGGATGGCGGAGTTTAG 
GABRT NM_018558.3 
Forward TGGTAGAGAGCTATGGTTACACG 
Reverse TAGACATACTCCAGCAAGGACAG 
GABRP NM_014211 
Forward TCCTTACAGCAGATGGCAGC 
Reverse AGTGCTAGGACTTCTACACAGC 
GABBR1 NM_001470.2 
Forward GACAGATATGGACACACCCAG 
Reverse CCAGGTGAATCGAACGCCA 
GABBR2 NM_005458 
Forward TAGGAAGCCAACCTTCCCTG 
Reverse CACTGCCGCTTCTGGTTGT 
SLC12A1 NM_001184832 
Forward AGTGCCCAGTAATACCAATCGC 
Reverse GCCTAAAGCTGATTCTGAGTCTT 
SLC12A2 NM_001256461 
Forward TGGGTCAAGCTGGAATAGGTC 
Reverse ACCAAATTCTGGCCCTAGACTT 
SLC12A4 NM_001145963 
Forward CCTCATCGTGCTTATCTGCTG 
Reverse GGCTGCTGCGAATGTTGTTC 
SLC12A5 NM_001134771 
Forward AGGAAAGCAGTCCCTTCATCA 
Reverse GCCTCTTCATGCTCCCTACTT 
SLC12A6 NM_001042494 
Forward TCACAGTGATGACGCACTCAA 
Reverse CCAAGATGGACACAATGACACA 
SLC12A7 NM_006598 
Forward CTGGCGGGTCCTACTACATGA 
Reverse AAAATCTCGATGGTCCCCAAAAT 
 
 
2.3.2 qRT-PCR 
qRT-PCR experiments contained 25 ng cDNA at a final concentration of 1.25 
ng/L, 300 nM forward and reverse oligonucleotide (MWG Eurofins, Germany) 
and 1 x PrecisionPLUS qRT-PCR master mix in a final volume of 20 L. 
Reactions were prepared in BrightWhite 96-well plates in triplicate 
(PrimerDesign, UK). Transcripts were amplified and quantified using the 
StepOnePlus qRT-PCR system (Applied Biosystems, UK) using SYBR green 
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detection chemistry with the following instrument settings: 95 °C for 10 minutes 
followed by 40 cycles of; 95 °C for 15 seconds and 58-60 °C annealing 
temperature for 1 minute. Negative controls include a non-RT control and a 
reaction replacing cDNA with DEPC-treated water (template–ve). Amplification of 
a single PCR amplicon was determined by generating melt curves by heating the 
final PCR product from 60 °C to 95 °C in 0.3 °C increments followed by a final 
15-second hold. Melt curves for test samples were compared to those of the 
positive control and no-template control in order to differentiate between the 
desired target gene product and unwanted primer oligomers or potential genomic 
DNA contamination. 
 
2.3.3 Identification of reference genes 
Analysis of candidate reference genes was performed using geNorm 
oligonucleotide kit (PrimerDesign, UK) and qBase+ software (Biogazelle, 
Belgium). A panel of 7 candidate references genes (CYC1, UBC, ACTB, RPL13A, 
ATP5B, SDHA, EIF4A2) was screened against LNCaP, DU-145, PC-3 cells in 
triplicate and using a range of passage numbers. The reference gene with the 
most consistent expression across all cell lines and treatments (ACTB) was 
determined using qBase+ software geNorm M analysis (Biogazelle, Belgium). 
 
2.3.4 Data analysis / quantification of fold change in gene expression 
The expression of unknown target genes were analysed relative to the reference 
gene ACTB as an internal control, and fold change in gene expression was 
calculated using the 2(-ΔΔCt) method (Livak & Schmittgen, 2001). Fold change 
values were calculated using Excel 2016 (Microsoft) as follows: experiments were 
analysed in biological triplicate with average Ct values of reference genes 
subtracted from the average Ct value of the gene of interest to give ΔCt values, 
followed by subtraction of the control group ΔCt from the treatment/comparison 
group ΔCt, these ΔΔCt values were then expressed as 2(-ΔΔCt) to give fold change 
values. The mean fold change values were then plotted as graphs using 
Graphpad Prism 7.0 (GraphPad Software Inc). Results are shown as the mean 
of three independent experiments ± SEM. Unless otherwise stated, qPCR data 
was presented normalised to expression in untreated LNCaP cells (shown as 1) 
with the expression level of other samples shown relative to untreated LNCaP. 
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For time course experiments, each treatment had its own matched untreated 
control which were seeded and harvested at the same time and processed as 
part of the same batches during RNA extraction and cDNA synthesis.  
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2.4 Protein analysis 
2.4.1 Protein extraction 
Cell pellets were lysed in approximately 3 x the pellet volume of lysis buffer (50 
mM Tris pH 8, 150 mM NaCl, 1 mM EDTA, 1 % (w/v) Triton-X and 1 % (v/v) Halt 
protease inhibitor cocktail (Thermo Fisher Scientific, UK)) on ice for 30 minutes. 
Lysates were clarified by centrifugation at 13000 RCF at 4 °C for 5 minutes in a 
5415R refrigerated centrifuge (Eppendorf, Germany) and supernatant containing 
protein was transferred to a sterile, pre-cooled microfuge tube. Protein 
concentration was determined via Bradford assay (Bradford, 1976). Alternatively, 
samples were stored at -80 °C. 
 
2.4.2 Bradford analysis of protein concentration  
Bradford reagent was prepared by dissolving 50 mg of Coomassie Blue G250 in 
50 mL methanol before adding 100 mL 85 % phosphoric acid. The solution was 
diluted to 1 L with dH2O and filtered using a syringe filter to remove any precipitate 
and stored in the dark at 4 °C. Stock bovine serum albumin (BSA) solution was 
prepared at 10 mg/mL and serial dilutions of BSA were prepared in dH2O at 
concentrations of 0.125, 0.250, 0.500, 0.750, 1.00 and 1.50 mg/mL. Cells lysates 
(section 2.4.1) were diluted by 1:5 by adding 1 L of protein sample to 4 L of 
dH2O.  Bradford reactions were prepared in a standard 96-well plate containing 
200 L of Bradford reagent per well and 1 L of either BSA standards or diluted 
protein sample. Blank wells contained only Bradford reagent. BSA standards 
were prepared in a single replicate, whereas protein sample reactions were 
prepared in triplicate. All reactions were mixed thoroughly by pipetting and 
incubated for 5 minutes at room temperature. Samples were analysed using an 
LT-5000MS plate reader (LabTech, UK) using Manta software (LabTech, UK). 
Absorbance at 595 nm was measured and the blank sample background was 
subtracted from all samples. The protein concentration was calculated using a 
standard curve generated by using the bovine serum albumin standard 
concentrations between 0.125 and 1.5 mg/mL from the equation of the line 
(y=mx+c). Final protein concentrations were multiplied by the original dilution 
factor in order to obtain the final estimated concentration. 
  
  
57 
 
2.4.3 Cell protein lysate preparation 
Protein lysates were prepared to a final concentration of 1 g/L in 4 x Loading 
Sample Buffer (LSB) (20 % (w/v) glycerol, 200 mM Tris pH 6.8, 4 % (w/v) SDS, 
10 mM EDTA, 1 % bromophenol blue supplemented with 10 % (v/v) -
mercaptoethanol) in microfuge tubes. Samples were denatured at 95 °C for 5 
minutes in using a heat block before resolution by SDS-PAGE. 
 
2.4.4 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
SDS-PAGE was performed using the method of Laemmli (1970), using the Biorad 
mini-protean electrophoresis system. The resolving gel contained 12 % (w/v) 
acrylamide (30% protogel) (Thermo Fisher Scientific, UK), 375 mM Tris pH 8.85, 
0.1 % (w/v) SDS and 0.08 % (w/v) ammonium peroxidosulphate. The resolving 
gel was polymerised by addition of 0.005 % (w/v) N,N,N′,N′-Tetramethyl-
ethylenediamine (TEMED) and the mixture was pipetted between glass plates up 
to the level of the casting frame hinge. The resolving gel was covered in 2 mL 
isopropanol in order to polymerise the gel in the absence of oxygen. Once 
polymerised the isopropanol was removed and gel rinsed with distilled H2O 
before the stacking gel was added.  
 
The stacking gel contained 5 % (w/v) acrylamide, 130 mM Tris pH 6.8, 0.1 % SDS 
and 0.12 % (w/v) ammonium peroxidosulphate. Stacking gels were polymerised 
by addition of 0.01 % (w/v) N,N,N′,N′-Tetramethyl-ethylenediamine (TEMED) and 
then pipetted onto the resolving gel and a gel comb was inserted into the stacking 
gel. After the stacking gel was fully polymerised, the cast gel was either stored at 
4 °C wrapped in paper towel soaked in 1x Running buffer (25 mM Tris pH 8.3, 
192 mM glycine and 0.1 % (w/v) SDS) or used immediately. Gels were 
submerged in electrophoresis running buffer and PageRuler Prestige protein 
ladder (2 L) (Thermo Fisher Scientific, UK) was loaded onto the first well of the 
gel.  Equal amounts of protein sample were then loaded into the SDS-PAGE gel, 
(typically 10 g) and any vacant wells were filled with an equal volume of loading 
sample buffer to ensure even running of the samples through the gel. Protein 
samples and protein ladder were resolved on the gel via electrophoresis using 
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electrophoresis running buffer at 185 V for 50 minutes or until the loading sample 
buffer dye front reached the bottom of the gel.  
 
2.4.5 Immunoblotting 
Immunoblots were performed by the method of Towbin et al (1979). Resolved 
SDS-PAGE gels were assembled as follows: Sponge, 2 x 3MM paper, gel, 
nitrocellulose membrane, 2 x 3MM paper, sponge in a cassette whilst submerged 
in transfer buffer (25 mM Tris, 190 mM glycine and 20% (w/v) methanol). Air 
bubbles were removed by rolling the sandwich with a falcon tube. The Biorad 
Trans-Blot module was transferred to the electrophoresis tank and submerged in 
cool 1x transfer buffer (25 mM Tris, 190 mM glycine and 20% (w/v) methanol). A 
frozen cool block was also added to the tank to chill the buffer. Proteins were 
electrophoretically transferred onto nitrocellulose membrane at 100 V for 60 
minutes in 1x transfer buffer at 4 °C.  
 
After transfer membranes were blocked with 5 % (w/v) non-fat dried milk powder 
(Marvel) in PBS-Tween (0.1 % v/v) for 1 hour with shaking at room temperature. 
Primary antibodies were prepared in 5% Marvel at a dilution of 1:200-1:1000 and 
incubated with the membrane overnight at 4 °C. After 3 washes in PBS-Tween 
(0.1% v/v) for 5 minutes with shaking, membranes were incubated with IRDye-
conjugated fluorescent secondary antibodies (LI-COR, UK) at 1:10000 in PBS-
Tween containing 0.01% (w/v) SDS, and were protected from light. Membranes 
were washed again 3 times in PBS-Tween (0.1% v/v) for 5 minutes with shaking 
before being analysed using an Odyssey imaging system and ImageStudio 2.0 
Software (LI-COR Biosciences, USA). Digital images of blots were captured using 
ImageStudio 2.0.   
 
2.4.6 Scratch Assays 
LNCaP, DU-145 and PC-3 were cultured in six well plates at a density of 5x105 
cells/well in a total volume of 2 ml RPMI 1640 at 37 °C until a confluent monolayer 
was formed, typically 24 h for DU-145 and PC-3 and 48 h for LNCaP. Wounds 
were created by scratching a single line through the monolayer from the top to 
the bottom of each well with a 200 μl pipette tip. Media was replaced to remove 
cell debris. The wound site was observed by microscopy and images captured at 
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time points 0, 6, 24, 30, 48, 54, 72 and 96 h of one field of view at the vertical 
centre of the wound area (10 x magnification). The rate of wound healing was 
assessed using ImageJ software (Schneider, Rasband, & Eliceiri, 2012) to 
analyse the area of the wound (i.e. surface area in one field of view not covered 
by cells) at each time point. The area was then expressed as a percentage of the 
total original wound area (at 0 h). Each time point was performed with three 
biological replicates. 
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Table 2.3 Primary antibodies used in this study for immunoblotting and 
immunofluorescence. 
Target 
Protein 
Host species Dilution factor 
Source and 
Catalogue 
Number 
Androgen 
Receptor 
(N-20) 
 
Rabbit Polyclonal 1:1000 
Santa Cruz 
Biotechnology 
(SC-816) 
-actin Goat Polyclonal 1:1000 
Santa Cruz 
Biotechnology 
CD44 Mouse Monoclonal 1:1000 
Cell Signalling 
Technology 
(5640) 
hASH1 Rabbit Polyclonal 1:1000 Abcam (Ab74065) 
NSE 
Mouse Monoclonal 
(85F11) 
1:1000 Abcam (Ab16808) 
PSA Goat Polyclonal 1:200 
Santa Cruz 
Biotechnology 
(sc-7638) 
REST Rabbit Monoclonal 1:1000 Abcam (Ab75785) 
GAD65/67 Rabbit Polyclonal 1:1000 Abcam (Ab11070) 
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Table 2.4 Secondary antibodies used in this study for immunoblotting and 
immunofluorescence. 
Name Species Reactivity Dilution factor 
Source and Cat. 
Number 
Alexa Fluor 
568 
Goat anti-mouse 1:10000 
Life Technologies 
(A11029) 
Alex Fluor 488 Goat anti-rabbit 1:10000 
Life Technologies 
(A11008) 
IRDye 800CW Goat anti-mouse 1:10000 
LI-COR 
(926-32210) 
IRDye 680LT Donkey anti-goat 1:10000 
LI-COR 
(926-68024) 
IRDye 800CW Goat anti-rabbit 1:10000 
LI-COR 
(926-32211) 
IRDye 680LT Goat anti-rabbit 1:1000 
LI-COR 
(926-68021) 
 
 
2.5 Immunofluorescence 
2.5.1 Fixing cells 
Paraformaldehyde 4% (w/v) was prepared by adding 40 g of paraformaldehyde 
powder (Sigma, UK) to 800 mL PBS and dissolved using a heated stirring block 
and stirrer bar at 60 °C. To facilitate the dissolving of the paraformaldehyde 
powder, sodium hydroxide was added until the solution became clear and the 
total volume was adjusted to 1 L with 1x PBS. The solution was stored at 4 °C.   
 
At day 15 of culture, LNCaP cells were fixed by removing medium and incubating 
with 800 L 4 % paraformaldehyde for 20 minutes at room temperature. Cells 
were washed three times with PBS and incubated for 1 hour at room temperature 
with blocking buffer (20 % v/v Goat Serum in PBS) containing 0.2 % (v/v) Triton-
X to block and permeabilise the cells.  
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2.5.2 Immunofluorescent staining of cells 
Cells fixed on coverslips were washed three times with PBS then incubated with 
primary antibodies at a dilution of 1:1000 in PBS containing 2 % (v/v) goat serum 
and 0.2 % (v/v) Triton-X, overnight at 4 °C. Cells were then washed in PBS and 
incubated with Alexa Fluor secondary antibodies at 1:1000 dilution in PBS 
containing 2 % (v/v) goat serum and 0.2 % (v/v) Triton-X for one hour at room 
temperature in the dark. Cells were washed again in PBS before mounting face 
down on microscope slides using VECTASHIELD mounting reagent containing 
DAPI (Vector Laboratories, UK). Mounted coverslips were air dried for 10 
minutes. Excess mounting medium was removed using paper towel and 
coverslips were sealed used nail varnish and allowed to set overnight at 4 °C. 
Prepared microscope slides were stored at 4 °C in the dark until being imaged on 
a Confocal LSM 880 microscope (Zeiss, UK).  
 
2.5.3 Confocal microscopy 
For confocal microscopy, cells were grown on glass coverslips as per section 
2.5.1. Cells were visualised using an LSM 880 Confocal microscope (Zeiss, UK) 
operated using Zen Black software (Zeiss, UK) at 20 x magnification. Cells were 
imaged using 8x8 tile scan and these images were used to select several 
representative areas of the cell monolayer to image at higher resolution. Cells 
were then imaged at 63 x magnification using oil immersion. Settings for laser 
power and channel gain were optimised using positive samples to ensure 
saturation in each channel did not occur and these acquisition settings were 
applied when viewing each microscope slide to ensure consistency as per North, 
(2006). Representative images were captured at 1024 x 1024 resolution in .czi 
format and exported in .tiff format. Any brightness and contrast adjustments to 
aid visual presentation were made uniformly. Scale bars were generated using 
Zen Blue software from original captured images (Zeiss, UK). 
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2.5.4 Neurite outgrowth staining kit 
To quantify the length of neurite-like projections from androgen-deprived LNCaP 
cells the Neurite Outgrowth Staining Kit (Thermo Fisher Scientific, UK) was 
utilised. LNCaP cells were seeded on 13 mm sterilised glass coverslips in 12-well 
plates (Corning, UK) at a density of 2 x104 cells per well. Cells were grown for 48 
hours at 37 °C in 5 % CO2 to 50 % confluence before replacing complete medium 
with appropriate treatment medium. Control LNCaP cells were grown in phenol 
red-free RPMI1640 medium supplemented with 10% (v/v) FBS, whereas 
androgen-deprived LNCaP cells were grown in the same medium but 
supplemented with 10% CS-FBS (Sigma, UK). According to manufacturer’s 
instructions, 1 x solution of Fix/Stain Solution was prepared by combining 10 L 
cell viability indicator and 10 L cell membrane stain in 10 mL 4 % (v/v) 
formaldehyde in PBS. Media was removed from wells; cells were washed with 
PBS and 800 L of 1 x Fix/Stain Solution was added to each well and incubated 
for 20 minutes at room temperature. A 1 x solution of background suppression 
dye was prepared by adding 120 L of the 100 x concentrate to 12 mL of PBS. 
The Fix/Stain Solution was removed and 800 L of background suppression dye 
was added and incubated at room temperature for 10 minutes. Glass coverslips 
containing fixed and stained cells were removed from wells and washed 5 times 
in PBS, dried and mounted face down onto microscope slides using 
VECTASHIELD Mounting Media containing DAPI as per section 2.5.2.  
 
2.5.5 Neurite outgrowth analysis  
Prepared microscope slides were imaged using a Confocal LSM 880 microscope 
(Zeiss, UK). Representative images were captured using a 20x/0.8 objective 
using a 5 x 5 tile scan to capture 3 separate areas of the slide across 3 different 
slides for control and androgen-deprived samples. The average length of cell 
bodies was calculated by measuring 100 cell body lengths using Zen Blue 2.3 lite 
software (Zeiss, UK). Neurite-like projections were then measured using the 
same software package, measuring 100 neurites per tile scan image. Projections 
that were greater than twice the average cell body length were considered to be 
neurite-like (Wang et al., 2012). Data was graphed and statistical analysis 
performed using Graphpad Prism 7.0 software (Graphpad software Inc.). 
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2.6 Analysis of statistical significance 
Graphpad Prism 7.0 (Graphpad Software Inc) was used to perform statistical 
analysis for qRT-PCR and neurite outgrowth experiments. Results are shown as 
the mean of three independent experiments ± SEM. SEM was used as it is 
descriptive of the expected variance in the mean of a specific determined value 
(e.g. fold change in gene expression), whereas the standard deviation would be 
more indicative of the range in which the individual values could occupy. 
Significance was determined using one-way ANOVA with Dunnett’s correction (p 
< 0.05).   
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3. Elucidating the molecular mechanisms of 
neuroendocrine differentiation of prostate cancer cells 
 
3.1 Introduction 
3.1.1 Characterisation of PCa cell lines 
Before investigating the effect of AD on PCa cell lines and the NED process, it 
was important to characterise and validate the cell lines used in this study and 
ensure that they displayed typical characteristics previously reported in the 
literature. Characterisation of the LNCaP, DU-145 and PC-3 cell lines involved 
the use of morphological analysis via microscopy, assessment of their growth 
and invasive potential using scratch assays and an assessment of key genes and 
proteins in an untreated state. This characterisation then continued to investigate 
the response of these cell lines to AD by culturing them in media containing 
charcoal-stripped FBS and determining responses at the morphological and 
molecular level.  
 
Fluorescent microscopy was also used to assess for the growth of neurite-like 
projections in response to AD, a phenomenon which has previously been 
reported as a morphological marker of PCa NED in vitro (Rapa et al., 2013; 
Farach et al., 2016). Scratch assays allowed for an initial comparison of 
androgen-sensitive LNCaP to castrate-resistant DU-145 and PC-3 cells in terms 
of their ability to close the scratch area, giving an insight in the aggressive growth 
and invasive characteristics of these different cell lines.  
 
On a molecular level, it was important to assess the expression of key genes and 
proteins that this study proposes as key drivers, readouts and effectors of NED 
and the potentially tumour modulatory mechanisms of PCa NED. This included 
an initial assessment of AR and PSA expression as these are extremely widely 
studied in these cell lines, thereby acting as an initial validation that LNCaP cells 
express the AR and have functional AR-signalling evidenced by PSA expression, 
whilst DU-145 and PC-3 are known to be AR and PSA negative. Next it was 
important to determine the expression of putative PCa cancer stem cell markers 
CD44, CD133 and CD166 in order to confirm previous reports that NED was 
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unlikely to be facilitated by a cancer stem cell niche (Sauer et al., 2006). 
Characterisation of the proposed NED pathway was then a priority, seeking to 
establish the basal expression of the instigators (PTOV1, hASH1), the preventers 
(REST), the biomarkers (NSE), the potential for GABA synthesis (GAD1) and a 
proposed downstream effector of NED (MMP-9) across all three cell lines.  
 
Having characterised these cell lines in a basal state, It was then important to 
verify their response to androgen deprivation. This was a two-stage process, first 
in assessing the morphological and molecular changes in response to AD at 
multiple time points (5, 10 and 15 d), then to establish whether these observed 
changes were specific to a reduction in androgen by culturing cells in AD 
conditions with the addition of a synthetic androgen (R1881) at concentrations 
used extensively throughout the literature (Bluemn et al., 2018; Vander Griend et 
al., 2014; DaSilva et al., 2009). Finally, to further investigate the activity of the 
proposed PCa NED driver hASH1, confocal microscopy was used to determine 
the cellular localisation of transcription factor hASH1 throughout the NED process 
alongside expression of NED biomarker NSE. The experiments in this chapter 
were critical to the validation and characterisation of the LNCaP, DU-145 and PC-
3 cell lines and provided both the confidence and foundational data to utilise the 
LNCaP cell line as a model of AD induced PCa NED. These experiments were 
also critical in identifying hASH1 as a potentially key transcription factor to the 
NED process. 
 
3.1.2 Castrate-resistant prostate cancer and study justification 
Long-term adjuvant and neo-adjuvant ADT is currently the standard of care for 
prostate cancer patients with locally advanced disease and is maintained 
throughout disease progression, including CRPC, in accordance with European 
Association of Urology guidelines (Heidenreich et al., 2014). Therefore, 
investigating mechanisms by which prostate cancer is able to adapt to the 
selective pressure of ADT and become castrate-resistant is critically important. 
CRPC tumours possess a more aggressive phenotype and are incurable once 
they have metastasised (Beltran et al., 2011). Elucidating the mechanisms 
facilitating resistance to AD will allow for more informed ADT treatment strategies 
and contribute to identifying new therapeutic targets. Optimisation of ADT and 
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extending the window of ADT efficacy has the potential to extend patient survival 
times and improve quality of life (Karantanos et al., 2013).  
 
One mechanism by which prostate cancer cells can escape the efficacy of ADT 
is neuroendocrine differentiation (NED) (Bonkhoff, 2001). Neuroendocrine (NE) 
cells comprise around 1% of the healthy prostate (Parimi et al., 2014) and are 
thought to have roles in regulating the secretory functions of the prostate gland, 
as well as guiding the differentiation and growth of epithelial prostate cells during 
development (Cox et al., 1999; Yuan et al., 2007). Neuroendocrine prostate 
cancer (NEPC) arising de novo is rare (Parimi et al., 2014; Beltran et al., 2011). 
However, features associated with NED, such as NED biomarkers neuron-
specific enolase (NSE) and Chromogranin-A (CGA) become commonplace in 
advanced prostate cancer and are correlated with poor prognosis for disease 
progression and overall survival (Bonkhoff, 2001; Komiya et al., 2009).  
 
 
Figure 3.1 Schematic diagram illustrating the enrichment of 
neuroendocrine phenotype cells in some prostate cancer tumours treated 
with androgen deprivation therapy. 
 
Enrichment of the NE cell niche is thought to arise through differentiation of 
epithelial prostate cancer cells, rather than from the prostate cancer (PCa)  stem 
cell population or existing NE cells (Sauer et al., 2006). In the developing 
prostate, androgen receptor (AR) signalling is vital for differentiation and 
maintenance of cells to the epithelial phenotype (Fig. 3.1) (Wilson, 2011). In the 
absence of AR signalling, healthy prostate cells undergo apoptosis, resulting in a 
vast reduction in size of the prostate gland (Wilson, 2011). However, some 
androgen-sensitive prostate cancer cells can survive and differentiate into a NE 
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phenotype in the absence of androgen (Fig 3.1) (Hu, Choo, & Huang, 2015). The 
precise molecular mechanisms facilitating this change, remain to be elucidated.  
 
The phenomenon of prostate cancer NED in response to ADT has been known 
for over two decades. NED was first observed in vivo using haematoxylin and 
eosin (H&E) staining and immunostaining for chromogranin-A (Di Sant’Agnese, 
1992) and also demonstrated in vitro in LNCaP prostate cancer cells (Shen et al., 
1997). The vast majority of research into NED in prostate cancer has focused 
upon identifying the treatment-based causes of NED, such as AD (Shen et al., 
1997) and ionizing radiation (Deng et al., 2008). Tumour microenvironment 
causes of NED such as hypoxia (Danza et al., 2012) and IL-6 secretion (Zhu et 
al., 2014) have also been described. Several NED biomarkers have previously 
been evaluated such as neuron-specific enolase (NSE), chromogranin-A and 
synaptophysin and these are now widely used in PCa NED studies (Bonkhoff, 
2001; Kamiya et al., 2003).  
 
In terms of research investigating the molecular pathways between the driver of 
NED and the resulting increase in NED biomarker expression and morphological 
change, there have been some studies investigating the roles of transcription 
factors snail family transcriptional repressor 1 (SNAI1) (McKeithen et al., 2010) 
and human achaete-scute homolog-1 (hASH1) (Rapa et al., 2008, 2013). These 
studies have demonstrated that transduction of hASH1 is associated with 
increased expression of NED markers chromogranin-A and synaptophysin (Rapa 
et al., 2013). Furthermore, hASH1 staining has previously been found in the 
nuclei of human PCa samples co-expressing chromogranin-A (Rapa et al., 2008).  
 
PCa NED is induced  by a variety of stimuli, including clinically-used therapies 
such as ADT and radiotherapy (Hu et al., 2015). NE-like cells are also known to 
have increased resistance to ADT, radiotherapy and chemotherapeutic 
interventions (Hu et al., 2015) and may be able to confer aspects of these 
advantages to other cell types within a PCa tumour through paracrine signalling. 
Therefore, research focus in this field has shifted to elucidating molecular 
pathways underpinning the NED process, which remains unclear, and could 
facilitate identification of potential biomarkers or novel therapeutic targets (Li, 
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Zhang, & Zhang, 2016). Finally, identifying the molecular components of the NED 
pathway could allow for earlier detection of NED. This could enable earlier 
selection of patients to receive non-AR targeting therapies, such as platinum 
chemotherapy, which are more effective against NED cancer cells (Beltran et al., 
2016).  
 
3.1.3 Hypothetical NED pathway 
Nuclear localisation of transcription factor Human achaete-scute homolog 1 
(hASH1) is a critical step in the formation of neurons during canonical 
neurogenesis (Kasim et al., 2016). Transduction of hASH1 to supraphysiological 
concentrations promotes an NE phenotype in prostate cancer cells (Axelson, 
2004; Rapa et al., 2008). Whilst expression of hASH1 is constitutively repressed 
in non-neuronal cells, aberrant expression of hASH1 could potentially be 
facilitated by Prostate Tumour Overexpressed 1 (PTOV1) overexpression, a 
common occurrence in prostate cancer carcinogenesis (Benedit et al., 2001; 
Cánovas et al., 2015). PTOV1 acts as a Notch1 signalling repressor (Alaña et al., 
2014). Since Notch1 signalling is fundamental to maintenance of cell fate  (Lai, 
2004), it is proposed that PTOV1 overexpression may allow prostate cancer cell 
fate to become increasingly malleable, allowing activation of different cell-
differentiation programs.  
 
The complete pathway facilitating NED remains to be clarified in an AD model at 
a molecular level. The extent of molecular reversibility of this proposed pathway 
in response to cessation of AD also remains unclear. The use of intermittent ADT 
(IADT) has long been touted as a possible clinical solution to the long-term effects 
of ADT, both to improve quality of life to patients by restoring sexual function and 
to delay onset of ADT resistance (CRPC) (Bruchovsky et al., 2000; Grossfeld et 
al., 2001; Klotz et al., 1986; Goldenberg et al., 1995; Oliver et al.,  1997). 
However, the effects of repeated bouts of ADT and therefore, potential 
differentiation events, have also not been studied in-depth at a molecular level. 
Furthermore, whilst hASH1 has been tentatively described as a potential 
therapeutic target for small cell lung cancer which shares many features with NED 
in PCa (Demelash et al., 2012; Nishikawa et al., 2011; Osada et al., 2008; Osada, 
Tatematsu et al., 2005), its utility in prostate cancer NED and role in AD 
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resistance remains to be proven. Providing insights into the NED pathway and its 
potential downstream effects is extremely valuable and could allow for clinicians 
to make more informed, evidenced-based choices in regards to ADT and IADT. 
 
3.1.4 Study aim and research questions 
Study aim: To establish and characterise an in vitro model of AD induced NED 
using androgen-sensitive LNCaP cells cultured in low androgen conditions to 
mimic the effects of ADT.  
 
Research questions: (1) What are the key molecular components underpinning 
the NED process in response to AD? (2) To what extent are NED cells neuronal-
like? (3) Can NED be induced specifically by AD? 
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3.2 Results 
3.2.1 Characterisation of prostate cancer cell lines 
In order to begin creating a model of prostate cancer disease progression, it was 
necessary to select and characterise a range of PCa cell lines which accurately 
recapitulate androgen-sensitive and castrate-resistant disease. In this study, 
LNCaP prostate cancer cells were used as a model of androgen-sensitive PCa 
and have been used previously for PCa NED studies (Farach et al., 2016; Rapa 
et al., 2013). In addition, the two classical prostate cancer cell lines DU-145 and 
PC-3 were used as a comparison and are well established models of castrate-
resistant prostate cancer (Alimirah et al., 2006). 
 
The LNCaP cell line was originally derived from a lymph node metastasis 
(Horoszewicz et al., 1983) and has become the prominent cell line used for 
androgen-sensitive prostate cancer research. PC-3 cells were first harvested 
from a bone metastasis (Kaighn et al., 1979) and DU-145 cells were derived from 
a brain metastasis (Stone et al., 1978) and as metastatic CRPC cells they are 
models of late-stage terminal disease (Karantanos et al., 2013). The inclusion of 
these three prostate cancer cell lines in this study allowed for the comparison 
between an androgen-sensitive model of prostate cancer and two models of 
castrate-resistant prostate cancer. These cell lines were subjected to extensive 
molecular and morphological characterisation to assess the differences between 
androgen-sensitive and CRPC cells and their response to AD treatments. 
 
3.2.2 Molecular characterisation of prostate cancer and CRPC cells 
Exploratory analysis in CRPC cell lines was performed using end-point PCR (data 
not shown), in which an initial ‘wide net’ of genes was consolidated to a focussed 
selection of transcriptional programs including the androgen axis, cancer stem 
cell (CSC) markers and NED. These initial experiments also contributed to the 
optimisation of PCRs and the development of a robust array of highly specific 
oligonucleotides for the genes of interest for this study. Following these initial 
experiments and the validation of the oligonucleotides, a quantitative analysis of 
gene expression in CRPC cells and androgen-sensitive LNCaP cells was 
conducted using qRT-PCR.  
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3.2.2.1 Androgen receptor and prostate-specific antigen expression 
AR expression was assessed in LNCaP, DU-145 and PC-3 cells via qRT-PCR 
(Fig. 3.2A) and AR expression was only detectable in LNCaP cells. Expression 
of AR protein was also only detected in LNCaP cells via immunoblot (Fig. 3.2C), 
bands visible on the immunoblot below 110 KDa are likely to be degraded forms 
of the AR protein or non-specific binding of the SC-816 antibody. PSA expression 
is driven by androgen receptor signalling as the kallikrein 3 (KLK3) gene which 
encodes PSA contains an androgen response element (ARE) (Luke and Coffey, 
1994). This makes PSA expression a useful indicator of AR signalling (Kim & 
Coetzee, 2004). PSA expression was detected in androgen-sensitive LNCaP 
cells, but was undetectable in DU-145 and PC-3 via qRT-PCR and 
immunoblotting (Fig. 3.2 panels B and C). Analysis of AR and PSA expression 
confirmed that the LNCaP, PC-3 and DU-145 cells used in this study are 
consistent with the previously published literature on these cell lines (Yadav et 
al., 2017). 
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Figure 3.2. Androgen receptor (AR) and prostate specific antigen (PSA) 
expression in androgen-sensitive LNCaP and castrate-resistant DU-145 and 
PC-3 prostate cancer cells. A. Expression of A. AR and B. PSA in LNCaP, DU-
145 and PC-3 prostate cancer cells was analysed by qRT-PCR and expressed 
as relative mRNA level normalised to ACTB (2-ΔΔCt). Data presented as mean ± 
SEM, (n=3), Not Detected (N.D). C. Representative immunoblot images of AR 
and PSA expression in LNCaP, DU-145 and PC-3 cells, -actin was used as a 
loading control.
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3.2.2.2 Prostate cancer stem-like cell marker expression 
As PCa stem-like cells do not express androgen receptor, they are inherently 
resistant to AD (Tu & Lin, 2012) and expression of PCa stem-like cell biomarkers 
is associated with higher tumorigenic and metastatic ability (Patrawala et al., 
2006; Tu & Lin, 2012). CD44, CD166 and ITGA2 are putative biomarkers of PCa 
stem-like cells (Patrawala et al., 2006; Reyes et al.,  2013; Tu & Lin, 2012; Zhang 
& Waxman, 2013).  
 
Expression of CD44, CD166 and ITGA2 was assessed to investigate differences 
in the PCa CSC marker expression between androgen-sensitive LNCaP cells and 
CRPC cell lines, DU-145 and PC-3. Expression of CD44, CD166 and ITGA2 was 
significantly higher in CRPC cell line DU-145 compared to androgen-sensitive 
LNCaP cells (Fig. 3.3). Interestingly, PC-3 cells did not show significantly higher 
expression of the three PCa stem-like cell markers, despite also being a castrate-
resistant cell line. Although DU-145 showed highest expression of CSC markers 
CD44, CD166 and ITGA2, expression in LNCaP and PC-3 was also robust. 
These findings indicate that expression of CSC markers is a feature of both 
androgen-sensitive and CRPC cell lines. 
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Figure 3.3.  Expression of cancer stem cell (CSC) markers in androgen-
sensitive LNCaP and castrate-resistant DU-145 and PC-3 prostate cancer 
cells.  Expression of CD44, CD166 and ITGA2 mRNA in LNCaP, DU-145 and 
PC-3 cells were analysed by quantitative qRT-PCR and expressed as relative 
expression normalised to ACTB (2-ΔΔCt). Data presented as mean ± SEM, n=3. 
One-way ANOVA with Dunnett’s correction was performed, p < 0.05 (*), p <0.01 
(**) and p < 0.001 (***).  
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3.2.2.3 Initial analysis of core protagonists in the NED pathway; biomarker, 
repressor and neurotransmitter synthesis. 
As an initial investigation of the hypothetical NED pathway, three ‘checkpoints’ 
were assessed in androgen-sensitive (LNCaP) and CRPC cells (DU-145 & PC-
3); A clinical biomarker of NED (NSE), a canonical repressor of neurogenesis 
(RE1-silencing transcription factor) and a neurotransmitter synthesis enzyme 
(GAD1).  
 
NSE is a glycolytic metalloenzyme (Rech et al., 2006). Expression of NSE occurs 
late into neuronal differentiation. It is therefore considered to be a marker of 
mature neurons (Isgro et al.,  2015). NSE is a clinical biomarker used to detect 
both primary NEPC and NED of PCa via immunohistochemistry (Isgro et al., 
2015; Komiya et al., 2013). NSE is considered to be one of the best and most 
studied biomarkers for this disease state (Komiya et al., 2013). 
 
RE1-silencing transcription factor (REST) is a master negative regulator of 
neurogenesis which can control the expression of hundreds of neuronal genes 
(Gao et al., 2011). Transcription factor hASH1 is a canonical promoter of 
neurogenesis and is a specific target gene of REST (Gao et al., 2011). Glutamate 
decarboxylase 1 (GAD1) is involved in the synthesis of -aminobutyric acid 
(GABA) from L-glutamic acid (Ippolito & Piwnica-Worms, 2014). GABA has 
previously been implicated in increased aggressive and metastatic activity  of 
prostate cancer (Azuma et al., 2003) and decreased disease free survival 
(Ippolito & Piwnica-Worms, 2014). Expression of GAD1 has also been reported 
to be increased in castrate-resistant prostate cancer cells compared to androgen-
sensitive prostate cancer cells (Ippolito & Piwnica-Worms, 2014). Therefore, to 
assess key points in the proposed NED pathway between androgen-sensitive 
and CRPC cells, expression of neuron-specific enolase (NSE), RE1-silencing 
transcription factor (REST) and glutamate decarboxylase 1 (GAD1) was 
investigated using qRT-PCR (Fig. 3.4).  
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Figure 3.4. Expression of neuroendocrine differentiation (NED)-related 
genes in androgen-sensitive and castrate-resistant prostate cancer cells. 
Basal expression of neuron-specific enolase (NSE), RE1-silencing transcription 
factor (REST) and glutamate decarboxylase 1 (GAD1) mRNA in LNCaP, DU-145 
and PC-3 cells were analysed by qRT-PCR and expressed as relative mRNA 
level normalised to ACTB (2-ΔΔCt). Data presented as mean ± SEM, (n=3). One-
way ANOVA with Dunnett’s correction was performed, p < 0.05 (*), p <0.01 (**) 
and p < 0.001 (***).  
 
Expression of the neuronal marker, NSE, was 38-fold higher in DU-145 cells 
when compared to LNCaP cells (p = 0.02), suggesting a higher degree of NED. 
Interestingly, expression of REST and GAD1 mRNA was also significantly higher 
in DU-145 cells, with 3-fold higher REST expression (p = 0.03) and 10-fold higher 
GAD1 expression (p = <0.001) compared to LNCaP cells. PC-3 cells displayed 
higher expression of NSE than LNCaP cells, although this was not statistically 
significant. Expression of REST and GAD1 was similar between LNCaP and PC-
3 cells (Fig. 3.4). Higher expression of neuronal marker, NSE, and GABA 
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synthetic enzyme, GAD1 would appear to suggest that DU-145 cells display 
increased evidence of NED compared to androgen-sensitive LNCaP cells. 
Interestingly, gene expression of REST, which represses neurogenesis, was also 
higher in DU-145 cells which is converse to what would be expected, considering 
the higher expression of NSE. However, this result is consistent with that of Lin 
et al., 2016 who found REST mRNA expression was unchanged after NED 
whereas REST protein was markedly downregulated. To support and validate the 
findings of qRT-PCR experiments, expression of key marker proteins in LNCaP 
DU-145 and PC-3 cells was analysed using immunoblotting (Fig. 3.5).   
 
 
 
Figure 3.5. Analysis of basal expression of key prostate cancer markers. 
Representative immunoblots showing expression of CD44 and glutamate 
decarboxylase (GAD65/67) in LNCaP, DU-145 and PC-3 PCa cells. Beta actin 
was used as a loading control. 
 
In contrast to qRT-PCR analysis of CD44 gene expression (Fig. 3.3), CD44 
protein was only detected in CRPC cell lines DU-145 and PC-3 (Fig. 3.5). 
Interestingly, higher CD44 expression has also been previously found in prostate 
cancer cells co-expressing higher levels of NED markers NSE and 
Chromogranin-A  (Hu et al., 2015; Palapattu et al., 2005). GAD65/67 protein was 
detected in all three cell lines (Fig. 3.5), in accordance with the qRT-PCR data 
(Fig. 3.4), suggesting that both androgen-sensitive LNCaP cells and CRPC cell 
lines may have -aminobutyric acid (GABA) synthesis potential (Ippolito & 
KDa
KDa
KDa
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Piwnica-Worms, 2014). Interestingly, the 10-fold higher relative GAD1 gene 
expression in DU-145 cells compared to LNCaP cells observed via qRT-PCR 
analysis was not reflected at a protein level (Fig. 3.5). In addition, CD44 was 
robustly expressed in both CRPC cell lines but undetectable in LNCaP, indicating 
that castrate-resistant cell lines display increased expression of at least one PCa 
stem cell marker.  Furthermore, expression of GAD65/67 indicates that these cell 
lines may be able to synthesise GABA, a neurotransmitter previously 
demonstrated to increase the metastatic potential of prostate cancer cells 
(Azuma et al., 2003). 
 
3.2.3.1 Androgen-sensitive LNCaP cells display significantly slower 
growth in scratch assays compared to CRPC cell lines 
A comparative assessment of growth and potential for migration of LNCaP, DU-
145 and PC-3 cells was conducted using wound healing assays which were used 
to quantitatively asses the time taken to close a wound made in a confluent 
monolayer of cells. These experiments also allowed for the observation of cells 
migrating into the centre of a wound area via light microscopy. Images of the 
wound area were captured at regular time points (Fig 3.6A) and quantified using 
ImageJ (Fig 3.6B) (Schneider et al., 2012). DU-145 cells displayed the fastest 
rate of wound closure, taking on average 24 h to fully close the original wound 
area. PC-3 cells took on average 96 h to close the original wound area and 
LNCaP cells displayed the slowest rate of wound closure, with 70% of original 
wound area still intact after 120 h. Images captured throughout the wound closure 
process showed that PC-3 cells consistently displayed greater migration into the 
centre of the wound at earlier time points than DU-145 cells despite an overall 
slower rate of wound closure. LNCaP cells showed minimal cellular migration into 
the centre of the wound area. The wound healing assay demonstrated the 
potentially more aggressive nature of castrate-resistant DU-145 and PC-3 cells 
which were considerably faster at wound closure than androgen-sensitive LNCaP 
cells.   
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Figure 3.6. Wound closure and migration of prostate cancer cell lines 
assessed via scratch assays. A. Images captured at time points 0, 24 and 48 
(h) of androgen-sensitive LNCaP and castrate-resistant DU145, PC-3 cells. As 
only LNCaP cells had remaining wound area at 120 h, measurements for DU-145 
and PC-3 were not taken at this time point. B. Graph showing the percentage of 
wound healing over time of prostate cancer cell lines LNCaP, DU-145 and PC-3. 
Wound area was quantified at designated time points using ImageJ. Mean ± 
SEM, (n=3). Images were captured of one field of view at the vertical centre of 
the wound area. The rate of wound healing was assessed using ImageJ software 
(Schneider, Rasband, & Eliceiri, 2012) to analyse the area of the wound (i.e. 
surface area in one field of view not covered by cells) at each time point. The 
area was then expressed as a percentage of the initial wound area.  
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3.2.4.1 Androgen deprivation triggers a neuroendocrine differentiation 
program in androgen-sensitive prostate cancer cells 
To assess the morphological and molecular effects of AD on prostate cancer, 
LNCaP, DU-145 and PC-3 cells were cultured in either standard, complete RPMI 
1640 media or, media containing charcoal-stripped FBS. Charcoal-stripped FBS 
contains a much lower level of androgen (Cao et al., 2009) and was therefore 
used to simulate AD for 0, 5, 10 and 15-days (Fig. 3.7), the 15-day time span was 
chosen as this has previously been shown to result in well-established NED 
phenotype in LNCaP cells (Rapa et al., 2013).  
 
 
Figure 3.7. Schematic diagram indicating the experiment design for 
androgen deprivation experiments. LNCaP cells were cultured in either control 
media (C) or androgen deprived (AD) media which contained charcoal-stripped 
FBS, for 5, 10 and 15-days.  
 
LNCaP, DU-145 and PC-3 cells were analysed by bright field microscopy (Fig. 
3.8). At day zero LNCaP, DU145 and PC-3 display typical epithelial morphology 
with few outgrowths or projections from the cell membrane. By 5 d, androgen-
sensitive LNCaP cells displayed noticeable changes in morphology, including 
development of short cytoplasmic protrusions (Fig. 3.8). These became extensive 
after 10 d in the absence of androgen by 15 d (indicated by black arrows in Fig. 
3.8). The outgrowth of neurite-like processes from these cells supports the 
hypothesis that androgen-sensitive LNCaP cells become more neuronal-like in 
response to AD. In addition, the increasing length, complexity and inter-cellular 
contact of these neurite-like extensions over time suggests that these cells 
5 10 15 days
C
C
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0
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become more mature in their neuronal differentiation (Mingorance-Le-Meur & 
O’Connor, 2009). Castrate-resistant cell lines, DU-145 and PC-3, did not display 
any observable morphological changes across 15 d AD, resembling untreated 
control cells throughout (Fig. 3.8). It must be acknowledged that images were not 
captured for LNCaP, DU-145 or PC-3 cells grown in control conditions at a 15 d 
timepoint, which is a clear limitation of this experiment, however they were for 
LNCaP in subsequent experiments (Fig. 3.10). 
 
 
 
Figure 3.8, Androgen-sensitive LNCaP cells undergo morphological change 
in response to androgen deprivation. Representative images of LNCaP, DU-
145 and PC-3 cells at 0 days (cells in control RPMI 1640 with 10% FBS) and 5, 
10 and 15 d after culture in AD conditions (RPMI 1640 with 10% charcoal-stripped 
FBS). Cell morphology was recorded using bright field microscopy (20 × 
magnification). Arrows point to neurite-like extensions. 
 
The impact of AD on AR signalling was also assessed by qRT-PCR (Fig. 3.9 
panel A) and immunoblot (Fig 3.9 panel B).  After 5 d of AD, qRT-PCR analysis 
revealed that expression of AR was slightly elevated (1.42-fold) in LNCaP cells, 
whilst PSA was down-regulated 14.23-fold compared to untreated LNCaP cells 
(Fig. 3.9). At 15 d, AR mRNA remained slightly elevated from basal levels (1.44-
fold) and AR protein expression remained stable, whereas PSA mRNA 
expression was dramatically downregulated (50.97-fold; p = <0.001) and PSA 
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protein expression was no longer detectable. The results demonstrate that under 
AD conditions, AR signalling is greatly reduced as expression of PSA is 
dependent upon AR signalling mediated by androgen response elements in the 
PSA encoding gene (Luke and Coffey, 1994). These findings validate that the 
charcoal-stripped FBS model of AD used in this study prevents canonical AR 
signalling. 
 
Figure 3.9. Effect of androgen deprivation on PSA and androgen receptor 
expression. A. Relative expression of AR, and PSA in LNCaP cells before and 
after 5 or 15 d androgen deprivation was analysed via qRT-PCR. Data is 
expressed as mean ± SEM, where n=3 p < 0.05 (*), p <0.01 (**) and p < 0.001 
(***).  
 
 3.2.4.2 Analysis of neurite growth 
The morphological changes observed in LNCaP cells following AD (Fig. 3.8) are 
typical of a more neuronal-like morphology (Rapa et al., 2013). To confirm this, 
LNCaP cells were stained with a neurite outgrowth staining kit, which allowed for 
quantitative analysis of neurite length using a cell membrane stain to aid 
visualisation (Fig. 3.10). It should be noted that this neurite outgrowth kit is purely 
used to aid the visualisation of neurites and is in no way a cell-type specific dye. 
Analysis showed that after 15 d in AD conditions LNCaP cells acquired neurite-
like protrusions, which were on average more than twice the length of the cell 
body they originated from. Thus, protrusions developed by LNCaP cells in 
response to AD meet the length criteria previously used to classify PC-12 cells 
as terminally differentiated, neuron-like cells (Wu et al., 2012).  
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This finding suggests that if androgen-sensitive LNCaP cells acquire morphology 
consistent with neuronal cells when androgen deprived, it is possible that they 
may also gain some of the functions facilitated by neuronal morphology. This data 
also demonstrates that this model is robust and the morphology and gene 
expression changes associated with AD are consistent with the previous literature 
(Shen et al., 1997). Therefore, this model was used to further investigate the 
molecular drivers of AD-induced NED of PCa cells. 
 
Figure 3.10. Androgen deprivation triggers significant morphological 
changes in LNCaP cells. A. Representative images of LNCaP cells cultured in 
media containing 10% (v/v) charcoal stripped FBS for 15 d and stained using 
neurite outgrowth staining kit. B. Cellular protrusions were analysed via 
fluorescent confocal microscopy (40 × magnification) and qualified as neurites 
when their length was greater than twice that of the cell body it originated from. 
Data was analysed using two-tailed t-test and expressed as mean ± SEM, where 
n=3 p < 0.05 (*), p <0.01 (**) and p < 0.001 (***). Each biological replicate had 3 
Control AD
A
B
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technical replicates, in which 100 neurite lengths were measured per technical 
replicate. 
 
3.2.4.3 Molecular changes resulting from androgen deprivation of LNCaP 
cells 
To assess molecular changes underpinning the shift to a neuronal-like 
morphology, expression of key genes and proteins relating to neurogenesis were 
assessed by qRT-PCR after 5 and 15 d AD periods (Fig. 3.11) and immunoblot 
at 5, 10 and 15 d AD periods (Fig. 3.12). Expression of AR remained highly stable 
throughout AD experiments whereas expression of PSA was greatly reduced 
under AD conditions, indicating a loss of AR signalling. PTOV1 is a Notch1 
signalling repressor postulated to be critical to facilitating differentiation (Alaña et 
al., 2014). PTOV1 was significantly upregulated after 5 d of AD and remained 
elevated at 15 d of treatment. hASH1 expression was upregulated 3.5-fold at 5 d 
of AD and this trend continued up to 15 d of treatment (Fig. 3.11). Gene 
expression of neuronal marker NSE was also significantly upregulated at 5 d of 
AD but returns to basal levels at 15 d of treatment (Fig. 3.11). 
 
Immunoblot analysis revealed that AR expression remained stable throughout 
the 15 d AD period (Fig. 3.12). NSE expression appears to increase by 10 d and 
is highly pronounced by 15 d of AD (Fig. 3.12). Whilst expression of NSE protein 
steadily increased with longer periods of AD, LNCaP cells cultured in control 
media displayed a steady decrease in NSE expression between 5, 10 and 15 d 
AD periods. PSA expression was markedly downregulated by 5 d AD, declined 
further by 10 d and became undetectable by 15 d. Expression of hASH1 appears 
to remain unchanged by 5 d AD, however expression was increased compared 
to untreated control at 10 d and remained slightly elevated compared to the 
untreated control at 15 d.  Overall, this data supports the hypothesis that AD 
activates a canonical neurogenesis pathway in LNCaP cells.  
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Figure 3.11. Androgen deprivation (AD) activates the canonical 
neurogenesis pathway. Relative expression of PTOV1, hASH1 and NSE in 
LNCaP cells before and after 5 or 15 d AD was analysed via qRT-PCR. Data is 
expressed as mean ± SEM, where n=3 p < 0.05 (*), p <0.01 (**) and p < 0.001 
(***) as determined by one-way ANOVA with Dunnett’s correction.  
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Figure 3.12. Androgen deprivation downregulates PSA expression and 
expression of NSE is markedly increased. Representative immunoblot 
analysis (n=3) of androgen receptor (AR), NSE, PSA and hASH1 in LNCaP cells 
at 5, 10 and 15 d of control or AD culture conditions. -actin was used a control 
for equal loading. 
 
3.2.4.4 Visualisation of hASH1 and NSE expression and localisation before 
and after AD induced NED 
Nuclear localisation of hASH1 is a critical step in formation of neurons during 
canonical neurogenesis and transduction of hASH1 has previously been shown 
to promote a NE phenotype in prostate cancer cells (Axelson, 2004; Rapa et al., 
2008). In addition, hASH1 has also been described as a useful therapeutic target 
in lung cancer displaying NED (Osada et al., 2005) and has more recently been 
demonstrated to have a function in increasing the migratory capacity of lung 
cancer cells (Demelash et al., 2012; Osada et al., 2008). Aberrant expression of 
hASH1 may be the result of Notch1 signalling repression mediated by PTOV1 
overexpression (Alaña et al., 2014; Lai, 2004). Neuron specific enolase (NSE) is 
a glycolytic metalloenzyme (Rech et al., 2006) and expression of NSE occurs late 
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into neuronal differentiation. It is therefore considered to be a marker of mature 
neurons (Isgro et al., 2015). NSE is a clinical biomarker used to detect both 
primary NEPC and NED of PCa via immunohistochemistry and is considered to 
be one of the best and most studied biomarkers for this disease state (Komiya et 
al., 2013). Expression and localisation of hASH1 and NSE following AD was 
assessed using immunocytochemistry and visualised via confocal microscopy 
(Fig. 3.13).  
 
Figure 3.13. Androgen deprivation triggers neuronal-like changes in LNCaP 
morphology associated with hASH1 nuclear localisation. Representative 
confocal microscopy images (from n=3) of LNCaP cells stained with anti-hASH1 
and anti-NSE antibodies and DAPI after 15 d of culture in androgen deprived (AD) 
or control (C) conditions (63 x magnification). Scale bar represents 50 m. Z-
stack images were taken at 63 x magnification with additional digital zoom to 
confirm the presence and absence of detected hASH1 in the nuclei of cells, a 
representative image taken from the centre of the z-stack is shown for control 
and AD conditions. For control condition z-stack, 22 vertical slice images with 
6.685 m spacing were captured and for AD conditions 26 vertical slice images 
with 8.173 m spacing were captured, the spacing between images was 
determined using the optimal pre-set in Zen Blue software controlling a Confocal 
LSM 880 microscope (Zeiss, UK). 
 
When cultured in control media, LNCaP cells showed almost undetectable 
expression of NSE and very low intensity hASH1 staining, which appeared to be 
exclusively cytoplasmic (Fig. 3.13, upper panel). NSE staining was intensely 
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upregulated in LNCaP cells after 15 d of culture in AD conditions with profuse 
staining throughout the cell body and neurite-like extensions (Fig. 3.13, lower 
panel). In addition, the staining intensity of hASH1 was markedly increased and 
showed abundant staining throughout the cell, including the nucleus (Fig. 3.13). 
Zoomed images and z-stack analyses taken of representative individual cells 
revealed that nuclear hASH1 was exclusive to cells which had been AD and had 
acquired neuronal-like morphological changes. This data demonstrates that the 
transcription factor hASH1 is excluded from the nucleus of LNCaP cells in the 
presence of androgen, but becomes localised to the nucleus in AD conditions. 
This data suggests that hASH1 nuclear localisation may be an important step in 
NED, as evidenced by markedly increased NSE staining alongside hASH1 
nuclear localisation. Ideally, future experiments could be conducted to further the 
evidence that hASH1 is sequestered within the nucleus after AD and to confirm 
that hASH1 is bound to chromatin and transcriptionally active. This could be 
achieved using Chromatin immuno-precipitation (ChIP) and ChIP-Seq or ChIP-
qPCR to identify potential hASH1 target genes.  
 
3.2.5 Validation of AD mediated effects using synthetic androgen 
Since charcoal-stripping of FBS does not exclusively remove androgens, 
experiments using synthetic androgen R1881 were performed to control for this 
and investigate whether the morphological and molecular changes observed thus 
far were specific to the presence or absence of androgens in the culture media. 
As AD has been shown to trigger NED (Fig. 3.8) (Shen et al., 1997) the role of 
AR signalling in preventing NED was investigated and as a control for the 
limitations of using charcoal-stripped FBS. Concentrations of R1881 and DMSO 
vehicle were derived from the literature (Svensson et al., 2014) and assessed 
empirically for their effect on cell viability using Alamar blue assay (Fig. 3.14).  
 
3.2.5.1 Effect on cell viability of synthetic androgen R1881 
Concentrations of R1881 synthetic androgen were derived from the literature 
focussing on the prevention and reversal of PCa NED (Svensson et al., 2014). 
The effect of R1881 on cell viability was assessed using Alamar blue assay (Fig. 
3.14) at 1 nM and 10 nM and DMSO at a concentration of 0.01% which was used 
as a vehicle for the R1881. Analysis of the data showed that neither R1881 or 
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DMSO significantly increased or decreased the percentage reduction of the 
Alamar blue reagent. Since the data demonstrated that 1 nM and 10 nM R1881 
did not significantly alter LNCaP, DU-145 or PC-3 cell viability when using a 
0.01% DMSO vehicle these concentrations were selected for use in further 
experiments.  
 
Figure 3.14. Assessment of synthetic androgen R1881 and DMSO vehicle 
on cell viability of prostate cancer cell lines. Prostate cancer cell lines LNCaP, 
DU-145 and PC-3 cells cultured in the presence of 0 (vehicle only), 1 and 10 nM 
R1881 or untreated control (media only). DMSO was used as a vehicle at a final 
concentration of 0.01%. Data is expressed as mean ± SEM, (n=3) analysed using 
one-way ANOVA with Dunnett’s correction.
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3.2.5.2 Further refinement of AD experiment design 
To investigate the effect of androgen signalling on NED, LNCaP cells were 
cultured in control media or, charcoal-stripped media ± synthetic androgen 
(R1881) for 5, 10 and 15 days (Fig. 3.15). 
 
Figure 3.15, Visual representation of experiment design for androgen 
deprivation experiments. LNCaP cells were cultured in either control media (C), 
androgen deprived (AD) media which contained charcoal-stripped foetal bovine 
serum, or AD media with synthetic androgen R1881 (AD+R1881), for 5, 10 and 
15-days. Protein lysates were collected at 5, 10 and 15 days, whilst RNA was 
extracted at 15 days with time matched controls cultured in complete media.  
 
3.2.5.3 Androgen-sensitive LNCaP cells display altered morphology during 
androgen deprivation 
LNCaP cells were cultured in control media and AD media ± synthetic androgen 
R1881 and visualised using light microscopy at day 15 of culture (Fig. 3.16). As 
previously shown, 15 d AD induced development of long, neurite-like extensions. 
Correspondingly, this differentiation was inhibited by the synthetic androgen 
R881. AD + Vehicle treated cells continued to undergo differentiation, mirroring 
the morphology of the AD cells.  
 
These findings demonstrate that the morphological changes of LNCaP cells 
cultured in charcoal-stripped media are likely to be predominantly mediated by a 
reduction in androgen concentration rather than any other FBS constituent 
removed through charcoal-stripping. 
5 10 15 days
C
AD + R1881
AD
Control
Androgen Deprived
0
AD + R1881
  
92 
 
 
Figure 3.16. Presence of androgen prevents neuroendocrine differentiation. 
Representative bright field microscopy images of LNCaP cell morphology after 
15 d of culture in either control, androgen deprived (AD) and androgen deprived 
± DMSO (vehicle) or 1 nM R1881 synthetic androgen (R1881) conditions (20 × 
magnification). Representative images of an n=3. Arrows indicate neurite-like 
extensions. 
 
3.2.5.4 Validating the effect of AD on NED related genes in LNCaP cells  
Expression of a key panel of genes in LNCaP cells cultured in complete culture 
media with 10% FBS and AD conditions (10% charcoal-stripped FBS)  synthetic 
androgen was assessed using qRT-PCR analysis (Fig. 3.17). This panel of genes 
was selected through extensive literature searches and refining a shortlist of 
genes that appeared to be at ‘crux’ points of the proposed NED pathway, i.e. the 
initiators and preventers (PTOV1/REST), the hypothetical driving transcription 
factor hASH1 (previous implication of hASH1 in pan-cancer NED is discussed in 
chapter 1), a well-established biomarker (NSE) and the downstream potential 
effectors of the NED phenotype (GAD1 and MMP-9). Data revealed that PSA 
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expression was greatly downregulated by AD but was maintained at basal levels 
by 1 nM R1881 (Fig. 3.17). As previously stated, expression of NSE returns to 
basal levels after 15 d of AD (Fig. 3.12), however addition of 1nM R1881 to 
charcoal-stripped media resulted in significant downregulation of NSE (-3.12-fold; 
p = 0.02), becoming highly significant when cultured in the presence of 10 nM 
R1881 (-2.77-fold; p = 0.0017) (Fig. 3.17). PTOV1 expression was slightly 
elevated by 15 d of AD, whilst 1 nM R1881 was sufficient to prevent this increase 
and maintain PTOV1 expression below basal levels. Importantly, hASH1 was 
upregulated 3.41-fold after AD and was downregulated 3.8-fold in the presence 
of 1 nM R1881, becoming significantly downregulated in the presence of 10 nM 
R1881 (8.6-fold; p = 0.044) (Fig. 3.17). This data demonstrates that hASH1 
expression can be modulated by the availability of androgen, a finding that 
robustly supports the proposed pathway of AD induced NED in prostate cancer 
cells. 
 
Expression of REST is, perhaps surprisingly, robustly expressed under both 
control and AD conditions (Fig. 3.17). REST expression is also significantly 
downregulated by 1nM R1881 treatment (p = 0.009) but to a lesser extent by 10 
nM R1881 (p = 0.08). Expression of GAD1 was assessed as a possible source 
of paracrine support potential in AD LNCaP cells. It was found that whilst GAD1 
was upregulated by AD (2-fold), unlike other associated changes in gene 
expression, GAD1 was not downregulated by 1 nM or 10 nM R1881, suggesting 
modulation of GAD1 expression was not specifically androgen mediated.  
 
MMP-9 is a tumour aggression marker that is potentially inducible by GABA 
receptor signalling (Azuma et al., 2003). Due to discovery of GAD1 upregulation 
(Fig. 3.17), expression of MMP-9 was investigated. Expression of MMP-9 was 
not significantly upregulated by AD (1.85-fold), but was significantly 
downregulated when charcoal-stripped media contained 1 nM R1881 (p = 0.04) 
and more so with 10 nM R1881 (2-fold; p = <0.001). In all cases where gene 
expression responded to synthetic androgen, 1 nM R1881 was sufficient to 
reduce expression below basal levels. This data demonstrates that key 
components of the proposed NED pathway are specifically modulated by the 
availability of androgen.   
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Figure 3.17. Androgen supplementation prevents activation of the 
canonical neurogenesis pathway. A. Relative expression of PSA, PTOV1, 
hASH1, NSE, REST, GAD1 and MMP-9 was analysed in LNCaP cells before and 
after 15 d of culture in control, androgen deprived or androgen deprived 
supplemented with 1nM or 10nM R1881 conditions via qRT-PCR. Data is 
expressed as mean ± SEM where n=3 p < 0.05 (*), p <0.01 (**) and p < 0.001 
(***).  
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3.2.5.5 Protein expression in response to androgen deprivation 
Expression analysis of key proteins was performed using immunoblot. Analysis 
determined that AR expression remained stable between untreated, AD, vehicle 
and 1 nM R1881 treatment at 15 d (Fig. 3.18B). However, PSA expression was 
undetectable after 15 d AD, whereas PSA expression was robustly maintained in 
LNCaP cells treated with 1 nM R1881. These results support the gene expression 
data generated via qRT-PCR analysis (Fig. 3.17) and further validate the model 
of AD used in this study and that PSA is a reliable indicator of androgen signalling 
activity.  
 
Protein expression of hASH1 was elevated by 10 d of AD and increased further 
by 15 d (Fig. 3.18A). Supplementation of charcoal-stripped media with 1 nM 
R1881 was not sufficient to prevent increased hASH1 expression. This suggests 
that a higher concentration of androgen may need to be maintained in order to 
prevent upregulation of hASH1, this data strongly supports the qRT-PCR data 
which demonstrated that hASH1 was only significantly downregulated when in 
the presence of 10 nM R1881 synthetic androgen. 
 
NSE expression was detected at a low level in untreated cells and did not become 
considerably upregulated until 10 d of AD, becoming substantially higher at 15 d 
of culture. Up to 10 d the presence of 1 nM R1881 did not appear to prevent NSE 
upregulation. However, by 15 d of culture with 1 nM R1881, expression of 
neuronal marker NSE was undetected. This data suggests that expression of 
NSE is regulated by androgen signalling, evidenced by the data showing that 
when PSA is robustly detected, NSE is only expressed at a very low level. 
Whereas when PSA expression is lost, there is a dramatic increase in NSE 
expression (Fig. 3.18B).  
 
Interestingly, whilst the data suggests that 1 nM R1881 prevents increased NSE 
expression, it does not downregulate expression of hASH1. Confocal analysis 
(Fig. 3.13) demonstrated that during AD the localisation of hASH1 changes from 
excluded from the nucleus to prevalent in the nucleus. In the context of the 
localisation data (Fig. 3.13), the data presented in Fig. 3.18 would suggest that it 
is the localisation of hASH1 which is significantly more important in the NED 
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process than its overall level of expression. Expression of PCa stem cell marker 
CD44 was not detectable in LNCaP cells throughout the NED process, whilst 
CD44 was robustly expressed by castrate-resistant cell line DU-145 (Fig. 3.18A). 
 
 
 
Figure 3.18. Androgen supplementation prevents activation of the 
canonical neurogenesis pathway. A. Representative immunoblot analysis of 
CD44, hASH1 and NSE in LNCaP cells at 5, 10 and 15 d of control, androgen 
deprived or androgen deprived supplemented with 1nM R1881 culture conditions. 
B. Representative immunoblot analysis of AR, PSA and NSE expression in 
LNCaP cells after 15 d of culture in control (C), androgen deprived (AD) or 
androgen deprived ± 0.01% DMSO vehicle (V) or 1 nM R1881. Beta actin was 
used as a loading control.  
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3.2.6 Conclusions 
A panel of the most frequently studied androgen-sensitive and castrate-resistant 
prostate cancer cell lines were thoroughly characterised at a molecular and 
cellular level (Figs. 3.2-3.7). The androgen-sensitive LNCaP cell line was used to 
establish a model of AD-induced NED (Fig. 3.8-3.10). This model was validated 
and used to investigate the hypothetical NED pathway proposed in this study 
(Fig. 3.11-3.18). In summary, AD induced NED in androgen-sensitive LNCaP 
cells. Addition of synthetic androgen to AD conditions confirmed that reduction of 
available androgen is a specific inducing stimulus of NED. AD-induced NED is 
associated with a neurite-like morphology, nuclear localisation of hASH1 and 
upregulation of NSE, alongside downregulation of PSA. All of these NED 
associated changes were prevented when AD conditions were supplemented 
with synthetic androgen. Therefore, this data shows that NED is specifically 
inducible by reduction of androgen and that canonical neurogenesis promoter 
hASH1 may be facilitating this phenotypic change (Figure 3.19).  
 
Figure 3.19. Schematic summary of chapter 3 results in relation to the 
proposed model of AD induced PCa NED. 
AD of LNCaP
Nuclear Localisation of hASH1
Upregulation of proposed NED 
pathway components: PTOV1, 
NSE, MMP-9
Downregulation of 
AR target gene PSA
Inconclusive effect on REST 
and GAD1
Overall, data supports hypothesis that hASH1 could be 
a key driving transcription factor of PCa NED 
warranting closer investigation
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These results, summarised in Figure 3.19, strongly support the proposed 
pathway of PCa NED initiation and maintenance and warrants further 
investigation, particularly whether the nuclear localisation of hASH1 and the 
concurrent development of the NED phenotype could be prevented or reversed.   
 
3.3 Discussion 
Escape from ADT and the progression of prostate cancer to CRPC remains one 
of the greatest challenges in the treatment and management of prostate cancer. 
Therefore, the development and study of models of ADT resistance are critical to 
illuminating the molecular drivers of the CRPC transition. Recent research has 
demonstrated that ADT resistance and NED not only remains a challenge, but 
that NED is becoming more frequent. A cohort study showed that the percentage 
of patients exhibiting NED more than doubled to 13.3% in the year 2012-2016, 
compared to 6.3% in 1998-2011 (Bluemn et al., 2017). Critically, this increase in 
incidence of NED occurred after the implementation of current generation ADT 
drugs enzalutamide and abiraterone acetate, suggesting that the increased 
potency of androgen-blockade could be contributing to the development of NED 
(Bluemn et al., 2017).  
 
The aim of this study was to assess the basal characteristics of androgen-
sensitive and castrate-resistant prostate cancer cell lines and to establish an in 
vitro model of AD induced NED. The first objectives using this model were to 
identify the molecular components of the NED pathway and to assess how 
neuronal-like these differentiated cells were. The next objective was to ascertain 
whether these molecular and phenotypic changes observed in the AD-induced 
NED model were specifically mediated by androgen availability. 
 
3.3.1 Characterisation of prostate cancer cell lines 
Validation of the prostate cancer cell lines used in this study was performed using 
morphological and molecular analysis to ensure that these cells were conforming 
to their known characteristics. The first step was to assess the expression of the 
AR and AR target gene PSA. As previously reported in the literature (Alimirah et 
al., 2006), LNCaP cells displayed robust AR and PSA expression as assessed 
  
99 
 
by qRT-PCR and immunoblot, whilst CRPC cell lines DU-145 and PC-3 did not 
show detectable expression of AR or PSA (Fig. 3.2).  
 
Quantitative scratch assays (Fig. 3.6) were used to assess the growth 
characteristics of LNCaP, DU-145 and PC-3 cells. Consistent with previous 
literature, CRPC cell lines DU-145 and PC-3 displayed faster growth and more 
rapid wound closure than LNCaP cells (Alimirah et al., 2006; Valero et al., 2012). 
Overall, this initial assessment of these cell lines confirmed that their major 
characteristics conformed to those reported in the literature (Horoszewicz et al., 
1983; Kaighn et al., 1979; Stone et al., 1978). Future experiments to further 
assess the proliferative rate of these cell lines could be performed using incuCyte 
(Essen Biosciences, Germany) imaging to quantify confluence and cell number 
over time, or the use of fluorometric assays such as MTT or Alamar blue which 
assess cellular respiration to indicate proliferation.  
 
Availability of PCa cell lines faithful to the clinical presentation of the disease are 
widely regarded to be lacking in the field of PCa research. Although LNCaP cells 
were isolated from a patient after ADT relapse, LNCaP is androgen-sensitive and 
although AD does not result in mass LNCaP cell death, it greatly slows their 
growth rate compared to CRPC cell lines like DU-145 and PC-3 which are known 
to be unaffected and androgen-independent (Horoszewicz et al., 1983; Kaighn et 
al., 1979; Stone et al., 1978). 
 
For this study, DU-145 and PC-3 were gifts and funding was only available for 
one additional cell line. Given that LNCaP cells have been used previously as 
models of PCa NED (Rapa et al., 2013; Farach et al., 2016), LNCaP cells were 
the clear choice for this study. Criticisms of DU-145 and PC-3 are that they do 
not express AR or PSA, however these cell lines continue to be widely used in 
the field as androgen-independent models of CRPC. 
 
Alternative options to DU-145 and PC-3 are CWR22Rv1 and VCaP cell lines. 
VCaP has been previously grown in mice and is contaminated with the Bxv-1 
retrovirus. VCaP cells also have extremely slow growth rate making them less 
practical to work with than DU-145 and PC-3, they also grow in colonies which 
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makes them unsuitable for scratch assays (Korenchuk et al., 2001; Knouf et al., 
2009; Sfanos et al., 2011). 
 
CWR22Rv1 is an increasingly popular cell line model of CRPC, however 
CWR22Rv1 is known to be castrate resistant through expression of AR-V7 which 
is not a mechanism that we wished to focus on in this study. This study aimed to 
investigate androgen receptor independent mechanisms of castrate-resistance, 
therefore DU-145 and PC-3 are appropriate models as they do not express AR 
or PSA and are unaffected by AD (Sramkoski et al., 1999; Knouf et al., 2009). 
 
3.3.2 Androgen receptor signalling in androgen-sensitive and CRPC cell 
lines. 
LNCaP cells are described as androgen-sensitive and express AR and PSA 
robustly (Wu et al., 2014). When discussing the androgen receptor signalling 
status of CRPC cell lines DU-145 and PC-3, it must be considered that whilst 
these cells are AR negative, the majority of CRPC tumours are AR positive 
(Shukla et al., 2017). This distinction is important because AR positive CRPC 
tumours do not rely on androgens but they do retain the AR signalling 
transcriptome through other mechanisms (Jones et al., 2015; Kong et al., 2015). 
Therefore, the majority of CRPC tumours are androgen-independent but certainly 
not AR-independent as they rely on mechanisms to reactivate AR signalling 
during ADT (Shukla et al., 2017). Nonetheless, DU-145 and PC-3 remain the 
most frequently used in vitro models of CRPC. Androgen-pathway independent 
prostate cancers are known to exist and occur relatively frequently clinically, 
despite AR positive CRPC tumours comprising the majority of cases (Bluemn et 
al., 2017). Another study found that DU-145 and PC-3 cells express AR but only 
at a very low level (Alimirah et al., 2006), which is likely why it was not detected 
in this study or the vast majority of the published literature using these cell lines 
(Alimirah et al., 2006; Yadav et al., 2017). The PSA encoding gene, KLK3, 
contains androgen response elements and can therefore be a useful indicator of 
intact, canonical AR signalling (Luke and Coffey, 1994).  
  
  
101 
 
3.3.3 Advantages and disadvantages of different Androgen-deprivation 
simulation methods 
Charles Huggins discovered that prostate cancer could be modulated by 
hormones as early as 1941 (Huggins, 1941). It is therefore unsurprising that there 
have been a wealth of studies utilising hormone modulation as a method of 
investigating the mechanistic biology of prostate cancer, both in vivo and in vitro.  
Despite a broad array of published literature, there remains several different 
approaches to simulating ADT, not least because approaches to ADT itself have 
changed drastically over the last 75 years, with new anti-androgens, combination 
therapies and treatment strategies continuing to be developed (Ryan et al., 2015; 
Beltran et al., 2011; Satoh et al., 2014). 
 
There are several models for inducing NED via AD in PCa, including serum 
reduction, charcoal stripping of serum and direct use of ADT therapeutics.  The 
most commonly used model of AD (and the one used for this study) is to use 
charcoal-stripped FBS in cell culture media in order to reduce testosterone and 
dihydrotestosterone in the media (Rapa et al., 2013; Shen et al., 1997). Although 
charcoal-stripping FBS is not specific to removing only androgens, use of DHT or 
synthetic androgens such as R1881 can be used to confirm whether changes 
resulting from culture in CS-FBS are androgen mediated (Svensson et al., 2014). 
The effects of charcoal-stripping on FBS has previously been investigated and 
found to effect hormones and vitamins; cortisol, oestradiol, folic acid, thyroxine, 
progesterone, triiodothyronine, vitamin B12 and testosterone (Cao et al., 2009). 
The reduction in androgen concentration from charcoal-stripping FBS was found 
to be 86% (Cao et al., 2009).  
 
An alternative approach that has not been reported in the literature, which could 
further enhance the charcoal-stripping method, would be to determine the 
depletion of non-androgen hormones via ELISA or mass-spectrometry 
approaches. The non-androgen components reduced by charcoal-stripping could 
then be manually replaced to match the concentration in non-charcoal stripped 
FBS of the same batch. This method could provide a refinement to the charcoal-
stripping methodology widely used in the field of hormone-related cancer 
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research. However, it is also likely to be considerably more expensive than the 
standard charcoal-stripping approaches used in this study. 
 
Clinically, successful application of ADT is regarded as a target serum androgen 
concentration <500 ng/L (173 pM) and after orchiectomy <200 ng/L (69 pM) 
(Bertaglia et al., 2013; Mottet et al., 2011). However, the latest ADT regimens 
utilising abiraterone acetate and/or enzalutamide are able to consistently  achieve 
serum testosterone levels <50 ng/L (Breul et al., 2017; Hashimoto et al., 2017). 
The level of serum testosterone found in FBS and CS-FBS was previously 
determined as 22 ng/L and 5 ng/L respectively (76.3 pM and 17.3 pM) (Sedelaar 
& Isaacs, 2009) which is consistent with the 86% reduction reported in a separate 
study (Cao et al 2009).  
 
It is an important consideration that serum androgen concentration of prostate 
cancer patients is not likely to be representative of the level of androgen localised 
within the tumour mass or metastases. Due to variation in vascularisation, access 
to serum androgen is likely to differ within the tumour micro-environment. It is 
also of note that NED has also been demonstrated through hypoxia (Danza et 
al., 2012) and serum starvation (Farach et al., 2016). Therefore, it would be 
expected that areas of the tumour micro-environment that are poorly vascularised 
would produce a strong selective pressure towards the NE phenotype as these 
areas would have poorest access to oxygen and serum androgen.  
 
An alternative AD simulation method is to reduce the amount of FBS used in the 
media to also reduce concentration of androgens. The problem with this serum 
starvation approach is that it is the most non-specific method for removing 
androgens from the media and is likely to induce an array of cell stress responses 
that are non-specific to AD. In some cases, partial serum starvation is used in 
combination with charcoal-stripped FBS (Belandia et al., 2005; Svensson et al., 
2014), however this approach makes it difficult to delineate whether observed 
effects were due to specific AD or serum starvation. Finally, several studies have 
directly utilised pharmacological methods of AD using anti-androgens such as 
enzalutamide directly (Svensson et al., 2014). Importantly, each of these models 
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has been reported to induce differentiation of LNCaP cells in vitro, despite the 
differences and limitations of each approach. 
 
Although charcoal-stripping of FBS is non-specific to androgen, critically, it has a 
higher degree of specificity than the serum starvation technique utilised by 
(Farach et al., 2016) and others. The rationale for not using ADT pharmaceuticals 
directly is as follows; (1) LHRH agonists and antagonists target T and DHT 
production, which is not a consideration in vitro. (2) antiandrogens such as 
enzalutamide, flutamide and bicalutamide target the AR, however, AR mutations 
and differing expression of AR splice variants can alter the efficacy of these 
compounds or lead to off-target effects (Bassetto et al., 2016; Scher & Kelly, 
1993). (3) Calculating suitable working concentrations of these drugs would likely 
be non-representative of that of the in vivo environment, mainly due to differences 
in bioavailability of both the compound and serum androgens. Using ADT drugs 
at too high concentration may have resulted in a greatly exaggerated effect on 
NED. (4) Using serum starvation would likely have activated autophagy pathways 
which would have dramatically altered the cellular metabolism and have had 
genome wide effects not directly associated with NED (Adachi, Koizumi, & 
Ohsumi, 2017). (5) Using the well-established CS-FBS model allows for this 
project to be taken in context of previous similar studies and aids elucidation of 
the NED process through consistency. 
 
3.3.4 Neuroendocrine gene expression signatures of prostate cancer cells 
As an initial investigation of the proposed NED pathway, the expression of REST, 
clinical NED biomarker NSE and GABA synthesis enzyme GAD1 was analysed. 
CRPC cell line DU-145 showed a significantly higher expression of NSE (38-fold), 
and REST (3-fold) and GAD1 was also upregulated although not significantly (10-
fold) compared to LNCaP cells (Fig. 3.4). Although it would be expected that 
higher NSE expression should be concurrent with lower REST expression, the 
REST protein is known to be regulated post-transcriptionally via ubiquitin ligase 
beta-TrCP (Guardavaccaro et al., 2008). PC-3 cells also displayed much higher 
NSE expression (14-fold) than LNCaP cells, whilst expression of GAD1 and 
REST were similar to LNCaP cells (0.75-fold and 1.13-fold respectively). These 
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findings demonstrate that CRPC cells may possess increased NED compared to 
androgen-sensitive PCa cell line LNCaP.  
 
3.3.5 Androgen-deprivation triggers neuronal-like morphological changes 
in androgen-sensitive LNCaP prostate cancer cells 
The phenomenon of AD inducing morphological changes in LNCaP cells has 
been observed previously (Shen et al., 1997). However, the extent to which these 
cells mimic neurons or NE cells at a molecular level has not yet been fully 
elucidated. It has previously been demonstrated that in response to AD, LNCaP 
cells acquire neuronal-like morphology and increased expression of NSE, which 
was reversed when cultured in complete media (Shen et al., 1997). Research on 
PCa NED has focussed upon four main areas; the origin of these differentiated 
cells and the molecular pathways of differentiation (Rapa et al., 2008, 2013; 
Sauer et al., 2006), the extent to which these cells are NE or neuronal in 
phenotype (Grigore et al., 2015; Farach et al., 2016), how these cells may be 
resistant to treatment (Hu et al., 2015) and the advantages these cells may grant 
to surrounding cancer cells (Ippolito et al., 2006; Ippolito & Piwnica-Worms, 2014; 
Komiya et al., 2009; Wu et al., 2014).  
 
In this study, AD LNCaP cells gained long neurite-like extensions (Fig. 3.8) similar 
to those previously reported in the literature (Shen et al., 1997). At 5 d short 
projections were observed, at 10 d these projections became more pronounced 
and by 15 d neurites had become long and well-developed with many cells 
connected physically by these projections. Using confocal microscopy to image 
large regions of microscope slides containing untreated and AD LNCaP cells it 
was possible to visualise and quantify the length of these neuronal-like 
projections. The cells which appeared to differentiate most clearly under AD were 
on the edges of colonies of cells and those in lower density areas. Often, images 
showed that two or more distant cells had become interconnected by these 
neurite-like extensions. This suggests that there may be some mechanism of 
chemotaxis encouraging these projections to extend towards nearby cells, 
although this was not investigated in this study. Growth of neurites has previously 
been described as a non-random process with different neurite branching 
patterns observed uniquely between different neuron types within the central 
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nervous system (Wong & Ghosh, 2002). It is unclear what, if any, methods of 
intracellular communication these neurite-like projections might provide. Having 
established a model of AD-induced NED which produced a morphology similar to 
that previously reported in the literature (Hu, Choo, & Huang, 2015; Lin et al., 
2016; Rapa et al., 2013), the next aim was to investigate the molecular pathways 
facilitating this phenotypic shift. 
 
3.3.6 Molecular characterisation reveals neuronal-like signature of 
androgen deprived LNCaP cells. 
To assess the underpinning pathway of NED of LNCaP cells in response to AD, 
the involvement of the androgen axis and the components of the proposed NED 
pathway were characterised. AR and PSA expression was assessed to validate 
that culture in CS-FBS conditions reduced AR signalling. PTOV1 is highly 
prevalent oncogene in prostate cancer development and has been previously 
demonstrated to be a powerful antagonist of Notch1 signalling (Alaña et al., 2014) 
which in turn is known to upregulate hASH1 degradation (Sriuranpong et al., 
2002). Therefore, PTOV1 expression may be a core pre-requisite of the proposed 
pathway of NED. 
 
Analysis of PSA expression at 5 d of AD showed a decrease in mRNA expression 
and continued to decline at 15 d (Fig. 3.12). Analysis of PSA by immunoblot 
demonstrated a similar trend in protein expression Fig. 3.13). Given the stable 
AR expression demonstrated throughout the AD treatment, the sharp reduction 
in PSA expression indicates that there has been a reduction in AR signalling 
caused by a lack of available androgen in the cell culture media. Taken together, 
these data indicate that the CS-FBS culture conditions model for AD simulation 
are working as intended and in accordance with previous studies using this 
model.  
 
In keeping with the proposed pathway of NED, PTOV1, hASH1 and NSE were 
significantly upregulated by AD (Fig. 3.11). This data supports the analysis 
performed on hASH1 and NSE expression by confocal microscopy (Fig. 3.13) 
where strong upregulation was observed in addition to hASH1 nuclear 
localisation. This is an indication that the canonical neurogenesis pathway may 
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have been activated by AD via disruption of Notch1 signalling by increased 
PTOV1 expression. This suggestion is supported by previous studies which have 
demonstrated PTOV1 inhibition of Notch1 signalling (Alaña et al., 2014).  
 
3.3.7 Morphological changes are associated with hASH1 nuclear 
localisation and activation of canonical neurogenesis pathway.  
Previous studies have investigated Notch1 signalling not only in relation to 
neurogenesis, but in the wider context of cancer progression in multiple different 
cancer types (Axelson, 2004; Capaccione & Pine, 2013; Danza et al., 2012; Orr 
et al., 2009; Pedrosa et al., 2015; Ristorcelli et al., 2009). Notch1 signalling is a 
vital component in the determination and maintenance of cell fate (Lai, 2004), 
therefore, a reduction in Notch1 expression or signalling could lead to aberrant 
cell differentiation and transdifferentiation (Danza et al., 2012). Notch1 signalling 
has been implicated in hypoxia-induced PCa NED (Danza et al., 2012). In 
response to hypoxia, LNCaP cells showed decreased expression of Notch1 
which resulted in lowered expression of Hes1 and Hey1 (Danza et al., 2012). One 
previously discovered mechanism of Notch1 signalling disruption is transduction 
of protein prostate tumour overexpressed-1 (PTOV1), which was demonstrated 
to downregulate Notch1 targets Hes1 and Hey1 by occupying their promoter 
regions, thus blocking transcriptional activity of Notch1 (Alaña et al., 2014).    
 
Interestingly, Notch1 signalling is known to cause rapid degradation of hASH1 
(Sriuranpong et al., 2002). In addition, hASH1 has previously been demonstrated 
to be correlated with in PCa tumours with  NED and tumours treated with ADT 
(Rapa et al., 2008). Furthermore, transduction of hASH1 in LNCaP cells induced 
NED morphology and expression of NED markers chromogranin A and 
synaptophysin (Rapa et al., 2013). The present study builds upon these findings 
and provides a more complete molecular analysis of involvement of hASH1 in the 
process of NED. The first step in achieving this was the assessment of hASH1 
protein expression and localisation during the differentiation process via confocal 
microscopy.  
 
The data shows, for the first time, that untreated LNCaP cells possess low-level 
basal expression of hASH1 protein that is rigorously excluded from the nucleus 
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(Fig. 3.13). After AD, expression of hASH1 increases and confocal microscopy 
demonstrated that hASH1 became localised to both the nucleus and cytoplasm 
of LNCaP cells. In addition, expression of neuronal marker NSE dramatically 
changed from low and punctate to robust and perfuse throughout the cell body 
and neurite-like extensions concurrent with hASH1 nuclear localisation (Fig. 
3.13). These findings suggest that hASH1 nuclear localisation may be a key 
trigger of neuronal-like phenotype acquisition. Interestingly, hASH1 has 
previously been postulated as a potential therapeutic target in small cell lung 
cancer, which also possesses NE-like features (Castro et al., 2011; Meder et al., 
2016; Osada et al., 2005). Prompting further investigation into the role of hASH1 
and the potential to for hASH1 nuclear localisation to be reversed. 
  
3.3.8 Neuronal-like molecular profile is suppressed by androgen receptor 
signalling.  
Having demonstrated the effects of AD in inducing neuronal differentiation of 
LNCaP cells in vitro, the next step was to demonstrate that this effect was indeed 
specific to AR signalling and not mediated by any other factor removed through 
the charcoal-stripping of FBS in the media. R1881 in AD media maintained 
expression of PSA at basal levels and PTOV1 expression was reduced to below 
basal level by treatment with R1881 (Fig. 3.17). Previously it has been reported 
that PTOV1 is androgen inducible in human aorta and is necessary for the 
androgen mediated proliferation of aorta tissue (Nakamura et al., 2006). PTOV1 
is also known to contain an androgen responsive element (Benedit et al., 2001; 
Cánovas et al., 2015). This study is the first to directly investigate PTOV1 
expression in response to AD in LNCaP prostate cancer cells. This data 
demonstrates that PTOV1 expression is upregulated by AD and reduced below 
basal levels by R1881 (Fig. 3.17). PTOV1 is typically regarded as an androgen 
inducible gene (Nakamura et al., 2006), the increase in PTOV1 expression in 
response to AD and the decrease in the presence of R1881 may indicate that 
mechanisms regulating PTOV1 expression have become distorted in the setting 
of prostate cancer.  
 
This increase in expression of hASH1 by AD was prevented and reduced to below 
untreated levels by R1881 (Fig. 3.17). However, increased expression of hASH1 
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protein did not appear to be prevented by R1881 (Fig. 3.18). This data posed the 
question that if 1 nM R1881 was able to prevent morphological change but did 
not downregulate hASH1 expression, perhaps it is localisation of hASH1 to the 
cell nucleus which is the critical factor instigating morphological change and not 
expression level alone, since only nuclear hASH1 will be transcriptionally 
relevant. siRNA knockdown of hASH1 expression previously prevented 
expression of NE  biomarkers synaptophysin and chromogranin A  after 15 d of 
AD (Rapa et al., 2013). Significant downregulation of NSE was observed in 
LNCaP cells cultured in the presence of R1881. Downregulation of PTOV1, 
hASH1 and NSE by R1881 treatment indicates that three critical components of 
the proposed pathway of neurogenesis and NED of prostate cancer are mediated 
by AD primarily, rather than any other serum component which may have been 
altered by charcoal-stripping the FBS.  
 
Potential repressors of neurogenesis were also assessed in order to assess 
whether a reduction in their expression may be associated with AD and therefore 
facilitating increased neurogenesis and NED. Expression of REST was slightly 
increased by AD and was decreased in the presence of R1881. This data 
suggests that REST is constitutively expressed by LNCaP cells in order to 
prevent aberrant differentiation, yet is unable to prevent differentiation of LNCaP 
cells under AD conditions. It is possible that degradation of the REST protein, 
which is mediated via ubiquitin ligase beta-TrCP (Guardavaccaro et al., 2008), 
may be increased under AD conditions. REST acts as a controller of 
neurogenesis by preventing transcription of neuronal genes such as 
synaptophysin in non-neuronal tissues (Lapuk et al., 2012) and has been 
identified as a tumour suppressor (Westbrook et al., 2005). In this study, LNCaP, 
and PC-3 cells showed similar expression of REST but DU-145 showed 
significantly higher levels (Fig. 3.4). NSE was significantly higher in CRPC cell 
lines and AD LNCaP cells. Mutation and silencing of  REST is a common feature 
in colorectal cancer (Westbrook et al., 2005). However, the data supports the 
finding of Lin et al., (2016) who demonstrated that REST gene expression is 
unaffected during NED but that REST protein expression reduction is essential 
to the hypoxia induced NED process (Lin et al., 2016). This is consistent between 
two very different methods of NED induction, AD and hypoxia.  
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Having established that hASH1 nuclear localisation is concurrent with acquisition 
of NED phenotype in AD LNCaP cells, alongside the prior knowledge that hASH1 
is able to promote development of GABAergic neurons (Castro et al., 2011), the 
GABA synthesis potential of these cells was investigated. Gene expression of 
GAD1 was found to be slightly upregulated by AD, however, expression was not 
downregulated in the presence of R1881. This finding suggests that GAD1 
upregulation may not be mediated specifically by AD but by other factors 
associated with charcoal-stripping the FBS. 
 
Expression of MMP-9 has previously been demonstrated to be induced by GABA 
signalling in prostate cancer (Azuma et al., 2003) and so therefore MMP-9 
expression was assessed in response to AD as a potential indicator of GABA 
signalling. The data shows that MMP-9 expression was upregulated by AD and 
significantly downregulated in the presence of R1881. LNCaP cells were also 
found to lack detectable expression of CD44, a PCa stem cell marker (Patrawala 
et al., 2006; Tu & Lin, 2012; Zhang & Waxman, 2010). Although no conclusive 
statements can be made from this analysis, this data would appear to suggest 
that LNCaP cells are not particularly ‘stem-like’ and nor do they become ‘stem-
like’ during differentiation to the neuronal phenotype. This is supported by data 
demonstrating that NED LNCaP cells arise from transdifferentiation from 
epithelial phenotype cells (Sauer et al., 2006).  
 
3.3.9 Neuronal-like morphological changes are prevented and reversed by 
androgen receptor signalling. 
LNCaP cells which retained expression of PSA and therefore AR signalling, were 
prevented from undergoing morphological change and did not grow neurite-like 
extensions. This demonstrates that the AR is the critical mediator of 
morphological changes associated with culture in charcoal-stripped media. 
Acquisition of the neuronal-like phenotype can be avoided when a low level of 
androgen signalling is maintained. These findings are potentially of interest 
clinically, where the assumption that maximal androgen blockade as an optimal 
treatment goal may be significantly flawed and overly simplistic in approach.  
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3.3.10 Disruption of Notch1 signalling may promote aberrant cell fates 
Notch1 is critical to regulation of prostate development and is also expressed in 
progenitor cells of the prostate basal membrane where it regulates cell 
differentiation (Belandia et al., 2005). Notch signalling is a vital component of cell 
fate determination and its repression may result in differentiated prostate cells 
being more malleable and plastic in their phenotype and thus more responsive to 
changing conditions. Notch1 negatively regulates hASH1 via upregulation of 
bHLH transcriptional repressor genes Hes1 (Paquette, Perez, & Anderson, 2000) 
and Hey1 (Axelson, 2004; Ishibashi et al., 1995). Prostate tumour over-
expressed 1 (PTOV1) acts as a negative regulator of Notch1 signalling by 
interacting with the Notch repressor complex (Alaña et al., 2014). It has previously 
been demonstrated that Notch1 signalling is downregulated in hypoxic conditions 
and associated with increased expression of NED markers (Danza et al., 2012).  
Downregulation of Notch1 signalling could potentially allow for increased hASH1 
expression (Danza et al., 2012), which could promote NED. AD has been 
demonstrated to increase expression of hASH1 and is associated with NED in 
PCa (Rapa et al., 2008). Overall, the data presented in this study would suggest 
that prostate cancer cells likely have multiple transcriptional profiles that are 
repressed by AR signalling. However, under the conditions of ADT the pressure 
of the AR on cell fate is greatly reduced, allowing for aberrant transcriptional 
signatures to become ‘de-repressed’ (Bishop et al., 2017; Bishop et al.,  2015) 
and making the determination of cell-fate a more fluid and malleable dynamic that 
is better able to conform to the conditions of the microenvironment. Research has 
also demonstrated that activation of a gastrointestinal transcriptome gave rise to 
a castrate-resistant phenotype in prostate cancer cells (Shukla et al., 2017), 
suggesting that utilisation of aberrant transcriptional profiles is an effective ADT 
resistance mechanism in PCa. 
 
3.3.11 hASH1 as a therapeutic target 
Whilst transcription factors are often considered to be intractable drug targets, 
their upstream interactors are often druggable and can provide the desired 
attenuation of the transcription factors activity (Johnston & Carroll, 2015). ADT 
has remained the first line treatment for advanced prostate cancer for over half a 
century, becoming increasingly more refined and potent with successive 
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generations of drugs, yet the problem of ADT escape through NED is increasing. 
Therefore, research which could lead to adjuvant therapeutics alongside ADT to 
prevent NED is vitally important, as this could greatly extend the period of time in 
which ADT is able to restrict tumour growth. The research undertaken in this 
study has helped to illuminate one mechanism of ADT induced NED (hASH1 
nuclear localisation) in an in vitro LNCaP model. However, further research is 
greatly required to demonstrate that hASH1 could be a viable therapeutic target. 
Previously hASH1 has been touted as a therapeutic target for small cell lung 
cancer (Osada et al., 2005) as well as maintenance of REST expression, which 
could obviate the activity of hASH1 in response to ADT (Chang et al., 2017). IN 
order to further confirm that nuclear hASH1 in NED PCa is both bound to 
chromatin and transcriptionally active, it will be important to conduct further 
experiments. These would include chromatin fraction western blots, which would 
confirm the presence of hASH1 on chromatin. ChIP-Seq or ChIP-qPCR 
experiments to identify the likely target genes of hASH1 in AD conditions and 
ideally RNA-Seq, which could be integrated with ChIP-Seq data to support the 
hypothesis that hASH1 is transcriptionally active in NED PCa cells.  
 
3.4 Conclusions 
The aim to develop and characterise of a model of AD induced NED using the 
androgen-sensitive prostate cancer cell line LNCaP has been completed. Key 
molecular components of the AD induced NED pathway such as hASH1, PTOV1, 
and REST have also been investigated at a molecular level. Confocal microscopy 
analysis demonstrated that transcription factor hASH1 is excluded from the 
nucleus in untreated LNCaP cells but localises to the nucleus after AD. Bright-
field microscopy demonstrated that alongside this change in hASH1 localisation, 
LNCaP cells also develop a neuronal-like morphology, the extent of which has 
been quantified using confocal microscopy to measure the length of neurite-like 
extensions.  
 
Analysis of gene and protein expression during the course of AD induced NED 
also largely supported the hypothesis that PTOV1 and REST may be important 
facilitators and regulators of the activation of neuronal-like differentiation 
programs in LNCaP cells respectively. The ability of low concentrations of 
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synthetic androgen to prevent the NED process was also demonstrated, 
highlighting a key finding that hASH1 upregulation is insufficient to cause NSE 
upregulation without nuclear localisation of hASH1, potentially identifying hASH1 
as a candidate protein for further investigation, either as a biomarker of early (pre-
NSE upregulation) NED or as a therapeutic target.  
 
3.5 Limitations, weaknesses and future experiments  
As the majority of work in this chapter served to characterise the three PCa cell 
lines and the AD LNCaP based model of PCa NED, much of the results are not 
novel. However, this robust characterisation was necessary in order to study the 
proposed NED pathway and to provide a robust understanding of how these cell 
lines behaved in an untreated state. In terms of the scratch assays performed, it 
is important to consider that these assays are only a very simplistic method of 
assessing growth and the invasive and metastatic potential of cell lines. For 
example, as cells are confluent when the scratch is made, the speed at which 
they close the wound is likely to be different to when cells are still in the 
exponential phase of growth. Therefore, growth rate would have been better 
assessed by measuring cell number over time via methods such as IncuCyte. 
Secondly, scratch assays are only a basic indicator of invasive potential, to 
properly assess invasion, transwell culture plates coated with Matrigel or collagen 
could have been used as these assays more closely represent the process of 
invasion. Finally, when assessing migration via scratch assay it is important to 
consider that to properly delineate migration activity from growth, it would be ideal 
to employ a real time image capture system (such as Incucyte) and to track and 
quantify individual migrating cells via software analysis (Liang, Park & Guan, 
2007). Furthermore, using the scratch assay, even when performing multiple 
careful washes after the scratch is made, it is inevitable that some free-floating 
cells will remain which could mistakenly be identified as migrating cells at early 
timepoints. Overall, migration as assessed by scratch assay is a qualitative 
measure, that could be adapted to a quantitative analysis (either via software, or 
using a GFP reporter tag on EMT related genes such as N-cadherin) (Liang, Park 
& Guan, 2007; Camand et al., 2012). However, in most cases, a transwell assay 
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(without substrate) would be a preferable, yet more expensive, methodology for 
quantifying migration activity in vitro (Gianelli et al., 1997; Justus et al., 2014). 
 
As discussed in section 3.3.3, the charcoal-stripped FBS method of AD has many 
inherent limitations, including the non-specificity to androgen and the fact that 
concentrations of androgen are likely to vary between lots of FBS and CS-FBS 
from suppliers. As the concentration of androgen in either the control or AD media 
were not empirically tested, i.e. via ELISA, the variability in androgen and other 
off-target effects of charcoal-stripping could not be assessed or accounted for. A 
potential improvement to the CS-FBS method would have been to individually re-
supplement each component back to the concentrations found in standard FBS. 
In addition, only a small number of timepoints were assessed for gene and protein 
expression (5 and 15 d) in response to AD. This meant that perhaps the very 
early molecular changes associated with NED would not have been observed, 
further experiments to capture timepoints at 2, 4 and 6 h of AD treatment would 
likely add value and understanding to the molecular drivers of PCa NED. 
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4. Molecular reversibility of neuroendocrine 
differentiation in prostate cancer cells 
4.1 Introduction 
The role of NED cells within prostate tumours and metastases remains unclear 
and is an under-researched area of prostate cancer biology (Grigore et al., 2015). 
However, NED has been shown to confer therapeutic resistance upon prostate 
cancer cells (Beltran et al., 2016; Hu, Choo, & Huang, 2015; Karantanos, Corn, 
& Thompson, 2013; Zou et al., 2017). A key aspect of NED prostate cancer cells 
is their very low proliferative capabilities compared to epithelial PCa cells (Danza 
et al., 2012). This has led to speculation that forcing PCa cells towards NED could 
be a viable therapeutic option to slow the growth of tumours.  However, a recent 
study showed that the pan-tyrosine kinase inhibitor Dovitinib induces NED in 
LNCaP cells and in PC-3 xenografts in mice (Yadav et al., 2017). This study 
demonstrated that whilst dovitinib initially reduced tumour growth rate, after nine 
days PC-3 xenografts became dovitinib resistant. These resistant tumours 
displayed significantly increased growth rate and greatly upregulated expression 
of the NED biomarker NSE (Yadav et al., 2017).  
 
Usually in the cancer paradigm, the development of therapeutic resistance results 
in an increased growth rate, due to selection of cancer cells that proliferate best 
under the specific selection pressure of the therapeutics (Friedman, 2016). This 
poses the question as to why NED is associated with more advanced, more 
aggressive disease. One possible mechanism by which NED could support 
disease recurrence is if NED cells could act as a ‘reservoir’, similar to the cancer 
stem-cell reseeding paradigm, where resistant NED cells could transdifferentiate 
back into epithelial phenotype PCa cells (Shen et al., 1997). Another possible 
mechanism could be that NED cells exert survival and growth promoting effects 
upon other cells within the tumour via paracrine signalling (Chang et al., 2017). 
This chapter focuses on determining the effects of intermittent androgen 
deprivation (IAD) and discusses the potential clinical implications. 
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4.1.1 Clinical use of intermittent ADT 
It is well established that PCa tumours treated with ADT often display increased 
NED (Shen et al., 1997; Terry & Beltran, 2014). As such, intermittent (I)ADT has 
long been touted as a solution to delaying the development of CRPC in response 
to ADT (Feldman & Feldman, 2001). The intermittent use of radio and 
chemotherapeutics clinically is well accepted, primarily because poorly tolerated 
toxicity necessitates discontinuous use. Whereas, in the case of ADT, intermittent 
treatment is proposed to delay hormone therapy resistance, improve patient 
quality of life and reduce financial costs (Shore & Crawford, 2010). Indeed, 
Seruga et al. (2008) argue that IADT should be the standard of care for PCa 
(Seruga & Tannock, 2008).  However, European Association of Urology 
guidelines continue to mandate that ADT be constant (i.e. no treatment holidays) 
and do not support the use of IADT clinically (Heidenreich et al., 2014).  
 
Early IADT trials focussed on the quality of life enhancements offered by IADT 
and were very favourable (Klotz et al., 1986). Unfortunately, the small sample 
size (n=20) makes it impossible to draw accurate conclusions on overall survival 
or disease progression. Higher powered studies (n=3040 and n=1386) focussing 
on overall survival, found that IADT was at best non-inferior to constant ADT 
(cADT) or performed considerably worse than cADT (Crook et al., 2012; Hussain 
et al., 2013; Mottet et al., 2012). One study used eight-month treatment cycles, 
with treatment holiday length determined by rising PSA level or disease 
progression (Crook et al., 2012). Whereas, another study began with 6 months 
ADT, followed by 30 days on, then 30 days off therapy with PSA concentration 
10 ng/mL or disease progression as a cut off to resume ADT (Mottet et al., 2011). 
A lack of molecular stratification of tumours in these trials means that it is not 
possible to infer if IADT reduced NED or benefitted/harmed patients with high 
NED compared to cADT. This lack of stratification, to account for tumour 
heterogeneity, could also explain the inconclusive findings of IADT clinical trials 
to date (Hussain., 2017). Evidently, before more structured clinical trials can 
investigate the effects of IADT on NED, a greater understanding of the molecular 
drivers of NED is required.   
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4.1.2 Potential implications of NED reversibility 
The implications of NED reversibility could be advantageous or detrimental to 
patient survival. NED is correlated with disease progression and poor prognosis 
(Hu et al., 2015), therefore prevention of NED and mechanisms to target NED 
cells are considered desirable. In addition, NED can be induced by a variety of 
clinically used therapeutics, including ADT, radiotherapy and some 
chemotherapeutics such as docetaxel (Hu et al., 2015). NED cells are also 
inherently resistant to these therapies (Hu et al., 2015). The preferred 
chemotherapeutic option for NED PCa are platinum based therapeutics such as 
cisplatin (Vlachostergios & Papandreou, 2015). At first glance, if NED was a 
reversible process, these effects could be mitigated and potentially slow disease 
progression. However, considering the high therapeutic resistance of NED cells, 
reversibility to an epithelial phenotype could also become a method of tumour 
reseeding, similar to that of the cancer stem cell (CSC) niche paradigm (Fig. 4.1). 
 
 
 
Figure 4.1 Schematic diagram depicting proposed interactions between 
neuroendocrine differentiation (NED) in prostate cancer cells and the 
tumour environment. ADT (androgen deprivation therapy), CRPC (castrate-
resistant prostate cancer).  
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The CSC niche can contribute to disease recurrence and progression through 
classical tumour reseeding (Chang, 2016). The CSC niche has low proliferation 
and high therapeutic resistance, meaning that after the application of therapeutic 
regimens such as ADT, CSCs can remain (Lang et al., 2009), these cells can 
then contribute to disease progression by repopulating the tumour with castrate-
resistant or androgen-independent cells (Lang et al., 2009). The less 
differentiated state of CSCs grants increased ability to adapt under the selective 
pressure of applied therapeutics (Chang, 2016; Lang et al., 2009). It is a 
possibility that the NED niche may also be able to fulfil a similar role, by becoming 
treatment resistant (Hu et al., 2015) and later transdifferentiating back into an 
epithelial PCa  (Shen et al., 1997) or castrate-resistant prostate cancer (CRPC) 
phenotype (Fig. 4.1). An example of a similar phenomenon would be breast 
cancer dormancy, where micro-metastases can remain hidden within the bone 
marrow niche, sometimes for decades, before disease recurrence (Price et al., 
2016). The NED niche may also influence the growth, survival and differentiation 
of surrounding tumour cells through paracrine support (Chang et al., 2017). 
These paracrine secretions from the NED cell niche could also influence the 
differentiation of residual CSCs remaining after treatment along with NED cells, 
or provide mechanisms for PCa to become androgen-independent (Fig. 4.1). 
 
4.1.3 Previous NED reversibility studies 
The reversibility of the AD-induced NED phenotype was first investigated by Shen 
et al. (1997), who found that the NED morphology was reversed when NED 
LNCaP cells were returned to media containing 10% FBS. Interestingly, 
supplementation of AD culture conditions with 1 nM dihydrotestosterone (DHT) 
was insufficient to revert the NED morphology, but was sufficient to prevent its 
acquisition (Shen et al., 1997). Remarkably, only two subsequent studies in the 
literature have since investigated the reversibility of the NED phenotype (Cox et 
al., 1999; Deng et al., 2008). An early study first identified that NED of LNCaP 
cells was inducible by cAMP and after withdrawal of the inducing cAMP, the NED 
phenotype was lost (Cox et al., 1999). Interestingly, upon loss of the NED 
phenotype, activity of tyrosine kinase and MAPK proteins was increased and cells 
re-entered the cell cycle (Cox et al., 1999). In addition, LNCaP growth was 
powerfully inhibited by cAMP and induced expression of NSE. Upon withdrawal 
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of cAMP, expression of NSE was reduced to basal levels. Thus, the NED 
phenotype induced by cAMP is reversible in terms of morphology and NSE 
expression (Cox et al., 1999). The second NED reversibility study identified that 
the NED phenotype is also induced through irradiation Deng et al., 2008). 
Activation of cAMP response element-binding protein (CREB) and activating 
transcription factor 2 (ATF2) were sufficient to reverse radiation-induced NED 
(Deng et al., 2008). This study aims to be the first investigation of the reversibility 
of the underpinning pathway facilitating AD induced NED, and to examine the 
effects of IADT on NED LNCaP cells.  
 
4.1.4 Development of an IAD model 
IADT was investigated using Charcoal stripped FCS to induce NED in LNCaP 
cells. In order to mimic treatment cessation periods, NED cells were 
supplemented with R1881 for 15 days before they were subjected to a second 
cycle of AD conditions via CS-FCS. For comparison, LNCaP cells were also 
maintained in complete media or AD media or AD media with DMSO vehicle for 
the entire 30 d period as a control (Fig. 4.2).  
 
Figure 4.2, Schematic diagram detailing the experiment design for 
androgen deprivation cessation experiments. LNCaP cells were cultured in 
either control media (C) or androgen deprived media (AD) for 15 d. LNCaP cells 
were then either maintained for a further 5, 10 or 15 d in AD media supplemented 
with synthetic androgen (AD+R1881).  
15 30 days
C
AD + R1881
AD
Control
Androgen Deprived
0
AD + R1881
+5 +10 +15
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Importantly, this model uses treatment lengths which would be realistic to apply 
clinically (Mottet et al., 2012) and also allows for substantial development of NED 
before AD cessation. A key difference between this model and any previously 
used model of NED reversibility is the use of synthetic androgen R1881. Whilst 
Shen et al., 1997 supplemented cultures with DHT, R1881 is known to be more 
stable than DHT in cell culture media and is not metabolised (Bonne & Raynaud, 
1976; Brown, Rothwell, & Migeon, 1981).  Thus, the concentration of R1881 
remains more consistent than when using endogenous DHT. Furthermore, this 
study aimed to specifically assess the effects of androgen re-introduction, which 
would not be possible using normal FBS as a source of androgens due to the 
many other hormones which would also be re-introduced.  
 
4.1.5 Investigating the molecular and morphological reversibility of NED  
Previous experiments demonstrated that a NED transcriptional profile and 
resulting phenotype can be specifically induced by AD (Chapter 3). This lead to 
the investigation of whether reintroduction of androgen to NED cells could reverse 
the changes, at both a molecular and morphological level. This specific research 
question has high clinical relevance as the use of IADT has long been proposed 
by clinicians as a method of delaying the transition to CRPC (Oliver, et al., 1997). 
Current European Association of Urology guidelines mandate that patients 
should continue to receive ADT even after the progression to CRPC (Heidenreich 
et al., 2014). Therefore, studies providing data on the molecular response of 
androgen-sensitive PCa cells to successive cycles of ADT and the effects upon 
NED are of significant clinical relevance and interest. The reversibility of NED 
induced by AD has never been investigated in depth at a molecular level (Grigore, 
Ben-Jacob, & Farach-Carson, 2015; Hu, Choo, & Huang, 2015). 
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4.1.6 Study aim and research questions 
Study aim: To establish an in vitro model of intermittent androgen deprivation 
and use this model to investigate the reversibility of NED and the phenotypic and 
molecular effects of a second cycle of AD on NED in LNCaP cells.   
 
Research questions: (1) To what extent are the molecular (NSE expression and 
hASH1 nuclear localisation) and morphological (neurite-like extensions) changes 
associated with NED reversible? (2) How does intermittent AD effect the NED 
pathway? 
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4.2 Results 
4.2.1 Reversibility of neuroendocrine morphology 
The morphology of LNCaP cells was observed using light microscopy during AD 
and 5, 10 and 15 d after supplementation with R1881. During AD, LNCaP cells 
developed long neurite-like processes (Fig. 4.3 Panel ii). Interestingly, the 
majority of these neurite-like extensions appeared to have been lost after a further 
15 d of culture in the presence of 1 nM R1881 synthetic androgen (Fig. 4.3 panel 
iii-v) and the cellular morphology closely resembled that of untreated LNCaP cells 
(Fig. 4.3 panel i).  
 
Figure 4.3. Reintroduction of androgen reverses neuroendocrine 
differentiation morphology. Representative bright field microscopy images of 
LNCaP cells which were untreated (i) for 30 d, androgen deprived (AD) for 15 d 
(ii) and then 15 d supplemented with 1 nM R1881 (iii, iv and v) (20×)). Arrows 
indicate presence of neurite-like extensions.   
30	di)
ii) iii)
iv) v)
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The absence of neurite-like processes from NED LNCaP cells treated with 
synthetic androgen, suggests that NED is unlikely to be an immutable change 
and that these cells may retain androgen sensitivity. The implications of NED 
plasticity are multi-faceted; since NED cells have high therapeutic resistance, 
particularly to radiotherapy (Hu et al., 2015), the reversal of NED could re-
sensitise these cells to treatment. Conversely, the ability to revert from NED back 
to an epithelial phenotype could be a mechanism of post-treatment tumour 
reseeding (Shen et al., 1997), a paradigm usually associated with the cancer 
stem-cell niche (Fig. 4.1). To better understand the nature and extent of NED 
reversibility, the molecular components underpinning NED were investigated. 
 
4.2.2 Molecular reversibility of NED 
Previous experiments demonstrated that AR expression remained stable 
throughout 15 d of AD (Chapter 3), by 30 d of AD, expression of AR was 
upregulated (Fig. 4.4). After reintroduction of synthetic androgen, AR expression 
was reduced compared to 30 d AD treated cells, but remained elevated compared 
to untreated LNCaP cells. Curiously, upon AD, an additional band with a MW of 
~90 kDa was detected on the AR immunoblot, (Fig. 4.4) this could be an AR 
splice variant. Furthermore, upon reintroduction of R1881, the expression of this 
band was lost. Many AR splice variants  are known to be ligand independent (see 
Appendix 1) (Dehm et al., 2011; Jones et al., 2015).  
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Figure 4.4. Molecular changes associated with reversal of neuroendocrine 
differentiation via androgen reintroduction. Representative immunoblot 
images of androgen receptor (AR), neuron-specific enolase (NSE),human 
Achaete-scute homolog 1 (hASH1) and prostate specific antigen (PSA) 
expression in LNCaP cells after 30 d of culture in control (C) or androgen deprived 
(AD) conditions or 15 d in androgen deprived media, followed by a further 15 days 
± DMSO vehicle (V) or 1nM R1881 (1 nM). 
 
PSA is a marker of canonical AR transcriptional activity (Luke & Coffey, 1994), 
immunoblotting confirmed that PSA expression was robust under control culture 
conditions, undetected under AD conditions and in AD conditions with vehicle 
control (Fig. 4.4). This indicates that despite robust expression of AR, canonical 
AR signalling was effectively disrupted by AD. Expression of PSA in NED LNCaP 
cells was restored after 15 d of R1881 supplementation to the AD culture 
conditions (Fig. 4.4). Interestingly, the expression of PSA in AD and R1881 
treated cells was considerably lower than in untreated LNCaP cells. This data 
revealed that NED LNCaP cells not only retain AR expression, but potentially the 
capacity for canonical prostatic AR-directed gene transcription.  
?
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The expression of NSE was also assessed as a marker of the NED phenotype 
(Fig. 4.4). In keeping with previous data, NSE is considerably upregulated by AD. 
Remarkably, after reintroduction of androgen, and restoration of PSA expression, 
NSE expression remains elevated. These findings demonstrated that 1 nM 
R1881 was sufficient to reverse NED morphology (Fig. 4.3), however 
transcription factor hASH1 and NED biomarker NSE remain elevated (Fig. 4.4), 
suggesting that AR and hASH1 transcriptional activity may not be mutually 
exclusive after cessation of AD.  
 
Data in chapter 3 identified hASH1 nuclear localisation as a potential key driver 
of NED, hASH1 upregulation has previously been demonstrated to be associated 
with PCa NED (Rapa et al., 2013), therefore the expression of hASH1 was 
assessed in response to the reintroduction of androgen to NED LNCaP cells. 
hASH1 expression after 30 d of AD was upregulated (Fig. 4.4). Of critical 
importance, expression of hASH1 remained elevated even after re-introduction 
of androgens (Fig. 4.4). The sustained elevation of hASH1 expression suggested 
that whilst the morphology and some molecular characteristics of NED may be 
reversible, these NED LNCaP cells treated with R1881 may retain some aspects 
of the NED phenotype.   
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4.2.3 hASH1 retains nuclear localisation upon reintroduction of androgen  
Previous analysis of hASH1 localisation demonstrated that hASH1 is excluded 
from the nucleus of untreated LNCaP cells (Fig. 3.13). However, after AD and 
acquisition of the NED phenotype, hASH1 localises to the nucleus. Coupled with 
the evidence that upregulation of hASH1 was not reversed by cessation of AD, 
the localisation of hASH1 was investigated using confocal microscopy (Fig. 4.5). 
 
Figure 4.5. Neurogenesis promoter hASH1 retains nuclear localisation 
despite a reversal of neuroendocrine morphology.  Representative confocal 
microscopy images of LNCaP cells stained with anti-hASH1 and anti-NSE 
antibodies after 30 d of culture in complete RPMI1640 media (control) or 
androgen deprived conditions (AD) or 15 d androgen deprivation followed by 15 
d in the presence of 1 nM R1881 (AD+R1881) (63 x with digital zoom onto a 
single representative cell). Scale bar represents 5 m. 
 
Untreated LNCaP cells (control) displayed very low hASH1 expression which was 
exclusively cytoplasmic (Fig. 4.5), matching previous findings (Fig. 3.13). 
Correspondingly, expression of NSE was not detected when hASH1 was 
excluded from the nucleus (Fig. 4.5). After 15 d of AD, NSE expression is detected 
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in the cytoplasm, consistent with previous results (Fig. 3.13). hASH1 is also 
upregulated and was intensely localised to the nucleus. When R1881 synthetic 
androgen was added to NED LNCaP cells, NSE expression decreased, in line 
with the immunoblot analysis (Fig. 4.5, Panel AD+R1881 15 Day). However, 
whilst the cytoplasmic hASH1 returned to basal levels, these cells robustly retain 
hASH1 within their nucleus. This demonstrated that despite the high degree of 
reversibility of other molecular changes associated with NED, the localisation of 
hASH1 to the nucleus may be a more permanent adaption. Analysis of hASH1 
localisation has never previously been performed in a model of IAD and 
represents an important finding of clinical interest, as hASH1 could be utilised as 
a biomarker of NED or as a therapeutic target.  
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Figure 4.6. Retention of nuclear hASH1 is widespread and neurite-like 
processes containing hASH1 are lost.  Representative confocal microscopy 
images of LNCaP cells stained with anti-hASH1 after 30 days of culture in 
complete RPMI1640 media (control), androgen deprived conditions for 30 d (AD) 
or 15 d AD followed by a further 15 d in the presence of 1 nM R1881 (AD+R1881) 
(63 x magnification), Scale bar represents 50 m.  
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Using a wider field of view for confocal analysis demonstrated that hASH1 nuclear 
exclusion is ubiquitous in LNCaP cells maintained in control conditions, however 
a key limitation must be acknowledged that signal for hASH1 and DAPI in these 
images was low and not easily visible (Fig. 4.6). After 30 d of continuous AD (cAD) 
hASH1 was concentrated in the cell nucleus and prevalent in the cytoplasm, 
including throughout the neurite-like projections (Fig. 4.6). After culture in media 
containing 1 nM synthetic androgen, LNCaP cells reverted to a morphology 
similar to control untreated LNCaP cells, losing their neurite-like extensions. After 
AD cessation, where cells were AD for 15 d and were then supplemented with 
synthetic androgen for 15 d, hASH1 appears to be retained and enriched within 
the nucleus, whilst cytoplasmic hASH1 is diminished (Fig. 4.6). Interestingly, NED 
LNCaP cells not only display strong nuclear hASH1 localisation, but hASH1 
expression was detected throughout the neurite-like extensions of these cells. 
This data supports the notion that hASH1 localisation is a durable change during 
AD-induced NED and is retained, despite the reversibility of other NED features. 
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4.2.4 Investigating the reversibility of NED and effects of IAD 
After analysing the response of AD-induced NED LNCaP cells to reintroduction 
of androgen (AD cessation), the model was further extended to recapitulate IADT. 
Following reintroduction of androgen, NED LNCaP cells were then subjected to 
a second cycle of AD, by culturing NED LNCaP cells in media containing 10% 
charcoal-stripped FBS for a further 15 d. Thus, following 15 days AD, NED cells 
were then exposed to synthetic androgen for 15 days, followed by a second 15 
day-period of AD. Details of experimental conditions are shown in figure 4.7. 
 
 
Figure 4.7. Schematic diagram showing the experimental design for 
investigation of IAD, including two 15-day cycles of AD separated by a 15-
day intermediate period of androgen reintroduction. LNCaP cells were 
cultured in either control media (C), androgen deprived for 15 d (AD1), AD for 15 
d then AD media with 1 nM R1881 for 15 d (AD+R1881) or AD media for 15 d 
then AD media with 1 nM R1881 for 15 d and finally AD media for a further 15 d 
(AD2).  
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4.2.5 Effect of IAD on LNCaP cellular morphology 
 
The effects of IAD on the morphology of LNCaP cells was assessed using 
confocal microscopy using a membrane stain to visualise the cells (Fig 4.8). 
 
 
Figure 4.8 Morphological changes of LNCaP cells throughout intermittent 
AD.  Representative confocal microscopy images of LNCaP cells stained with 
neurite outgrowth staining kit (non-specific membrane stain) maintained in 
complete media (Control), androgen deprived conditions for 15 days (AD 1st 
Cycle), intermittent AD consisting of 15 d AD and 15 d with 1 nM R1881 
(AD+R1881) or a second 15 d androgen deprivation cycle (AD 2nd Cycle) (20 x 
magnification, 5x5 tile scan, digital zoom to representative field), Scale bar 
represents 100 m, red arrows indicate neurite-like projections.  
AD	+	R1881
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Consistent with previous experiments, LNCaP cells acquired neurite-like 
projections after the first 15-day AD cycle which were lost after introduction of 
synthetic androgen. After a second 15 d period of AD, LNCaP cells re-acquired 
neurite-like projections, further highlighting the plasticity of LNCaP cell 
phenotypes (Fig. 4.8). 
 
4.2.6 Molecular analysis of the effect of IAD on AR signalling 
To investigate the effects of simulated IAD with two 15 d cycles of AD, expression 
of genes involved in the AR signalling axis and NED pathway were assessed 
using qRT-PCR. Consistent with previous results, AR and PSA were robustly 
expressed in LNCaP cells cultured in control media (Fig. 4.9). After 15 days of 
AD, AR expression was slightly elevated and remained similarly elevated after 
androgen reintroduction. As expected, PSA expression rapidly declined after 15 
d AD (p = <0.001). After 15 d of reintroduction of androgen, PSA expression 
returned to basal levels but AR remained slightly increased. This further supports 
the immunoblot data and confirms that NED LNCaP cells may re-establish 
aspects of canonical AR signalling after androgen reintroduction (Figs. 4.4 and 
4.15). Unexpectedly, after a second 15 d AD cycle, NED LNCaP cells lost 
detectable expression of AR (Fig. 4.9), with a concurrent loss of detectable PSA 
expression.  
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Figure 4.9 Expression of and androgen receptor (AR) and prostate specific 
antigen (PSA) in LNCaP cells after two androgen deprivation cycles. 
Relative expression of AR and PSA in LNCaP cells that were either untreated 
(CTRL), subjected to constant AD (AD1), AD followed by cessation of AD 
(AD+R1881) (1.027-fold change) or a second cycle of AD (AD2) after the AD 
cessation period, analysed via qRT-PCR. Data is expressed as mean ± SEM, 
(n=3) p< 0.05 (*), p<0.01 (**) and p< 0.001 (***) as determined by one-way 
ANOVA with Dunnett’s correction. N.D, not detected. In AD2 samples, robust 
expression of reference gene ACTB was detected at Ct 15.10 ( 0.26) which is 
consistent with other experiments, demonstrating that the cDNA generated was 
viable. 
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4.2.7 Molecular analysis of the effect of IAD on NED pathway 
Following investigation of the androgen signalling axis, the changes in 
expression of key genes in the NED pathway were assessed in response to 
IAD. 
 
Figure 4.10 Expression of key NED associated genes during intermittent 
(I)AD. Relative expression of PTOV1, NSE, REST, hASH1, SYP and MMP-9 in 
LNCaP cells that were subjected to either one 15 d AD cycle (AD1), AD followed 
by cessation of AD for 15 d (AD+R1881) or a second 15 d AD cycle after AD 
cessation (AD2), compared to cells maintained in complete media (CTRL), 
analysed via qRT-PCR. Data is expressed as mean ± SEM, (n=3) p< 0.05 (*), 
p<0.01 (**) and p< 0.001 (***) as determined by one-way ANOVA with Dunnett’s 
correction, N.D, not detected.  
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After the first AD cycle expression of PTOV1 was slightly upregulated (Fig. 4.10). 
Interestingly, PTOV1 expression was significantly upregulated (4.5-fold) (p = 
<0.001) by the reintroduction of androgen. Whilst this was surprising, it aligns with 
the hypothesis that PTOV1 may be involved in the disruption of cell fate (Alaña 
et al., 2014; Meder et al., 2016). An even more unexpected result was that 
expression of PTOV1 became undetectable after the second 15 d AD cycle. 
 
NSE expression was not significantly upregulated by the first cycle of AD. 
Interestingly, NSE expression was significantly downregulated (p = <0.001) by 
the reintroduction of androgen to the NED LNCaP cells, supporting the 
hypothesis that reintroduction of androgen can ablate molecular and 
morphological features of NED (Fig. 4.8 and 4.9). Curiously, after the second 15 
d cycle of AD, gene expression of NSE increased compared to the reversed NED 
LNCaP cells, but remained significantly below basal levels (p = 0.01).  
 
The proposed pathway of NED implicates REST as a key inhibitor of NED under 
the pressure of canonical AR signalling. Previously, REST reduction has been 
demonstrated to be essential to hypoxia driven NED in PCa (Lin et al., 2016). 
This data shows that REST gene expression is unchanged by one AD cycle but 
is significantly upregulated (4-fold; p = <0.001) when NED is reversed by the 
reintroduction of androgen (Fig. 4.10). This result, when paired with the REST 
immunoblot data (Fig. 4.11) strongly supports the hypothesis that REST can 
inhibit the NED pathway and even reverse it in an androgen signalling dependent 
manner. After the second cycle of AD, expression of REST was undetected (Fig. 
4.10).  
 
Consistent with the data produced by confocal microscopy hASH1 expression of 
was slightly upregulated by one AD cycle and this elevation was retained even 
after reintroduction of androgen. Following the second cycle of AD, hASH1 
expression remained elevated above basal levels. SYP, is a clinically used 
biomarker of prostate cancer NED (Altree-Tacha et al., 2017). Expression of SYP 
was slightly elevated after 1 cycle of AD and remained at this level during 
androgen reintroduction. Interestingly, synaptophysin expression was further 
elevated by a second cycle of AD, becoming statistically significant (p = 0.002).  
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MMP-9 expression is closely correlated with progression to CRPC and increased 
prostate cancer aggression (Azuma et al., 2003). Interestingly, the expression of 
MMP-9 steadily increased throughout the treatments. MMP-9 was slightly 
upregulated after the first AD cycle, becoming significantly upregulated after AD 
cessation (p = 0.001) and increasing further to 10-fold above basal levels after a 
second cycle of AD (p = <0.001). 
 
Figure 4.11 Expression of key neuroendocrine associated proteins during 
IAD. Representative immunoblot images of androgen receptor (AR), RE-1 
silencing transcription factor (REST), prostate specific antigen (PSA), neuron 
specific enolase (NSE) and human achaete-scute homolog 1 (hASH1) in LNCaP 
cells which were either untreated (CTRL), subjected to one 15 d AD cycle (AD1), 
AD followed by cessation of AD (AD+R1881) or a second 15 d AD cycle after AD 
cessation (AD2). Beta actin was used as a loading control. 
 
Expression of AR protein remained stable throughout IAD (Fig. 4.11), which is in 
contrast with the qPCR data (Fig. 4.9) where expression of AR was not detected 
in the AD2 sample. A possible explanation for this inconsistency between the 
gene and protein expression of AR in the AD2 samples is that in the long-term 
absence of androgen (2 AD cycles) the AR protein is not being activated and 
C AD1
AD	+
R1881 AD2
KdAkDa
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therefore remains membrane bound and less able to be degraded in comparison 
to when it is translocating to the nucleus during AR-signalling. It is also possible 
that gene expression may be below detection whilst the AR protein remains 
present, thereby causing a discrepancy between the qPCR and immunoblot data. 
Another consideration is that the binding sites of the AR antibody and AR 
oligonucleotides used in qPCR are not the same. This could result in detection of 
other splice variants which retain that antibody binding site being detected via 
immunoblot, but not in qPCR experiments (see appendix 1; Fig. 8.1). However, 
in this case that difference is unlikely to be the main contributing factor to the 
discrepancy between the immunoblot and qPCR results, since the transcript 
variants with potential to be targeted by the AR antibody also have substantially 
different molecular weights and this was not apparent on the immunoblot 
analysis. 
 
 In addition, PSA protein expression is in consensus with the qPCR data for 
control and AD1 samples, but where the gene expression is restored to basal 
levels after re-introduction of R1881, this is not reflected at the protein level. This 
is potentially highlighting a ‘lag time’ between the restoration of PSA gene 
expression and the restoration of PSA protein concentrations to basal levels. In 
consensus with the qPCR data, PSA expression in the AD2 samples is extremely 
low when assessed via immunoblot and was undetected in the qPCR experiment.  
Interestingly, at the protein level, NSE expression appeared to peak at the end of 
the androgen reintroduction period and remain slightly higher than basal levels 
during the second AD period (Fig. 4.11). This discrepancy with the qRT-PCR data 
for NSE expression could be due to differences in the turnover of NSE mRNA 
and protein within the cells. Expression of hASH1 was notably upregulated at 
protein level after the second cycle of AD (Fig. 4.11). Expression of REST 
appeared to be moderately downregulated during the first AD cycle and remained 
this way throughout IAD, in future work this change could be quantified by 
employing additional methodologies such as densitometry or ELISA.  
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4.2.8 Analysis of hASH1 localisation throughout IAD 
Previous analysis of hASH1 localisation during IAD (Fig. 4.5 and 4.6) showed 
that hASH1 nuclear localisation was enriched after cessation of AD. Therefore, 
the localisation of hASH1 was assessed after a second cycle of AD at 10 d (Fig. 
4.12 and 4.13).  
 
Figure 4.12 Schematic diagram detailing the experiment design for 
androgen deprivation cessation experiments assessing hASH1 
localisation. LNCaP cells were cultured in either control media (C), androgen 
deprived for 15 d (AD1), AD for 15 d then AD media with 1 nM R1881 for 15 d 
(AD+R1881), AD media for 15 d then AD media with 1 nM R1881 for 15 d and 
finally AD media for a further 15 d (AD2) or continuous AD (cAD) for 30 days.  
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Figure 4.13 hASH1 localisation throughout IADT and 10 days into a second 
AD cycle.  Representative confocal microscopy images of LNCaP cells stained 
with anti-hASH1 and anti-NSE after one 15 d androgen deprivation cycle (AD), 
intermittent ADT consisting of one 15 d AD cycle then 15 d AD cessation 
(AD+R1881), 10 d into a second androgen deprivation cycle after AD cessation 
(AD2) or continuous AD for 30 d (cAD) (63 x magnification, digital zoom into 
representative cells), Scale bar represents 5 m, n=3.  
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Consistent with previous data hASH1 was excluded from the nucleus of untreated 
LNCaP cells. After the first AD cycle hASH1 was profuse throughout the cell 
including the nucleus (Fig. 4.13). After reintroduction of androgen and loss of 
neurite-like projections, hASH1 became enriched within the nucleus, which was 
consistent with previous confocal analysis. After 10 days into the second AD 
cycle, hASH1 remains intensely localised to the nucleus, neurite-like projections 
are reacquired but expression of NSE remains low. In addition, cytoplasmic 
hASH1 is reduced whilst nuclear hASH1 remains high. These results establish, 
for the first time, the localisation of hASH1 during IAD and confirm that hASH1 is 
present within the nucleus throughout successive cycles of AD. This data would 
also suggest that the shift to nuclear localisation of hASH1 under AD is persistent. 
This is in alignment with hASH1 localisation during the commitment of neural 
stem cells to a neural cell fate, where chromatin-bound hASH1 is resistant to 
degradation compared to cytoplasmic hASH1 (Gillotin, Davies, & Philpott, 2018), 
further supporting that hASH1 is likely to be chromatin bound in NED LNCaP 
cells. 
 
4.3 Discussion 
4.3.1 Research objectives and key findings 
On the basis of previously published studies demonstrating AD induces NED of 
PCa, both in vitro (Shen et al., 1997) and in vivo (Bluemn et al., 2017; Rapa et 
al., 2008), alongside the present studies characterised molecular pathway of AD-
induced NED; the NED model was adapted to investigate the reversibility of NED. 
In addition, insight was sought into the molecular implications of Intermittent 
(I)ADT on the NED pathway and the effects of a 2nd successive AD cycle. Given 
the controversy that exists around the clinical use of IADT (Heidenreich et al., 
2014; Klotz et al., 1986; Mottet et al., 2012; Shore & Crawford, 2010) and the 
conflicting strategies on NED prevention, this study aimed to provide new 
evidence to facilitate a better-informed debate on these issues. The 15 day cycle 
length used for IADT experiments in this study is likely to be sufficiently long 
enough to be clinically relevant, because the change in androgen concentration 
from switching cells to CS-FBS media and back to full media is effectively instant. 
In patients, the half-life of enzalutamide is 5.8 days (USFDA, 2012), therefore a 
cycle time of 15 days using CS-FBS in vitro would be representative of longer 
  
140 
 
time frame clinically, which would give patients a longer window between cycles 
and be more realistic to implement. However, it must be considered that this is a 
limitation of this model and study. 
 
Importantly, the model of NED reversibility used in this study is consistent with 
previous NED reversibility studies, which found NED morphology could be 
reverted to an epithelial phenotype after reintroduction of androgen (Shen et al., 
1997). For the first time, the underpinning molecular components underpinning 
the NED pathway were analysed during the reversal process and revealed that 
key molecular components of NED revert to basal states. This includes the 
restoration of AR signalling driving PSA expression and a significant upregulation 
of neurogenesis repressor REST. However, molecular investigation of NED 
reversibility also revealed unexpected complexity, namely the retention of hASH1 
exclusively in the nucleus and elevated NSE expression. The retention of nuclear 
hASH1, when androgen was reintroduced, despite the loss of NED morphology 
and restoration of canonical AR signalling aspects, could suggest that hASH1 
may retain transcriptional activity, which was previously mutually exclusive with 
androgen receptor signalling. This possibility of a hybrid phenotype was further 
evidenced by the data showing that NSE protein expression was highest after 
reversal of NED and remained elevated after the second AD cycle. In the context 
of the proposed NED model, this would suggest that some of the transcriptional 
activity induced by hASH1 is maintained when androgen is reintroduced which 
could mean that some of the resistance mechanisms of NED PCa persist.  
 
Critically, these experiments demonstrated that reversal of NED could be a viable 
mechanism of disease recurrence and if hASH1 retains transcriptional activity, 
the resistance mechanisms of NED could also be retained. The ability for these 
cells to undergo a second NED would certainly support this notion. In addition, 
reversal of NED resulted in significant upregulation of MMP-9, which further 
increased after a second cycle of AD. Taken as a whole, this study demonstrates 
that the paradigm of complete NED reversibility is actually considerably more 
complex than previously thought. Furthermore, the evidence generated using this 
model suggests that reversal of NED may actually result in a more aggressive 
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phenotype, supported by the data showing increased MMP-9 gene expression 
and hASH1 nuclear localisation. 
 
4.3.2 Morphological NED reversal and the relationship between form and 
function 
Before investigating the molecular reversibility of NED, first a morphological 
assessment was made using light microscopy. The supplementation of synthetic 
androgen to NED LNCaP cells was sufficient to cause a loss of neurite-like 
projections, reacquisition of untreated morphology and restart cell proliferation 
evidenced by an observed increase in cell confluency compared to constant AD 
(Fig. 4.6), although this was not quantified. This return to a proliferative state was 
also observed in a cAMP induced model of NED (Cox et al., 1999). The use of 
androgens to revert NED has previously been tested (Shen et al., 1997), where 
1 nM DHT prevented NED but was insufficient for NED reversal (assessed by 
morphology). However, replacing media containing CS-FBS to media containing 
unmodified 10% FBS was sufficient for loss of NED morphology (Shen et al., 
1997). Here, R1881 was used, the rationale for using R1881 is that it is not 
metabolised and has high affinity for the androgen receptor (Brinkmann et al., 
1986). Thus concentrations of R1881 remain stable throughout the cell culture 
period and the effects of metabolites is greatly minimised (Bonne & Raynaud, 
1976; Brown et al., 1981). The use of R1881 in PCa studies has become wide-
spread and favoured over using endogenous ligands (Bishop et al., 2017; Bluemn 
et al., 2017; Foley & Mitsiades, 2016; Hu et al., 2012; Reyes et al., 2013).  
 
Although morphological observation cannot reveal molecular mechanisms, the 
ultimate effects of many molecular actions depend upon the presence of specific 
morphology to facilitate their function. Previously, it has been suggested that NED 
PCa cells may facilitate the growth and survival of surrounding cancer cells via 
paracrine support (Bishop et al., 2017; Bluemn et al., 2017; Ippolito & Piwnica-
Worms, 2014; Mirosevich et al., 2006). Considering the seemingly sophisticated 
and highly interconnected structures formed by the neurite-like extensions of 
NED LNCaP cells, it is possible that disruption of these formations could erode 
some of their potential functions. Certainly, under AD conditions distant LNCaP 
cells appear to extend neurites towards other cells, even over significant 
  
142 
 
distances of up to 257 M, which is over 8.5 times greater than the average cell 
body width (Obin et al., 1999). Although speculative, it would seem unlikely for 
such powerful chemotaxis of neurite outgrowth to be undirected, especially 
considering the large number of neurite-like projections (over 500) measured for 
this study. 
 
4.3.3 Molecular reversibility of NED 
Previously studies have demonstrated that NED induced by cAMP treatment was 
reversible upon withdrawal of cAMP (Cox et al., 1999). Critically, the study 
investigating cAMP-induced NED did not analyse the molecular components of 
the NED pathway, merely the downstream biomarkers of NED (NSE expression 
and morphology) (Cox et al., 1999). Tyrosine kinase and MAPK activity was 
elevated upon cAMP-induced NED reversal and re-entry to a proliferative state, 
suggesting perhaps that inhibitors of these kinases could block this mechanism 
(Cox et al., 1999). Interestingly, the latest publications have demonstrated that 
pan tyrosine kinase inhibitor dovitinib also induces NED (Yadav et al., 2017). 
Unfortunately, the reversibility of NED upon withdrawal of dovitinib was not 
investigated (Yadav et al., 2017). Again, the wide variety of NED inducing agents 
would suggest an underlying NE transcriptional profile that, rather than being 
‘activated’, is merely de-repressed when the transcriptional pressure of AR-
signalling is lifted. In addition, the fact that even the most novel therapeutic 
strategies cannot escape NED (Wang et al., 2018; Yadav et al., 2017) is both 
concerning and a rationale to drive understanding of NED forward. Of particular 
interest, reintroduction of androgen caused a significant upregulation of REST 
mRNA expression. Taken in the context of a reduction in REST protein 
expression in NED LNCaP cells (Fig. 4.11), this further validates that REST 
expression is protective against NED.  
 
PTOV1 is a known repressor of Notch1 signalling (Alaña et al., 2014) and is 
upregulated by DHT LNCaP cells (Benedit et al., 2001). Notch1 signalling is 
critical to the maintenance of cell fate in both developing and mature tissues as 
well as in cancer cells (Capaccione & Pine, 2013; Crabtree & Miele, 2016; Lai, 
2004; Wang et al., 2010). Therefore, it is perhaps unsurprising that PTOV1 was 
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upregulated after re-introduction of androgens. Furthermore, PTOV1 expression 
was undetected after a second AD cycle, which also resulted in the loss of AR 
and PSA signalling. This further supports the notion that NED cells retain 
androgen sensitivity and capacity for canonical AR signalling, whilst after two 
cycles of AD these cells lose androgen signalling. Of particular interest is that 
PTOV1 is upregulated during NED, but also upregulated to a higher level after 
NED reversal. This could support the notion that reversed NED cells would have 
increased potential to explore aberrant cell fates and strengthens the concept 
that PTOV1 is a potential key mediator of cell fate malleability (Alaña et al., 2014; 
Cánovas et al., 2015). The only previous mention of PTOV1 as associated with 
NED is a conference abstract from 2010, describing PTOV1 as a potential 
biomarker of NE tumours (de Torres et al., 2010) from the same group that 
demonstrated PTOV1-mediated Notch signalling repression through repression 
of Notch1 target genes Hes1 and Hey1 (Alaña et al., 2014). 
 
4.3.4 Retention of nuclear hASH1 and the potential for hybrid phenotypes 
and heterogeneity 
Interestingly, hASH1 mRNA and protein expression remained elevated after NED 
reversal. Analysis of hASH1 localisation revealed that after NED reversal, hASH1 
is retained exclusively within the nucleus of LNCaP cells. This data, alongside the 
immunoblot data, points to an intense enrichment of nuclear hASH1. 
Functionally, if hASH1 is retained within the nucleus after NED reversal and 
restoration of AR signalling, these cells could possess a transcriptome influenced 
both by AR and hASH1, which were previously mutually exclusive in their activity. 
This hybrid phenotype could potentially utilise advantageous aspects of NED 
such as therapeutic resistance (Deng et al., 2011; Farach et al., 2016; Hu et al., 
2015), combined with the proliferative abilities of the epithelial phenotype (Wang 
et al., 2010) (Fig. 4.14).   
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Figure 4.14 Schematic diagram illustrating the shift in transcription factor 
activity between LNCaP in the presence, absence and re-introduction of 
androgen. In untreated LNCaP, data demonstrated that expression of hASH1 is 
low and exclusively cytoplasmic and therefore hASH1 is unlikely to be 
transcriptionally active. Under AD conditions, in NED PCa cells, canonical AR 
signalling is greatly reduced, evidenced by PSA downregulation. Simultaneously, 
hASH1 becomes localised to the nucleus where it is potentially transcriptionally 
active, evidenced by expression of NSE. In addition, AR splice variants (see 
appendix; Figure 8.1) can be constitutively active even in the absence of 
androgen (Dehm et al., 2011; Jones et al., 2015). After re-introduction of 
androgen, aspects of canonical AR signalling are restored such as PSA 
expression, however hASH1 is retained in the nucleus of these cells, which could, 
speculatively, facilitate a hybrid phenotype.   
AR	Directed	
Transcription
hASH1	Directed	
Transcription
Hybrid	
Phenotype?
Pre-AD AD Post-AD
AR-V hASH1AR
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It is important to note that whilst previous studies have implicated hASH1 as 
involved in NED in PCa (Rapa et al., 2013) and small cell lung cancer (Borromeo 
et al., 2016), an assessment of hASH1 localisation has never been performed in 
prostate cancer in response to androgen deprivation. Furthermore, the retention 
of nuclear hASH1 after NED reversal is entirely novel. To discuss the findings on 
hASH1 in prostate cancer NED it is necessary to compare studies which have 
analysed NED in the setting of small cell lung cancer, which shares NED 
properties (Ishii et al., 2013; Meder et al., 2016). A recent paper demonstrated 
that hASH1 is required for NED of lung cancer in a mouse model (Borromeo et 
al., 2016). This study also analysed the target genes of hASH1 during NED using 
ChIP-Seq, something that has never been applied to hASH1 in the prostate 
cancer NED setting. In lung cancer NED, hASH1 target genes include a plethora 
of Notch signalling genes including DLL1, DLL2, DLL3, JAG2 and HES1 which 
were conserved between the mouse model and human tumour samples 
(Borromeo et al., 2016). These findings corroborate the hypothesis that hASH1 
can influence Notch signalling in a cancer setting to facilitate NED. In addition, 
GABA related genes GAD2 (GABA synthesis) and GABRB3 (GABA receptor 
beta 3 subunit) were found to be direct target genes of hASH1 in lung cancer 
NED (Borromeo et al., 2016). Further strengthening the rationale to investigate 
the GABA receptor as a mechanism of paracrine support in prostate cancer NED, 
discussed in the following chapter.  
 
Whilst the hASH1 transcriptional profile of NED lung cancer will likely differ to that 
of prostate cancer NED, the ability for hASH1 to target these genes, in a similar 
cancer NED setting, remains of interest. The next stage of hASH1 evaluation in 
prostate cancer NED will be to apply genomic approaches (ChIP-Seq, RNA-Seq) 
to validate target genes and proteomics to identify the protein-protein interactions 
of hASH1 and its effects as a pioneer factor on the chromatin landscape in 
untreated, AD and IAD treated LNCaP cells. Unfortunately, transcription factors 
such as hASH1 are often viewed as intractable drug targets (Johnston & Carroll, 
2015), however, identification of the co-factors facilitating hASH1 transcriptional 
activity has the potential to reveal backdoor mechanisms of hASH1 therapeutic 
targeting (Johnston & Carroll, 2015).  
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4.3.5 Effect of IAD on the proposed NED pathway 
The responsiveness of proposed key components of the NED pathway (PTOV1, 
hASH1, NSE, REST) to reintroduction of androgen served to further validate the 
hypothesis that these genes are in fact involved in NED. The finding that hASH1 
was retained in the nucleus of cells that had been reverted from the NED 
phenotype back to a more epithelial phenotype led to speculation that this 
retention could facilitate increased sensitivity to successive periods of AD. 
Analysis of mRNA and protein expression after a second cycle of AD revealed 
significant complexity rather than the expected exaggerated expression of NED 
pathway components. It must be noted that the model of IAD takes place over  
45-days, whereas the NED reversal model uses a 30-d end point. This 
considerably longer period of AD must be considered when comparing data 
between these two models. For example, LNCaP cells that had undergone two 
rounds of AD with a 15-d period of AD cessation in-between, displayed 
undetectable AR and PSA mRNA expression. However, analysis via immunoblot 
revealed that strong AR expression was maintained but confirmed that PSA 
protein expression was extremely low. This indicates that perhaps the rate of AR 
degradation has been reduced, causing AR protein to remain present in the 
absence of transcription. In addition, although AR protein is present, expression 
of PSA is still greatly reduced, indicated that AR activity remains depressed or 
that perhaps the AR acquires an altered transcriptional profile which no longer 
drives expression of PSA.  
 
Importantly, the immunoblot data showing NSE expression highest in reversed 
NED cells suggests that the retention of hASH1 in the nucleus of these cells is 
likely to remain transcriptionally active. To confirm transcriptional activity, ChIP-
Seq experiments to demonstrate the binding of hASH1 to promoter and enhancer 
regions and RNA-Seq or qRT-PCR to validate that these sites drove expression 
could be employed. The mRNA expression of hASH1 remains elevated 
throughout NED, reversal of NED and after a second period of NED. Whereas, 
hASH1 protein expression is markedly higher in cells that have undergone a 
second NED period. During simulated IADT, the localisation of hASH1 to the 
nucleus after the first cycle of AD is persistent and robustly supports the gene 
and protein expression data obtained through qRT-PCR and immunoblot. The 
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persistent nuclear localisation of hASH1 throughout IAD also contributes to the 
hypothesis that NED LNCaP cells may deploy a hybrid phenotype where AR and 
hASH1 signalling may become non-mutually exclusive.  
 
Interestingly, NED biomarker synaptophysin becomes significantly upregulated 
after a second period of AD. In addition, MMP-9 expression is significantly 
elevated after NED reversal and rises considerably further after a second AD 
period. This data would suggest that IAD could actually be enriching the NED cell 
niche and that successive rounds of AD may contribute to the emergence of a 
phenotype with higher aggressive potential compared to constant AD. IAD may 
also promote increased prostate cancer aggression through the expression of 
MMP-9, which promotes invasive cell growth (Azuma et al., 2003). Furthermore, 
this study heavily implicates transcription factor hASH1 in PCa NED, which is 
substantiated by many high profile studies showing that hASH1 is crucial to NED 
in lung cancer (Miyashita et al., 2018; Borromeo et al., 2016; Lenhart et al., 2015; 
Augustyn et al., 2014; Castro et al., 2011). Canonically, hASH1 is responsible for 
the generation of GABAergic neurons (Mazurier et al., 2014; Peltopuro et al., 
2010), which led to the investigation of GABA receptor activity in PCa NED in 
Chapter 5. 
 
4.3.6 hASH1 as a potential therapeutic target 
Transcription factor hASH1 has been strongly implicated in disease progression 
of neuroblastoma and is considered to be a potential therapeutic target (Wylie et 
al., 2015). Furthermore, hASH1 has been tentatively described as a potential 
therapeutic target for small cell lung cancer (Demelash et al., 2012; Nishikawa et 
al., 2011; Osada et al., 2008, 2005) and has been demonstrated to be absolutely 
required for lung cancer NED (Borromeo et al., 2016). However, therapeutic 
targeting of transcription factors is often considered intractable due to the difficulty 
of direct drug inhibition (Johnston & Carroll, 2015). Therefore, identification of the 
co-factors and pioneer factors requisite for hASH1 DNA binding and 
transcriptional activity may elucidate novel mechanisms to target hASH1 
indirectly for therapeutic effect. Most importantly, a novel approach to delaying or 
reducing NED in PCa would add value to most existing PCa therapeutics by 
targeting a shared resistance mechanism between ADT, radiotherapy and 
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tyrosine kinase inhibition. PCa NED is increasing in prevalence (Borromeo et al., 
2016), yet there is currently no approved therapeutic specifically targeting NED, 
therefore validation of potential therapeutic targets such as hASH1 is a crucial 
research area.  
 
4.4 Conclusions 
To conclude, the aims of this work were to establish an in vitro model of IAD and 
to use this model to investigate the extent of AD-induced NED reversibility and 
the effects of IAD on the components of the proposed NED pathway. This study 
has shed new light on the molecular reversibility of the AD induced NED pathway 
in LNCaP prostate cancer cells. The data challenges the established paradigm 
that NED is entirely reversible and instead identifies hASH1 as a key NED driver 
and its nuclear localisation as a persistent feature of NED that is not reverted by 
AD cessation. The responsiveness of key NED pathway genes to NED reversal, 
further strengthens the evidence that they are involved in the regulation and 
promotion of NED. Finally, an in vitro model of IADT was established for the first 
time and the NED pathway subjected to molecular investigation. This revealed 
that in this particular model, IAD induced a significant upregulation of MMP-9 and 
the data appeared to support the hypothesis that the retention of nuclear hASH1 
promotes a hybrid phenotype which may be more aggressive. Therefore, this 
data would suggest that IADT may enrich NED and speed the acquisition of 
increased aggression compared to constant AD. 
 
4.5 Limitations, weaknesses and future experiments 
Although the key finding of this chapter is that hASH1 is a potential driving 
transcription factor in PCa NED, it must be acknowledged that this work has 
several limitations. Therefore, further experiments are necessary in order to 
robustly validate that hASH1 is a potential therapeutic target. First of all, the 
nuclear localisation of hASH1 after AD has only been demonstrated in the LNCaP 
cell line, which does not accurately represent the heterogeneity of patient 
tumours. Secondly, the present study did not assess hASH1 localisation in the 
presence of enzalutamide, which would have further validated that this is an AD 
specific effect and that direct inhibition of the AR could cause hASH1 nuclear 
localisation. Next, although the data presented in this chapter robustly 
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demonstrates the expression and localisation of hASH1 during intermittent AD, 
from these experiments it is not possible to conclude whether hASH1 is directly 
bound to chromatin or whether it is transcriptionally active. In order to assess the 
activity of hASH1 in these conditions, experiments such as ChIP-qPCR or ChIP-
Seq could have been performed in order to identify the likely target genes of 
hASH1. In addition, in order to further demonstrate that hASH1 is driving the NED 
process, siRNA or shRNA experiments could have been performed to knock 
down expression of hASH1 and investigate whether this prevented the onset of 
NED morphology and expression of biomarkers such as NSE under AD 
conditions. Finally, using confocal microscopy to also study the location of AR 
and hASH1 in the same samples would have given more clarity to the hypothesis 
of a potential hybrid phenotype and whether AR and hASH1 nuclear localisation 
are mutually exclusive throughout intermittent AD. 
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5. Preliminary investigation of GABAergic signalling in 
Prostate Cancer 
5.1 Introduction 
Transcription factor hASH1 is a key driver of GABAergic neurogenesis during 
development (Gillotin, Davies, & Philpott, 2018; Mazurier et al., 2014). Previous 
studies have demonstrated that GABA and other GABA receptor (GABAR) 
ligands can modulate the proliferation and aggression of many cancer types, 
including prostate cancer (PCa) (Abdul, Mccray, & Hoosein, 2013.; Azuma et al., 
2003; Wu et al., 2014; Zhang et al., 2013). Having confirmed the neurite-like 
phenotype of NED LNCaP cells (Chapter 3 & 4), and identification of nuclear 
localisation of hASH1 as a potentially key event in that process; the next step was 
to perform the first comprehensive assessment of GABAAR and GABABR subunit 
expression in PCa and NED PCa cells. 
 
5.1.1 Background and rationale for study 
Fundamentally, the impetus to investigate GABAR presence, functionality and 
role in NED PCa stems from four well established principles. The first that hASH1 
is a known key driver of GABAergic neuronal development (Castro et al., 2006; 
Gillotin et al., 2018; Mazurier et al., 2014), the second that GABA has previously 
been shown to have tumour modulatory effects (Abdul, Mccray, & Hoosein, 
2013.; Azuma et al., 2003; Wu et al., 2014; Zhang et al., 2013), the third that 
GABAergic signalling is important to the formation of neural networks (Gao, 
Stricker, & Ziskind-Conhaim, 2001; Khozhai & Il’icheva, 2017b, 2017a; Mäkinen, 
Ylä-Outinen, & Narkilahti, 2018) and the fourth that elements underpinning 
GABAergic signalling are directly and indirectly regulated by androgen receptor 
signalling.  
 
In addition, six GABAAR subunit promoter regions are known to have AR 
consensus sites (3, 4, 1, 1, 2 and ) (Steiger & Russek, 2004) although 
whether these sites are activated by AR in PCa cells has not been determined 
experimentally. Furthermore, GABAR activity in PCa has previously been linked 
to increased growth via GABAAR activation (Wu et al., 2014; Abdul, McCray & 
Hoosein, 2007) and increased invasive and metastatic potential via GABABR 
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activation as well as the effects of gabapentin (Azuma et al., 2003; Bugan et al., 
2016). In addition to GABAergic activity mediated through GABARs, there is also 
substantial evidence for a metabolic role for GABA in PCa NED as a mechanism 
of androgen-independence by using GABA metabolites to input into the TCA 
cycle (Ippolito et al., 2006; Ippolito et al 2014; Nemans et al., 2014; Olsen & 
DeLorey, 1999). The complex interdependencies between intermediates in the 
GABA metabolic and catabolic pathways and the TCA cycle result in several 
possibilities for GABA metabolism to be exploited for both growth or increased 
neurogenic potential (Ippolito et al., 2006; Ippolito et al 2014; Marmigere et al., 
2003). In addition to the ability to produce succinate from GABA to enter the TCA 
cycle, glutamate is also produced during this process. Glutamate has previously 
been demonstrated to increase expression of BDNF in hypothalamic neurons and 
contributes to the survival, differentiation and function of specific subpopulations 
of neuronal cells (Marmigere et al., 2003). It is also known that BDNF can drive 
cell proliferation through the activation of AKT and inhibition of the PTEN tumour 
suppressor (Takeda et al 2013; Temura et al 1999), both of which are key PCa 
oncogenes (Gundem et al., 2015). 
 
5.1.2 Clinical use of Gabapentin in prostate cancer patients 
A key challenge in the clinical treatment of metastatic (m)CRPC is the 
management of neuropathic pain, often caused by bone and particularly spinal 
metastases (occurring in 90% of mCRPC patients) which can be exceptionally 
painful for patients and often impossible to resect surgically (Bugan, et al., 2016). 
Therefore, many mCRPC patients require long term, highly-potent analgesia. 
This presents the challenge of poorly tolerated side-effects and addictive 
properties of most opioid-based pain relief treatments. For these reasons, non-
opioid-based analgesics such as gabapentin (GBP) (Fig. 5.1) have become 
increasingly popular and prescribed “off-label” to mCRPC patients (Caraceni et 
al., 2004; Vedula, Li, & Dickersin, 2013).  
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Figure 5.1 Chemical structures of GABA and Gabapentin. Gabapentin (GBP) 
was originally designed to be an analogue of GABA, despite this gabapentin is 
not thought to directly bind to GABARs, but instead binds to voltage-gated 
calcium channels (VGCCs) (Hendrich et al., 2008). GBP closely resembles GABA 
structurally, but with the addition of a cyclohexane ring (Rose & Kam, 2002), 
which is thought to increase the molecules ability to cross the blood brain barrier 
(Yogeeswari, 2006). Distribution, metabolism and pharmacokinetic (DMPK) 
analyses of GBP show that the bioavailability of a 300mg oral dose in humans is 
around 60%, with peak plasma levels between 2.7-2.99 mg/L three hours post-
ingestion (Rose & Kam, 2002). GBP concentrations in the cerebrospinal fluid are 
around 20% that of plasma concentration, whilst brain concentrations are 80% of 
serum concentration, highlighting the high capacity to cross the blood brain 
barrier. Furthermore, GBP cannot be metabolised by humans (Rose & Kam, 
2002), meaning that no metabolites are produced, unlike GABA which can be 
metabolised into succinic semialdehyde which can be further metabolised into 
succinic acid by succinic semialdehyde dehydrogenase (SSADH) and enter the 
TCA cycle (Olsen & DeLorey, 1999). 
 
Originally, GBP was developed and licensed to treat epilepsy in the late 1990’s, 
later becoming a popular analgesic (Goa & Sorkin, 1993; Taylor, 1997). In 
addition to improved therapeutic index and lower addictive properties compared 
to opioid analgesics, GBP can also alleviate the neurotoxicity caused by 
chemotherapeutics and reduce hot flushes, nausea, and vomiting, all of which 
are suffered frequently by mCRPC patients (Bugan et al., 2016). The impetus to 
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utilise GBP in mCRPC patients is clear, however, recent research has speculated 
that voltage-gated sodium channel blockers such as GBP could have the 
potential to modulate the tumour in addition to their analgesic effects (Lee et al., 
2014). GBP increases tumour growth of pancreatic cancers in Wistar rats 
(Dethloth et al., 2000; Sigler et al., 1995). More recently, GBP has been 
investigated in an in vivo rat model of PCa and found to modulate metastasis 
formation in a dose-dependent manner, whilst having no effect on primary tumour 
growth. At low doses (4.6 g/kg), GBP had no effect on metastasis formation, at 
medium doses (9.1 g/kg) GBP significantly decreased metastasis formation and 
at high doses (16.8 g/kg)  GBP increased metastasis formation and significantly 
reduced survival (Bugan et al., 2016). In clinical trials analysing the effect of GBP 
on neuropathic pain, patients received 12-50 mg/kg daily depending on the 
amount of pain management required (Backonja & Glanzman, 2003). Previously, 
GBP (100 M)  was demonstrated to reduce proliferation of LNCaP cells by 35% 
in vitro and when added to drinking water of LNCaP xenograft bearing mice 
(400mg/L; 60 mg/kg daily) also reduced primary tumour size, the effect on 
metastases was not investigated as LNCaP cells have previously been shown to 
not form metastases in vivo (Warnier et al., 2015). However, it should be noted 
that GBP is known to not be a direct GABAA or GABAB receptor agonist, but is 
postulated to exert effects indirectly through altered GABA secretion, uptake and 
metabolism (Lanneau et al., 2001). GBP is a known ligand of the 2-2 subunit 
of voltage-gated calcium channels (VGCCs), as are other gabapentinoids such 
as pregabalin and phenibut (Warnier et al., 2015; Zvejniece et al., 2015).  Despite 
widespread use of GBP, a recent double-blind randomised control study found 
no benefit of GBP for cancer induced bone pain compared to placebo (Fallon et 
al., 2016). Therefore, the rationale to investigate potential cancer modulatory 
effects of GBP is clear. 
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5.1.3 Study aim and research questions 
Study aim: To establish the expression profile of GABAA and GABAB receptor 
subunits in androgen-sensitive, castrate-resistant and NED PCa and to 
investigate the effects of GABAergic compounds on this study proposed PCa 
NED pathway.   
 
Research questions: (1) Do PCa cells express the necessary GABA receptor 
subunits to form functional GABARs? (2) How does AD and intermittent (I)AD 
effect the expression of these subunits? (3) Does the gene expression of PCa 
and NED PCa cells change in response to stimulus by GABAergic compounds? 
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5.2 Results 
5.2.1 Expression of GABAR subunits in PCa cell lines 
As an initial, comprehensive assessment of GABARs in different PCa cell lines, 
qRT-PCR was employed to screen for GABA receptor subunit expression in 
LNCaP, DU-145 and PC-3 cells (Table 5.1).  
 
Table 5.1 Assessment of GABAAR and GABABR subunit expression in 
LNCaP, DU-145 and PC-3 PCa cells. Quantitative reverse transcription 
(qRT)RT-PCR was used to detect expression of 16 GABAAR subunits and two 
GABABR subunits in PCa cell lines. cDNA from human brain was used as a 
positive control and presence (+) or absence (-) of expression was determined 
using melt-curve analysis. (n=3). 
  
GABA 
Receptor 
Subunit
LNCaP DU-145 PC-3
a1 + - -
a2 - - -
a3 + - -
a4 - - -
a5 + - -
a6 + - -
b1 - + +
b2 - - +
b3 + - +
g1 + + +
g2 - - -
g3 + - +
d - - -
e - - -
q + + -
p - - -
GABBR1 + + +
GABBR2 + + +
  
156 
 
Interestingly, substantial differences in the presence and absence of GABAA 
receptor subunit expression were identified between the androgen-sensitive 
LNCaP cells and the CRPC cell lines, DU-145 and PC-3 (Table 5.1). Most 
apparent was that expression of GABAA  subunits were only evident in LNCaP 
cells, with no detected expression in DU-145 or PC-3. Furthermore, only the 1, 
3, 5, and 6 subunits were detectable. Typically, formation of a functional 
GABAAR requires two  subunits, two  subunits and one other subunit, which is 
usually a  or  subunit (Miller & Aricescu, 2014; Mulligan et al., 2012). Thus, this 
initial analysis suggested that only androgen-sensitive LNCaP cells were likely to 
form functional GABAARs, although it should be considered that GABAARs can 
also be formed from five 3 subunits in a homomeric structure (Miller & Aricescu, 
2014), which could potentially grant PC-3 cells the ability to form GABAARs.  
However, homomeric 3 GABAARs are unable to bind GABA, since the GABA 
binding site is at the interface of the  and  subunits (Sigel & Steinmann, 2012). 
Conversely, all three of the PCa cell lines expressed both subunits of the 
GABABR. The ,  and  subunits remained undetected in all samples, but were 
detected in brain positive controls, so were likely expressed below the detection 
threshold. Interestingly,  is reported to be found in the healthy prostate gland 
(Hedblom & Kirkness, 1997; Watanabe et al., 2006), but was not detected in any 
of the tested PCa cell lines (Table 5.1). All three of the PCa cell lines expressed 
both subunits of the GABABR. 
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5.2.2 Quantification of GABAAR and GABABR expression in prostate cancer 
cell lines  
Having established which subunits were expressed in LNCaP, DU-145 and PC-
3 cells, the relative abundance of GABAR subunit cDNAs in these cell lines was 
assessed (Fig 5.4). 
 
 
 
Figure 5.2 Quantitative relative expression of GABAAR subunits in brain 
tissue and PCa cells. Heat map expression profile of GABAAR subunits in A. 
Human whole brain tissue, B. CRPC cell lines DU-145 and PC-3 and C. LNCaP 
PCa cells. Higher expression is indicated in red; lower expression genes in green, 
white indicates not detected. Data is displayed as percentage increase or 
decrease relative to expression of 1 in untreated LNCaP cells n=3 (except brain 
where n=1). 
 
Assessment of all GABAR subunit expression in PCa has only been undertaken 
previously in a presence/absence manner using end-point RT-PCR (Wu et al., 
2014). Although RNA-Seq experiments have also been performed and deposited 
into databases such as EMBL-EBI gene expression atlas and the cancer genome 
atlas (TCGA) and show expression of GABAAR and GABABR subunits at 9 
transcripts per kilobase million (TPM) and 7 TPM respectively, these datasets to 
not include NED LNCaP cells. Therefore, a quantitative assessment of GABAR 
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subunits in PCa cell lines and NED LNCaP cells via qRT-PCR is a useful 
contribution for researchers interested in the effects GABA and other GABAR 
ligands may exert on PCa cells as the response of the GABAR is highly 
influenced by its subunit composition.  
 
The 3 subunit has previously been shown to be upregulated in non-small cell 
lung cancer and is implicated in protein kinase B (AKT) activation and metastasis 
in breast cancer (Gumireddy et al., 2016) and was the most expressed subunit in 
LNCaP cells (Fig 5.5). Interestingly, in LNCaP cells, expression of subunit 3 was 
the second most expressed and has previously been linked to decreased 
proliferation of hepatocellular carcinoma in vivo (Minuk et al., 2007). In addition, 
the  subunit was present in LNCaP and DU-145 cells and is known to facilitate 
GABA mediated growth of hepatocellular carcinoma both in vitro and in vivo (Li 
et al., 2012). Overexpression of the  subunit increases proliferation of pancreatic 
cancer (Takehara et al., 2007), and is also overexpressed in breast cancer where 
it is considered a viable biomarker (Symmans et al., 2005). However, this subunit 
was not detected in any of the PCa cell lines tested. 
 
5.2.3 Quantification of the effect of AD on GABAA and GABAB receptor 
subunit expression in LNCaP cells 
The expression of GABAR subunits was also investigated in in LNCaP cells in 
response to five days of culture in AD conditions (Fig. 5.3). The decision to study 
changes in GABAR subunit expression at the 5 d time point was taken because, 
of the time points assessed by qRT-PCR, this is the time point where NSE and 
hASH1 expression was observed to be highest. Early morphological indicators of 
NED phenotype are also present after 5 days AD, suggesting that this is a good 
time point to study GABAAR subunits which are known to be involved in 
neurogenesis and synaptogenesis and their expression alters during 
development (Ben-Ari, 2002; Neelands et al., 1999). Furthermore, the early 
molecular changes associated with NED could act as useful biomarkers that the 
NED process is beginning, which could have clinical utility where avoidance of 
full NED would be desirable, especially in the context of IADT. GABAR subunits 
  
159 
 
have previously been demonstrated to be viable biomarkers in multiple cancer 
types (Li et al., 2012; Liu et al., 2009; Symmans et al., 2005).     
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Figure 5.3 Relative expression of GABAAR subunits in LNCaP cells 
subjected to androgen deprivation. Heat map expression profile of GABAAR 
subunits in control (CTRL) and 5 d androgen deprived (AD) LNCaP PCa cells. 
Highest expressed genes are indicated in red; least expressed in green, not-
detected in white. Data is displayed as percentage increase or decrease relative 
to expression of 1 in untreated LNCaP cells (n=3).  
 
Overall the expression of most subunits did not appear to be responsive to 5 d 
AD treatment, however, small changes in 3 and 3 were observed. Most 
importantly, there were no changes to presence and absence of different 
subunits. Displaying the GABAAR subunit expression relative to the 1 subunit of 
LNCaP cells allowed for the identification of the most expressed subunits, which 
were 3 and 3. It is perhaps surprising that there was no induction or complete 
repression of any GABAAR subunits in response to AD, however this would not 
preclude changes in the predominant GABAAR subtype.  
 
Once it was established that there was expression of selected GABAAR subunits 
in LNCaP cells and that expression of these subunit genes could be modified by 
AD – potentially in line with the onset of NED. The experiment was further refined 
by introduction of synthetic androgen to verify that the effects observed during 
AD were only attributable to lack of androgen, and not absence of other factors 
in the charcoal-stripped media. 
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Figure 5.4 Expression of GABAAR subunits in LNCaP cells cultured in 
androgen deprived (AD) conditions or in the presence of 1 nM or 10 nM 
synthetic androgen (R1881). Relative expression of GABAAR subunits in 
LNCaP cells that were either untreated (CTRL), subjected to 5 d of AD (AD) or 5 
d of AD conditions supplemented with either DMSO vehicle (V) or R1881 at 1 nM 
or 10 nM concentrations, were analysed via qRT-PCR, data was normalised to 
reference gene ACTB. Data is expressed as mean ± SEM, (n=3) p< 0.05 (*) and 
p<0.01 (**) as determined by one-way ANOVA with Dunnett’s correction.  
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Of the subunits previously identified to be expressed by LNCaP and AD LNCaP 
cells, there were observed changes in expression caused by AD and androgen 
supplementation. The 1 subunit was not significantly altered in mRNA 
expression by AD and the effects of supplementing R1881 synthetic androgen 
had no effect beyond the vehicle control. Subunit 3 was upregulated by AD and 
downregulated below basal levels by 1 nM (2.4-fold) and 10 nM (1.6-fold) of 
R1881, however, the presence of the vehicle control also downregulated 3 
subunit expression to basal levels, which would suggest that this effect is not 
androgen specific. Across the panel of GABAAR subunits, it is apparent that for 
some subunits the expression in the vehicle sample does not replicate what is 
observed in the AD sample. The likely reason for this is that expression of many 
of these subunits as shown in Figures 5.4 and 5.5 is very low, meaning that small 
variances in expression will result in large fold changes, which is a clearly 
established limitation of using relative quantification methods in qPCR. Although 
it would seem unlikely, it is also possible that the 0.01% vehicle is having an effect 
on the GABAAR subunit gene expression not previously observed with other 
transcripts, again an effect that would be amplified by the low expression of these 
targets. An ideal improvement to this analysis would have been to use absolute 
quantification method qPCR and to use TaqMan qPCR probes   The 5 subunit 
was slightly upregulated by AD (1.7-fold), downregulated by presence of the 
vehicle control (0.6-fold) and 1 nM R1881 (0.6-fold), but was upregulated 
compared to the untreated control in the presence of 10 nM R1881 (1.5-fold). 
Subunit 6 was upregulated by AD (11-fold) and in the presence of vehicle control 
(17-fold; p = 0.09), whilst 1 nM R1881 supplementation maintained expression 
closer to basal levels (3-fold) and 10 nM R1881 resulted in an upregulation similar 
to that of AD (15.6-fold; p = 0.14) which suggest that 6 subunit expression can 
be modulated by androgen. Interestingly, the 6 subunit, along with the 1 
subunit have been demonstrated to be important to the anchoring of the complete 
GABAAR to the cell surface (Peran, et al., 2004), this increase in 6 subunit 
expression in response to AD could be an indicator of increased GABAAR 
presentation on the surface of early NED PCa cells (Peran et al., 2004).  3 
subunit expression was slightly elevated by both AD (2.1-fold) and AD with 
vehicle control (2.3-fold) and was not suppressed by either 1nM (2.5-fold) or 10 
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nM (4.3-fold) R1881 supplementation, suggesting that the 3 subunit is unlikely 
to be regulated by AR signalling.  
 
The 1 subunit was the only transcript to be significantly downregulated by AD (p 
= 0.009), however, androgen supplementation (1 nM, 10 nM) did not affect 1 
subunit expression beyond that of the vehicle control (39.7-fold; p > 0.99). Finally, 
3 subunit expression was not significantly influenced by AD or vehicle treatment 
but, interestingly, was significantly downregulated (5.7-fold) by addition of 1 nM 
of androgen (p = 0.02), however, at a higher concentration of R1881, the  3 
subunit expression was upregulated 2.7-fold, although not significantly. Overall, 
these results would indicate that the majority of GABAAR subunit expression is 
not specifically altered by 5 days of AD, with the exception of the 6 and 3 
subunits.  
 
5.2.4 Assessment of the effect of intermittent (I)AD on GABAAR subunit 
expression in LNCaP cells 
Having established that expression of some GABAAR subunits were responsive 
to AD, the effects of IAD on expression in LNCaP cells was then investigated 
(Table 5.2). 
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Table 5.2 Presence and absence assessment of GABAR subunits during 
intermittent (I)AD. Using qRT-PCR, the expression of GABAAR and GABABR 
subunits in LNCaP cells subjected to IAD was assessed. Presence or absence 
of expression was investigated in untreated cells (LNCaP), after 5 d of AD (AD1), 
after 15 d in AD conditions supplemented with synthetic androgen (AD+R1881) 
and after a further 15 d period of AD (AD2). Detection was determined using melt 
curve analysis of PCa samples compared to human brain cDNA n=3. 
 
Interestingly, throughout IAD treatment, the same GABAAR subunit transcripts 
were expressed, with the exception of the 6 subunit, which became 
undetectable by the end of the second period of AD (Table 5.2). The loss of 6 
subunit expression is interesting because this subunit helps to anchor GABAARs 
to the cell surface (Peran et al., 2004). Both GABABR were also detected 
throughout IAD. This data suggests that LNCaP PCa cells retain the potential 
capacity to form GABAA and GABAB receptors at each stage of IAD during two 
GABA 
Receptor 
Subunit
LNCaP AD1
AD
+
R1881
AD2
a1 + + + +
a2 - - - -
a3 + + + +
a4 - - - -
a5 + + + +
a6 + + + -
b1 - - - -
b2 - - - -
b3 + + + +
g1 + + + +
g2 - - - -
g3 + + + +
d - - - -
e - - - -
q + + + +
p - - - -
GABBR1 + + + +
GABBR2 + + + +
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successive AD periods. Next, the changes in expression level were quantitatively 
assessed using qRT-PCR (Figure 5.7).  
 
Figure 5.5 Expression of GABAAR subunits in LNCaP cells subjected to IAD. 
Relative expression of GABAAR subunits in LNCaP cells that were either 
untreated (CTRL), subjected to 5 d AD (AD1), AD followed by cessation of AD 
(AD+R1881) or a second cycle of AD (AD2) after the AD cessation period, 
analysed via qRT-PCR normalised to ACTB. Data is expressed as mean ± SEM, 
(n=3) p< 0.05 (*) and p<0.01 (**) as determined by one-way ANOVA with 
Dunnett’s correction, N.D – not detected.  
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Analysis of GABAAR subunit expression throughout IAD identified that subunit 1 
expression did not significantly change throughout IAD. The 3 subunit was 
upregulated by the first (4-fold) and second (5.8-fold; p = 0.07) round of AD and 
was downregulated closer to basal levels by the intermediate period of cessation 
of AD (2-fold), rising again at the end of a second AD period. This would suggest 
that the 3 subunit, which is known to be upregulated in non-small cell lung 
cancer and contribute to metastasis in breast cancer (Gumireddy et al., 2016),  is 
modulated by IAD. The 5 subunit expression was slightly upregulated by the 
first round of AD (1.7-fold), appeared unchanged by AD cessation and was further 
upregulated after the second AD period (2.5-fold), although expression failed to 
become statistically significant compared to untreated cells. The 6 subunit was 
significantly upregulated by AD (11-fold; p = 0.003;), remained significantly 
upregulated during AD cessation (p = 0.02; 10.5-fold) and after the second round 
of AD, expression could not be detected.  
 
The 3 subunit was upregulated by AD (2.1-fold) and became significantly 
upregulated during AD cessation (p = 0.03; 2.7-fold), before returning to the same 
level as the first AD cycle by the end of the second cycle of AD (2.2-fold). This is 
particularly interesting because the 3 subunit is thought to decrease the 
proliferation of hepatocellular carcinoma cells, considering the 3 subunit is 
upregulated throughout IAD, this would fit with what would be expected during 
the application of AD to androgen-sensitive LNCaP cells and this upregulation is 
maintained even during AD cessation.  
 
Expression of the 1 subunit was downregulated by 39.6-fold during AD and 
subsequently upregulated, 11.4-fold by AD cessation, expression continued to 
increase, reaching 30.6-fold by the second cycle of AD. The 3 subunit 
expression was unaffected by the first round of AD (1.5 fold; p > 0.99) but was 
significantly upregulated during AD cessation (20-fold; p = 0.03), continuing to 
rise dramatically to a 30-fold upregulation after the second cycle of AD (p = 
0.002). 
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Overall, these experiments demonstrate that expression of GABAR subunits is 
differential between androgen-sensitive PCa cells and CRPC cells and that these 
cells could potentially possess functional GABARs. In addition, for the first time 
the differences in expression level have been quantified and the modulatory effect 
of androgen availability upon their expression has also been assessed. Finally, 
IAD appears to induce significant changes in GABAAR subunit expression, in 
particular, a loss of 6 expression after a second period of AD after AD cessation. 
 
5.2.5 Expression of CCCs during IAD 
The effects of the GABAAR can be both inhibitory and excitatory depending upon 
the polarity of the cell. Therefore, in order to gain a greater understanding of the 
potential involvement of the GABAAR in a PCa setting, the expression of selected 
NKCC and KCC transporters was assessed using qRT-PCR. Although all KCC 
and NKCC were initially assessed for expression, only NKCC1, KCC1, KCC3 and 
KCC4 were detected. Interestingly, KCC2 which is a de facto biomarker of mature 
neurons (Ben-Ari, 2002), was not detected in any of the experimental conditions, 
including NED LNCaP cells. This would support the notion that NED PCa cells 
are utilising a hybrid phenotype and are not truly committed to a neuronal cell 
fate, but perhaps utilise certain advantageous aspects of the neuronal phenotype 
only.  
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Figure 5.6 Expression of KCCs and NKCCs in LNCaP cells subjected to IAD. 
Relative expression of NKCC1 and KCC1, 3 and 4 in LNCaP cells that were either 
untreated (CTRL), subjected to 5 d AD (AD1), AD followed by cessation of AD 
(AD+R1881) for 15 d or a second 15 d cycle of AD (AD2) after the AD cessation 
period, analysed via qRT-PCR, normalised to reference gene ACTB. Data is 
expressed as mean ± SEM, (n=3) p< 0.05 (*), p<0.01 (**) and p< 0.001 (***) as 
determined by one-way ANOVA with Dunnett’s correction. 
 
Overall, the expression of NKCC and KCC genes was significantly modified 
depending on the androgen availability in LNCaP cells (Fig. 5.6). NKCC1, 
responsible for chloride influx, was upregulated by AD (2.7-fold) and then, 
interestingly, became significantly upregulated (3.7-fold) during AD cessation (p 
= 0.02). Expression increased further (4.4-fold) following a second cycle of AD (p 
= 0.006). A similar trend was also observed with KCC1, which increased 2-fold 
after the first AD cycle, 6-fold during AD cessation and 11.4-fold after the second 
AD cycle, but failed to become statistically significant from untreated cells. KCC3 
gene expression also showed a steady increase throughout IAD, being 
C
TR
L
A
D
1
A
D
+R
18
81
A
D
2
0
1
2
3
4
5
NKCC1
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
* **
C
TR
L
A
D
1
A
D
+R
18
81
A
D
2
0
5
10
15
20
25
KCC1
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
C
TR
L
A
D
1
A
D
+R
18
81
A
D
2
0
2
4
6
8
KCC3
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
**
***
C
TR
L
A
D
1
A
D
+R
18
81
A
D
2
0
1
2
3
4
5
KCC4
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
***
*
  
169 
 
upregulated by 2.6-fold the first cycle (p = 0.08) becoming significantly 
upregulated by 3.7-fold during AD cessation (p = 0.007) and increasing to 5.3-
fold higher levels after a second AD cycle (p = < 0.001). Expression of KCC4 was 
slightly lower under AD conditions compared to untreated cells, was significantly 
upregulated by 4.3-fold during AD cessation (p = < 0.001), and remained elevated 
at the end of a second round of AD (2.2-fold; p = 0.03).  
 
5.2.6 The effect of AD and IAD on GABABR expression  
Following assessment of GABAAR subunit expression, the expression of 
GABABR subunits in response to AD and IAD was assessed. Importantly, 
GABABRs are G-protein coupled receptors which are not influenced by the 
chloride gradient of cells and therefore function independently of NKCC and KCC 
activity. 
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Figure 5.7 Expression of GABABR subunits in LNCaP cells subjected to AD. 
Relative expression of GABABR subunits in LNCaP cells analysed via qRT-PCR 
that were (A) either untreated (CTRL), subjected to 5 d of AD (AD) or 5 d of AD 
conditions supplemented with either DMSO vehicle (V) or R1881 at 1 nM or 10 
nM concentrations. (B) Shows data for LNCaP cells that exposed to a longer, 15 
d AD. Data is expressed as mean ± SEM, (n=3) p< 0.05 (*), p<0.01 (**) and p< 
0.001 (***) as determined by one-way ANOVA with Dunnett’s correction. 
 
After 5 days of AD, expression of GABBR1 and GABBR2 was significantly 
downregulated in LNCaP cells (0.72-fold p = 0.004 and 2.7-fold p = 0.0026 
respectively). Expression of GABBR1 remained significantly downregulated 
when 1 nM (0.5-fold; p = 0.001) and 10 nM (0.34-fold; p < 0.001) of R1881 was 
present in AD media (Fig 5.11), which suggests that changes in GABBR1 
expression during AD were not mediated by androgen availability. Following 15 
days AD, GABBR1 was significantly downregulated (0.5-fold; p = 0.004). 
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Interestingly, supplementation to AD condition with 1 nM (p < 0.001) and 10nM 
(p < 0.001) R1881 further depressed GABBR1 expression, suggesting that 
GABBR1 expression is not specifically modulated by AD. GABBR2 expression 
was significantly downregulated (7-fold-fold, p = 0.0026) after five days AD and 
this downregulation was somewhat ameliorated by the presence of 1 nM (3.4-
fold) and 10 nM (0.8-fold) R1881 in culture media, suggesting that GABBR2 
expression is at least partly influenced by androgen availability. This effect was 
also observed when LNCaP cells were treated for a longer 15 d period. This data 
further supports that expression of GABBR2 may be changeable in relation to 
androgen availability in LNCaP cells. The GABABR is an obligate heterodimer 
(Gassmann & Bettler, 2012), so effects on GABBR2 would also mediate effects 
on the entire GABAB receptor since GABBR2 subunit is needed to allow the 
GABBR1 subunit to leave the endoplasmic reticulum (Benarroch, 2012). 
 
 
Figure 5.8 Expression of GABABR subunits in LNCaP cells subjected to IAD. 
Relative expression of the two GABABR subunits in LNCaP cells that were either 
untreated (CTRL), subjected to 15 d AD (AD1), AD followed by cessation of AD 
(AD+R1881) or a second cycle of AD (AD2) after the AD cessation period, 
analysed via qRT-PCR, normalised to reference gene ACTB. Data is expressed 
as mean ± SEM, (n=3) p< 0.05 (*), p<0.01 (**) and p< 0.001 (***) as determined 
by one-way ANOVA with Dunnett’s correction.  
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The expression of GABBR1 and GABBR2 was also assessed throughout IAD. 
As seen previously, expression of GABBR1 was downregulated by the first AD 
period but surprisingly was significantly upregulated (3.3-fold; p = 0.02) after 15 
d of AD cessation and remained significantly upregulated (3.8-fold; p = 0.005) 
after the second AD period. Although unexpected, a possible explanation is that 
over this longer experimental time course, the level of GABBR1 is adjusting to 
the availability of GABBR2, which is supported by the data showing that the trend 
in GABBR1 and GABBR2 expression are in sync. During IAD GABBR2 
expression decreased 2.7-fold after the first AD period, was significantly 
upregulated by AD cessation (11.4-fold; p = 0.04) and remained elevated above 
basal levels (although not significantly) by the end of the second AD period (4.1-
fold).   
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5.2.7 GABA synthesis and metabolism pathways during IAD 
Having established the presence of GABAR subunits in PCa cell lines and that 
expression of some of these subunits appeared to be responsive to AD, GABA 
signalling related gene expression was investigated (Fig 5.11). 
 
Figure 5.9. Expression of GABA synthesis and metabolism genes GAD1, 
GAD2 and GABA-T in PCa cells subjected to AD or IAD. (A) Relative 
expression of GABA transaminase (GABA-T) in LNCaP, DU-145 and PC-3 cells, 
or in LNCaP cells at five and fifteen days of AD and during IAD. (B) Relative 
expression of glutamate decarboxylase 1 and 2 (GAD1 and GAD2) in LNCaP 
cells subjected to IAD as follows, cells that were either untreated (CTRL), 
subjected to 15 d AD (AD1), AD followed by cessation of AD (AD+R1881) or a 
second cycle of AD (AD2) after the AD cessation period, analysed via qRT-PCR 
normalised to reference gene ACTB. Data is expressed as mean ± SEM, (n=3) 
p< 0.05 (*), p<0.01 (**) and p< 0.001 (***) as determined by one-way ANOVA 
with Dunnett’s correction.  
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The metabolism of GABA has previously been proposed as a mechanism of 
survival in PCa cells in response to stress by providing alternative inputs to the 
TCA cycle and overexpression of GABA synthesis enzyme GAD1 is correlated 
with decreased patient survival (Ippolito & Piwnica-Worms, 2014). GABA 
transaminase (GABA-T) was assessed across a range of PCa cells and brain 
tissue. CRPC cells had significantly lower (p = < 0.001) expression (up to 15-fold) 
expression of GABA-T when compared to untreated LNCaP cells. Subjecting 
LNCaP cells to AD showed a small increase (1.2-fold) in GABA-T expression at 
5 d of AD, rising slightly further (1.7-fold) by 15 days of AD. maintenance of 
androgen in the AD media via R1881 supplementation lowered the expression of 
GABA-T (0.7-fold). During IAD, GABA-T expression was downregulated to 0.7-
fold during AD cessation, and further downregulated (2.19-fold) after the second 
period of AD, although not significantly. Of interest is that CRPC cell lines DU-
145 and PC-3 displayed significantly lower GABA-T expression than LNCaP cells 
(6.7-fold; p = <0.001 and 17.3-fold; p = <0.001, respectively). This could suggest 
that CRPC cells may have less GABA catabolic activity, perhaps because they 
favour an environment richer in GABA, or potentially that LNCaP cells are 
preferentially utilising GABA to facilitate growth and survival. 
 
Expression of GAD1 was upregulated by 2-fold (p = 0.09) during AD (Fig 5.11 
panel B) and significantly upregulated, by 4.2-fold, during AD cessation (p = 
<0.001), returning back to similar levels (1.7-fold) seen during the initial AD by 
the end of the second AD cycle (Fig. 5.9). Similarly, GAD2 was significantly 
upregulated (6.3-fold) during NED reversal (p = <0.001) and remained 
significantly above basal levels (2.8-fold) after the second cycle of AD (p = 0.04). 
Interestingly, previous investigations into GAD1 expression in PCa did not detect 
GAD1 in LNCaP cells, but did in CRPC cell lines (Ippolito & Piwnica-Worms, 
2014). The increased expression of both GAD1 and GAD2 would suggest that 
successive rounds of AD are selecting for LNCaP cells with higher potential to 
produce GABA, which would coincide with the hypothesis that NED PCa cells 
may exert effects through GABAergic signalling. Furthermore, GAD2 is 
preferentially expressed during development and is significantly upregulated by 
AD cessation, which coincides with the loss of NED morphology, perhaps 
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supporting the idea that early developmental transcriptional profiles are utilised 
to facilitate the change in LNCaP cell fate (e.g. the Notch1 pathway). 
 
5.2.8 Effect on cell viability of GABAAR and GABABR agonists 
GABAAR agonist muscimol and GABABR agonist baclofen were used to 
investigate the effect of GABAAR and GABABR agonism on LNCaP and NED 
LNCaP gene expression. Concentrations of muscimol and baclofen were derived 
from the literature (Abdul et al., 2008.; Azuma et al., 2003). The effect of muscimol 
and baclofen on cell viability was first assessed using Alamar blue assay (Fig. 
5.10). A range of concentrations between 1-500 M and ethanol vehicle at a 
concentration of 0.01% were assessed. Analysis of the data showed that neither 
muscimol, baclofen or the vehicle ethanol impacted cell viability. Therefore, this 
range of concentrations was used to investigate the effect of GABAAR and 
GABABR agonism on LNCaP and NED LNCaP cells (Fig. 5.11) and this dose 
range and treatment length has been previously used in the literature (Abdul et 
al., 2008.; Azuma et al., 2003). 
 
Figure 5.10 Assessment of muscimol, baclofen and ethanol vehicle on 
LNCaP cell viability. LNCaP cells were cultured in the presence of 1, 10 and 
100 M muscimol, 10, 100 and 500 M baclofen or vehicle only with the 
reduction of Alamar blue reagent shown relative to untreated LNCaP cells. 
Ethanol was used as a vehicle at a final concentration of 0.1% (n=1). 
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5.2.9 Effects of muscimol and baclofen on NED LNCaP gene expression 
Having established the presence of GABAR subunits in PCa cells, the next aim 
was to investigate if these subunits might form functional receptors and to 
delineate whether these receptors exerted changes upon NED pathway 
associated gene expression and whether these were likely mediated by GABAA 
or GABAB receptor populations. 
 
Muscimol is a highly specific agonist of the GABAAR, whilst baclofen is a highly 
specific agonist of the GABABR (Napoleone, 1990). To investigate the potential 
effects on the NED pathway of GABAA or GABAB receptor agonism in LNCaP 
cells, drugs were added to normal cell culture media (10% FBS) for 48 h, LNCaP 
cells treated with vehicle in full media and AD LNCaP cells were included for 
comparison. Analysis of AR expression revealed a slight increase when LNCaP 
cells were treated with 1 M of muscimol but not at 10 M or 100 M whereas, 
the GABABR agonist baclofen appeared to have little effect upon AR expression 
(Fig. 5.11). Expression of PSA was also largely unaffected by treatment with 
either muscimol or baclofen compared to the vehicle control. Expression of NED 
related genes PTOV1, REST and NSE also remained stable during muscimol 
and baclofen treatments, with a slight decrease in NSE expression at 10 and 500 
M baclofen. MMP-9 expression has previously been demonstrated to be 
upregulated by baclofen in the rat hippocampus (Car & Michaluk, 2012) and this 
mechanism has been demonstrated to be conserved in the setting of PCa 
(Azuma et al., 2003). In this study, the increase in MMP-9 expression in response 
to baclofen was not observed, with MMP-9 expression significantly decreased in 
the presence of 500 M baclofen. This is likely because in this study baclofen 
was applied to NED PCa cells and not to previously untreated PCa cells, in 
addition the present study utilised LNCaP cells, whereas Azuma et al (2003) used  
the C4-2 CRPC sub-line of LNCaP (Azuma et al., 2003). This could suggest that 
whilst NED PCa cells possess greater potential for GABA production, perhaps it 
is other subtypes of CRPC cells which are GABA sensitive. Overall, it would 
appear that varying concentrations of muscimol and baclofen had no effect upon 
gene expression in the panel of genes associated with NED LNCaP cells.  
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Figure 5.11 Effect of muscimol and baclofen on LNCaP gene expression. 
Relative expression of a key panel of genes involved in NED in LNCaP cells that 
were either untreated (CTRL), subjected to 15 d androgen deprivation (AD), for 
the final 48 hours of AD, cells were treated with ethanol vehicle control (V) or 
muscimol (1-100 M) or baclofen (10-500 M) and analysed via qRT-PCR, 
normalised to reference gene ACTB. Data is expressed as mean ± SEM, (n=3) 
p< 0.05 (*), p<0.01 (**) and p< 0.001 (***) as determined by one-way ANOVA 
with Dunnett’s correction.  
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
0.0
0.5
1.0
1.5
2.0
2.5
AR
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Muscimol
Baclofen
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
0.0
0.5
1.0
1.5
2.0
MMP9
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Muscimol
Baclofen
**
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
0.0
0.5
1.0
1.5
2.0
2.5
PTOV1
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Muscimol
Baclofen
**
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
-40
-30
-20
-10
0
10
PSA
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Muscimol
Baclofen
***
***
***
***
*** ***
***
**
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
0.0
0.5
1.0
1.5
2.0
REST
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Baclofen
Muscimol
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
0.0
0.5
1.0
1.5
2.0
NSE
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Muscimol
Baclofen
**
C
TR
L
A
D V
1µ
M
10
µM
10
0µ
M
10
µM
10
0µ
M
50
0µ
M
0
2
4
6
hASH1
F
o
ld
 c
h
a
n
g
e
 i
n
 g
e
n
e
 e
x
p
re
s
s
io
n
Muscimol
Baclofen
  
178 
 
5.2.10 Effect of Gabapentin on NED pathway associated genes in LNCaP 
cells 
Gabapentin (GBP) is a painkiller that is frequently prescribed to manage the pain 
of PCa patients, particularly when painful bone metastases have occurred or 
spinal cord compression (Costigan, 2009). GBP is also used to treat hot flushes 
in patients treated with ADT (Moraska et al., 2010).  A recent study demonstrated 
that in an in vivo rat model of PCa, administration of GBP significantly increased 
metastasis and reduced survival time (Bugan et al., 2016). Importantly, although 
GBP mimics the chemical structure of GABA (Honarmand, Safavi, & Zare, 2011), 
it is not active at GABAA or GABABRs (Goa & Sorkin, 1993; Kammerer et al., 
2011; Taylor et al., 1992). Instead, the mechanism of action for GBP is thought 
to be as a ligand for the voltage-activated calcium channel (VACC), of which the 
2 calcium ion channel protein, which is expressed in prostate tissue (Chen et 
al., 2014; Rao et al., 2015; Scholl et al., 2013), and acts as an inhibitor. It is this 
action on calcium ion channels that is thought to block synaptic transmission and 
alleviate neuropathic pain (Calandre et al., 2008). Up-regulation of CACNA1D, a 
gene encoding one of the 2 subunits, is implicated in PCa progression (Scholl 
et al., 2013), suggesting that potential sensitivity to GBP would also increase 
during PCa progression. In addition, GBP is known to increase the availability of 
GABA in brain tissue (Cai et al., 2012), an effect which could potentially also 
occur within a PCa tumour. Furthermore, GBP has been demonstrated to 
increase GABA synthesis and non-synaptic GABA neurotransmission via its 
effects on GAD1 and GAD2 (Taylor, 1997). Given the widespread use of GBP by 
PCa patients, and the previous evidence of cancer modulatory activity of both 
GABA (which can be enriched during GBP treatment) (Cai et al., 2012; Taylor et 
al., 1997; Taylor et al., 1998) and GBP itself (Bugan et al., 2016) the gene 
expression changes of LNCaP cells treated with GBP was investigated. 
Concentrations and treatment times of GBP were derived from the literature 
(Bugan et al., 2016). 
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Figure 5.12 Effect of gabapentin on LNCaP cell AR and PSA expression in 
LNCaP cells not subjected to AD. Relative expression of AR and PSA in LNCaP 
cells that were either treated with ethanol vehicle control or Gabapentin (2-166 
M), analysed via qRT-PCR, normalised to reference gene ACTB. Data is 
expressed as mean ± SEM, (n=3), statistical analysis was performed using one-
way ANOVA with Dunnett’s correction. 
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Figure 5.13 Effect of gabapentin on key NED related genes in LNCaP cells 
not subjected to AD. Relative expression of a key panel of genes relating to 
NED in LNCaP cells treated with ethanol vehicle control or Gabapentin (2-166 
M), analysed via qRT-PCR, normalised to reference gene ACTB. Data is 
expressed as mean ± SEM, (n=3) p<0.01 (**) as determined by one-way ANOVA 
with Dunnett’s correction. 
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Expression of AR and PSA did not appear to be affected by GBP treatment. 
Similarly to the previous investigation of drugs influencing the GABA receptor and 
the findings of (Bugan et al., 2016), it was found that the response to GBP was 
dependent on the concentration. PTOV1 expression was elevated by 2 and 166 
M of GBP (3.8-fold and 3.5-fold), but downregulated by 20 M (2.5-fold). The 
same effect was seen on the expression of hASH1 with 20 M reducing 
expression to below basal (0.5-fold). In contrast, 166 M caused upregulation 
(16-fold) but variability in this experiment was very high. Consistent with these 
findings, NSE was significantly downregulated by 166 M of GBP (3.6-fold; p = 
0.001) but remained close to untreated levels when treated with 2 and 166 M 
GBP. This trend was also observed in REST expression which was higher with 2 
M and 166 M than with 20 M GBP treatment. Interestingly, under GBP 
treatment the expression profile of hASH1 and NSE were closely related, with 
NSE at lowest expression when hASH1 was also at lowest expression when 
treated with 20 M GBP. MMP-9 expression has previously been demonstrated 
to be inducible by GABA (Azuma et al., 2003) and GBP is known to increase the 
levels of GABA (Cai et al., 2012), leading to speculation that GBP might indirectly 
induce MMP-9 expression, although this did not occur in this  dataset, this could 
be because expression was only assessed at one timepoint (48 h).  
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Figure 5.14 Effect of gabapentin on key GABA synthesis and metabolism 
related genes in LNCaP cells not subjected to AD. Relative expression of the 
two isoforms of glutamate decarboxylase (GAD1 and 2) and GABA transaminase 
(GABA-T) in LNCaP cells treated with ethanol vehicle control (V) or Gabapentin 
(2-166 M), analysed via qRT-PCR, normalised to reference gene ACTB. Data is 
expressed as mean ± SEM, (n=3) p< 0.05 (*) as determined by one-way ANOVA 
with Dunnett’s correction. 
 
Interestingly, expression of GAD1, which encodes GAD67, was unchanged by 
GBP treatment, however at 166 M the expression of GAD2, encoding GAD65, 
was significantly upregulated (4.6-fold; p = 0.02) (Fig. 3.16), which is consistent 
with a previous publication asserting that GBP increases GABA synthesis in rat 
brain tissue  (Taylor, 1997). Interestingly, consistent with the upregulation of 
GABA synthesis enzyme GAD2, GABA-T a GABA metabolic enzyme was 
downregulated by 2 and 20 M of GBP (2.3-fold; p = 0.09 and 0.7-fold, 
respectively). This is consistent with previous studies showing that GBP 
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increases the level of GABA in the brain tissue (Cai et al., 2012) and would 
support the suggestion that a similar effect could manifest in PCa cells or 
potentially tumours. 
 
 
Figure 5.15 Effect of gabapentin GABABR subunit gene expression in 
LNCaP cells not subjected to AD. Relative expression of GABABR subunits in 
LNCaP cells treated with ethanol vehicle control (V) or gabapentin (2-166 M), 
analysed via qRT-PCR, normalised to ACTB. Data is expressed as mean ± SEM, 
(n=3), statistical significance was determined by one-way ANOVA with Dunnett’s 
correction. 
 
Although GBP is not thought to directly interact with GABARs, the expression of 
GABBR1 and GABBR2 was slightly suppressed by 20 M GBP treatment, 
although not significantly. Given that GAD1 and GAD2 both synthesise GABA, it 
is possible that GABA synthesis feedback mechanisms are being stimulated by 
the presence of GBP at specific concentrations. Interestingly, higher 
concentrations of GBP actually increased the expression of GABBR1 3.2-fold, 
but failed to reach statistical significance. For both GABBR1 and GABBR2, 20 
M of GBP caused the strongest downregulation of expression. Higher than 
expected variability was observed in GABBR2 expression when treated with 
vehicle, most likely due to technical error which is accentuated by the overall low 
expression of GABAR subunits in PCa cells. 
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Overall, the investigation into the effects of GBP on LNCaP gene expression 
demonstrated that GBP can have dose dependent effects upon the expression 
of genes proposed to be key to PCa NED including PTOV1, hASH1 and NSE. 
Furthermore, the analysis of genes involved in GABA synthesis and metabolism 
revealed that GBP may be able to increase GABA levels in prostate, a 
mechanism which has previously been described in brain tissue (Cai et al., 2012). 
Although this initial assessment of GBP effects on LNCaP cells, future 
experiments will seek to identify if NED LNCaP cells may respond differently or if 
the expression of GABAAR subunits is influenced by GBP. In a broader outlook, 
these experiments highlight the potential for non-oncological pharmaceuticals 
that are frequently prescribed to cancer patients to have unexpected modulatory 
effects upon cancer cells.  
 
5.3 Discussion 
Previous experiments implicated hASH1 as a driver of PCa NED (Chapter 3 & 4). 
hASH1 is known to promote the development of GABAergic neurons (Mazurier 
et al., 2014; Peltopuro et al., 2010). Therefore, the overall aims of this chapter 
were to establish whether prostate cancer (PCa) cells express the necessary 
GABAR subunits to form functional GABARs and assess how AD, IAD and NED 
effect their expression. Next, it was assessed whether PCa cells and NED PCa 
cells were sensitive to GABAergic compounds. The key contribution of this body 
of work has been to robustly map the expression of GABAA and GABABR subunits 
in the classical PCa cell lines and during NED in response to IAD. This is a useful 
tool for those researching the GABAergic effects and sensitivity of this disease, 
something which is a growing area of research (Ippolito & Piwnica-Worms, 2014; 
Wu et al., 2014; Xia et al., 2017) and is currently operating without a good 
knowledge of GABAR status under these conditions. Previously, quantitative 
assessment of GABAR subunit expression has never been performed in these 
cell lines or under IAD conditions.  
 
5.3.1 Presence of GABAA and GABABR subunits in PCa cell lines 
As an initial exploratory assessment of the potential for PCa cells to form 
GABARs, the expression of GABAAR and GABABR subunits was assessed in the 
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classical PCa cell lines LNCaP, DU-145 and PC-3. Interestingly, expression of 
GABAAR  subunits was exclusive to the androgen-sensitive LNCaP cells (Fig 
5.3). The 3 subunit is known to contain an AR consensus site within its promoter 
region (Steiger & Russek, 2004) and was only expressed in androgen-sensitive 
LNCaP cells, however, expression of the 3 subunit was actually slightly 
upregulated during AD. This would suggest that the 3 subunit expression is 
being modulated by other transcription factors independent of the AR. In contrast, 
the only other GABAAR subunit with an AR consensus site (the 1 subunit) did 
appear to be modulated by androgen availability in LNCaP cells (Fig. 5.4).  Whilst 
all PCa cell lines tested expressed at least one  and  subunit. This would 
suggest that both CRPC cell lines used in this study (DU-145 and PC-3) are likely 
to lack the ability to form functional GABARs, which typically require two , two  
and one  subunit to form a functional heteropentamer (Akinci & Schofield, 1999). 
However, expression of both the prerequisite GABABR subunits was detected in 
androgen-sensitive LNCaP cells and both CRPC cell lines.  
 
A previous study has detected expression of the 6 subunit via immunoblot 
analysis in LNCaP, DU-145 and PC-3 cells (Abdul et al., 2008). Expression of the 
6 subunit is associated with anchoring the completed GABAAR to the cell 
surface (Abdul et al., 2008). As such, the 6 subunit has previously been used 
as a biomarker for functional GABAARs (Abdul et al., 2008), the data herein 
supports that LNCaP cells express 6 subunit, although expression of 6 was 
not detected in DU-145 and PC-3 via qRT-PCR. 
 
Another difference in GABAAR subunit expression between LNCaP and CRPC 
cell lines was that LNCaP cells did not express the 1 subunit, whilst both CRPC 
cell lines had 1-subunit expression (Table 5.1). Furthermore, none of the PCa 
cell lines investigated co-express more than one of the components of the major 
mammalian heteropentamer (1, 2, 2) (Olsen & Sieghart, 2008). Interestingly 
both LNCaP and PC-3 cells express the 3 subunit, which is the only subunit 
capable of forming functional homomeric GABAARs (Miller & Aricescu, 2014). 
This could potentially allow PC-3 cells to form GABAARs despite lacking 
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expression of any  subunits, however, a GABAAR of that composition would lack 
the GABA binding site (Jacob et al., 2008). Previously, it has been reported that 
high GABBR2 alongside low 3 expression results in better prognosis for non-
small cell lung cancer patients (Zhang et al., 2013) and 3 is typically 
overexpressed in this cancer type (Gumireddy et al., 2016), considering that this 
data shows that LNCaP express the 3 subunit, whilst CRPC cell lines do not, 
this would suggest that a similar relationship is not present in the PCa setting, or 
may indeed be inverse.  
 
The  subunit of the GABAAR has previously been shown to specifically facilitate 
GABA mediated growth of hepatocellular carcinoma (Li et al., 2012) and in the 
present study was detected in LNCaP and DU-145 cells but not PC-3. What is 
particularly interesting is that the  subunit grants additional pharmacological 
properties to 31 containing GABAARs that would normally require the presence 
of a 1 or 2 subunit (Ranna et al., 2006). This is especially interesting, because 
LNCaP cells do not express the 1 or 2 subunits, whilst these are two of the 
most expressed subunits in CRPC cell lines PC-3 and DU-145. Furthermore, PC-
3 cells were the only PCa cell line tested found to express both 1 and 2 subunit 
but does not express the  subunit (Fig. 5.2). This data supports the notion that 
the  subunit is substituting the lack of 1 and 2 subunit expression in LNCaP 
cells.  
 
The only other presence and absence study conducted for GABAAR subunit 
expression in PCa LNCaP and PC-3 cells used semi-quantitative RT-PCR (Wu 
et al., 2014). In comparison to the findings in this study, there are many results in 
agreement and many which are differential. For example, in LNCaP cells, both 
the present study and the previous study assert that the 1, 3, 5, 6, 3 and 
 subunits are expressed and that 2, 1 and 2 were not detected. In conflict 
with a previous study, the 1 and 3 subunits were detected and the 4, 2, ,  
and  subunits were not (Wu et al., 2014). In PC-3 cells, the majority of these 
findings conflicts with the Wu et al (2014) study, only the 3 and 1 subunits were 
detected in both studies. Interestingly, Wu et al (2014) detected expression of 
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four out of six  subunits, whilst this study did not detect any  subunits in PC-3 
(Fig. 5.2). The overall low level of expression of GABAR subunits is consistent 
with the low TPM values reported in online databases such as EMBL-EBI gene 
expression atlas for prostate tissue. 
 
5.3.2 Expression of GABAARs and GABABRs subunits in PCa cell lines 
Data in this study suggests that LNCaP cells preferentially expressed the 3 and 
3 subunits, whilst the most prominent subunit in PC-3 cells was 2 (also 
observed in brain) and in DU-145 it was the 1 and 1 subunits that showed 
strongest expression. Interestingly, the 3 subunit, which is usually well 
expressed at birth in the mammalian brain, before receding in adulthood (Laurie, 
Wisden, & Seeburg, 1992; Ohlson et al., 2007) was the most expressed subunit 
in LNCaP cells. Furthermore, RNA editing of the 3 subunit is thought to be a key 
mediator of the shift from excitatory to inhibitory function of the activated GABAAR 
(Ohlson et al., 2007), as the RNA editing of this subunit can affect its properties 
(Nimmich, Heidelberg, & Fisher, 2009). RNA editing generally has also been 
implicated in the growth, progression and metastasis of cancer (Peng et al., 
2018). This could be an indicator that the expression profile of GABAR subunits 
in undifferentiated LNCaP cells more closely resembles that of the developing 
brain, rather than mature, which would be supported by the lack of detected 
KCC2 expression via qRT-PCR or immunoblot (Li & Xu, 2008). Although definite 
conclusions cannot be formed from expression data alone, this data would 
suggest that if GABAARs are functional within LNCaP cells, they are more likely 
to be excitatory rather than inhibitory (Ben-Ari, 2002), although this is dependent 
upon CCC expression profiles (Li & Xu, 2008). Although only mRNA expression 
of GABAR subunits was assessed, functional GABARs have previously been 
identified in the prostate and seminal vesicles of the rat,  suggesting that GABARs 
could possibly be present in human prostate (Napoleone et al., 1990).  
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5.3.3 Effect of AD on GABAAR and GABABR subunit expression 
Following discovery of GABAAR subunit expression in LNCaP cells, the effects of 
androgen deprivation (AD) induced NED on the expression of GABAR subunits 
in LNCaP cells was investigated. Using heat maps to show relative expression 
suggested little change in subunit expression, except the 3 subunit which was 
more prominently expressed after androgen deprivation and is known to be 
important to neuronal development, where 3 subunits are gradually replaced 
with 1 subunits during the switch from excitatory to inhibitory GABAAR activity 
(Succol et al., 2012). The expression of GABAR subunit expression and GABAR 
composition is known to change during the development of canonical neurons 
(Neelands et al., 1999). Expression of the  3 subunit was suppressed when 1 
nM and 10 nM of R1881 were supplemented to AD conditions, which would 
appear to suggest that the observed increase after AD may be genuine. 
Meanwhile, expression of the 1 subunit, which is important for the anchoring of 
GABAARs to the cell surface (Peran et al., 2004), did not appear to be altered by 
androgen availability.  
 
The 5 subunit was slightly upregulated by both AD and 10 nM of R1881, 
suggesting that 5 expression was not altered by AD. The 6 subunit was the 
most upregulated subunit by AD (15-fold), however was only statistically 
significant in the presence of vehicle in AD conditions, R1881 supplementation 
prevented this upregulation, supporting the notion that 6 expression might be 
modulated by androgen availability. This is particularly interesting because the 
6 subunit, along with the 1 subunit, helps to anchor GABAARs to the cell 
surface (Peran et al., 2004) and have previously been used a biomarker for 
GABAARs (Abdul et al., 2008). The 3 subunit was slightly upregulated by AD but 
not significantly and was also slightly upregulated during R1881 supplementation, 
indicating that the 3 subunit is unlikely to be androgen responsive. The 1 
subunit was the most downregulated under AD (38-fold) but in the presence of 
the vehicle this effect was not replicated, suggesting that 1 subunit expression 
is not modulated by androgen availability either. Interestingly, the 3 subunit was 
significantly downregulated by maintenance of 1 nM R1881 to AD conditions, but 
was slightly elevated in the presence of 10 nM R1881.  
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5.3.4 The effect of IAD on expression of GABAAR 
LNCaP cells were subjected to IAD consisting of 5 days AD, 15 days with R1881 
and a further 15 days in AD. GABAAR subunits were initially assessed at the 5 d 
time point because the interest was in seeing the changes during onset of NED 
and this time point matches the peak mRNA expression of both NSE and hASH1 
from previous experiments (Chapter 3). Assessing presence and absence, 
reveals that no previously undetected subunits were detected throughout IAD, 
however after the second period of AD, expression of 6 became undetected 
(Fig. 5.7). Considering that the 6 subunit helps to anchor GABAARs to the cell 
surface, a loss of 6 subunit expression after a second cycle of AD would suggest 
these cells would possess lessened GABAAR activity. Analysing fold change in 
expression, the 1 subunit was unaffected by IAD, whilst 3 was upregulated by 
AD, slightly downregulated during R1881 reintroduction and then upregulated 
once more under a second AD period. This finding supports the previous 
experiment which suggested that the 3 subunit could be modulated by androgen 
signalling (Fig. 5.7). Particularly exciting is that the 3 subunit in upregulated in 
non-small cell lung cancer and is implicated in AKT and metastasis in breast 
cancer (Gumireddy et al., 2016). This data would suggest that the 3 subunit 
could be important in hormone-sensitive cancer types. In addition, the 3 subunit 
was the most expressed subunit in untreated LNCaP, meaning that perhaps 
successive cycle of IAD are enriching LNCaP cells expressing the 3 subunit. 
 
The 5 subunit expression was unresponsive to IAD. The expression of the 3 
subunit, which has previously been shown to decrease the proliferation of 
hepatocellular carcinoma, was slightly upregulated by AD, became significantly 
upregulated during the reintroduction of androgen and remained slightly elevated 
by the end of a second period of AD. It is well established that the slower growth 
rate of NED PCa cells can inherently provide greater resistance to radiotherapy 
and some chemotherapeutics (Grigore, et al., 2015; Hu, et al., 2015). 
Interestingly, 1 subunit expression was downregulated by AD and was slightly 
upregulated during the reintroduction of androgen, increasing further by the end 
of a second period of AD. This would suggest that the successive cycles of AD 
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resulted in LNCaP cells becoming resistant to the lack of androgen causing a 
downregulation of 1 subunit and could indicate that the 1 subunit is particularly 
important to the partial loss of NED phenotype. The expression pattern of the 3 
subunit was similar to that of the 1 subunit during IAD, becoming significantly 
increased during AD cessation and upregulated further after a second cycle of 
AD. A previous study has shown that neurons with the highest expression of the 
1 and 3 subunits are the most resistance to neurodegeneration during the 
pathology of Alzheimer’s disease (Iwakiri et al., 2009). This data is particularly 
exciting as it could indicate that in response to IAD, NED LNCaP cells are 
increasing expression of the 1 and 3 subunits to increase their resilience. 
Further studies would be requires to investigate this further, but could lead to the 
establishment of the 1 and 3 subunits either as a useful biomarker of increasing 
NED resilience or interesting therapeutic targets for degradation in the prostate, 
for example utilising a benzodiazepine-like structure (which binds at the interface 
of an  subunit and a  subunit) conjugated to an anti-cancer agent for targeted 
delivery, especially considering two  subunits are also enriched in expression 
by IAD (3 and 6).   
 
5.3.5 Expression of selected CCCs during IAD 
Expression of CCCs during IAD was investigated primarily due to their influence 
on GABAAR activity (Li & Xu, 2008; Succol et al., 2012). However, there is also 
mounting evidence that CCCs are interesting modulators of cancer proliferation 
and metastasis in their own right, especially in cancers that are hormone sensitive 
such as breast (Hsu et al., 2007), ovarian (Chen et al., 2009) and cervical cancer 
(Chiu et al., 2014). Expression of NKCC1 was elevated (2.7-fold), although not 
significantly, following five days of AD, becoming significantly upregulated (3.7-
fold; p = 0.02) after a 15 d of androgen reintroduction and increasing further after 
a 15 d second period of AD (4.4-fold; p = 0.006). NKCC1 is typically expressed 
during early neuronal development, therefore it is interesting that NKCC1 is 
increasingly upregulated throughout IAD treatment and would be consistent with 
what would be expected if hASH1 nuclear localisation is driving neurogenesis 
(Mazurier et al., 2014; Peltopuro et al., 2010). NKCC2 is reported to be specific 
to kidney tissue, therefore it was expected that expression was not detected in 
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LNCaP PCa cells (Simon et al., 1996).  KCC2 expression was not detected 
throughout IAD, which is a further indicator that the neuronal-like morphology of 
NED PCa cells is more akin to developing neurons than mature neurons (Li & Xu, 
2008). Expression of KCC1 steadily increased throughout IAD but did not become 
significant. Expression of KCC3 also steadily increased throughout IAD and did 
become significant by the end of 15 days reintroduction of androgen, increasing 
further after a 2nd period of AD. KCC4 expression was unaffected by 5 days AD 
but was significantly upregulated after 15 days of reintroduction of androgen, 
expression then fell slightly at the end of the second AD period, but remained 
significantly above untreated control LNCaP cells.  
 
CCCs operate as heterodimers, KCC1 with KCC3, KCC2 with KCC4 and NKCC1 
with KCC4 (Kahle et al., 2015). The data presented herein would suggest that of 
these pairs, only KCC1 with KCC3 and NKCC1 with KCC4 would be applicable 
to LNCaP cells. Interestingly, KCC4 has been implicated in promoting invasion of 
cervical and ovarian cancer and is upregulated in metastases (Chen et al., 2009). 
The mechanism by which KCC4 is able to promote invasion is thought to be 
through interaction with insulin-like growth factor 1 (IGF-1) and epidermal growth 
factor (EGF) (Chen et al., 2009). KCC3 has also been demonstrated to be 
involved in cellular proliferation and significantly upregulated in ovarian cancer 
tissue, but not significantly upregulated in metastases (Chen et al., 2009), instead 
KCC3 is thought to be more involved in the tumourigenesis of cervical cancer 
rather than metastasis (Chiu et al., 2014). However, in oesophageal squamous 
cell carcinoma (OSCC) depletion of KCC3 via siRNA significantly reduced 
invasion and KCC3 was predominantly expressed on the invading front of the 
tumour (Shiozaki, et al., 2014). KCC3 and KCC4 upregulation have also been 
investigated in vivo using breast cancer xenografts, where depletion of KCC3 and 
KCC4 inhibited proliferation and invasion (Hsu et al., 2007). Furthermore, 
depletion of NKCC1 in OSCC cells reduced proliferation via G2/M cell cycle 
phase arrest (Shiozaki, et al., 2014).  In addition, KCC1 expression is also 
significantly higher in cervical cancer and was most expressed in the most poorly 
differentiated cells (Lu et al., 2007). Similarly, the mechanism of KCC1 
upregulation in cervical cancer is thought to be induced by IGF-II, acting through 
the ERK1/2MAPK and PI3K/AKT pathways (Zhang et al., 2009).  
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The importance of NKCC1 and KCC1, KCC3 and KCC4 upregulation in the 
progression of several cancer types, including hormone-sensitive cancers such 
as breast, ovarian and cervical cancer (Chen et al., 2009; Chiu et al., 2014; Hsu 
et al., 2007; Lu et al., 2007; Zhang et al., 2009) lends great context to the data 
discussed herein relating to prostate cancer and NED. The data in this 
investigation shows a stepwise increase in expression of CCCs after each stage 
of the IAD simulation, which not only fits with the role of CCCs in cellular 
differentiation, but also would suggest that IAD is selecting for a potentially more 
aggressive phenotype with significantly increased CCC expression. It would 
appear that the involvement of CCCs in estrogen driven cancer types is becoming 
well established. Considering that both the estrogen receptor (ER) and AR can 
both bind to chromatin at forkhead motifs, facilitated by pioneer factor FOXA1, 
70% of AR binding and 50% of ER binding occurs at sites co-occupied by FOXA1 
in prostate and breast cancer (Robinson & Carroll, 2012). Further investigation of 
the ability of AR or ER to modulate CCC expression in prostate cancer is clearly 
needed. Finally, the lack of KCC2 expression in LNCaP cells at any stage of IAD 
would support the theory that NED LNCaP cells are not mature neurons (Li & Xu, 
2008) and are instead utilising components of the canonical neurogenesis 
pathway to promote survival, AD resistance and acquire a hybrid phenotype after 
a second cycle of AD. 
 
5.3.6 Expression of GABABR subunits during AD and IAD 
GABABR activation has previously been linked to activation of EGR and 
increased migration of PCa cells (Xia et al., 2007), making it an interesting 
candidate as a mechanism of PCa NED mediated ADT resistance. After 5 days 
of AD, expression of GABBR1 was significantly downregulated, an effect which 
was also observed in the presence of the vehicle in AD conditions. The addition 
of R1881 to AD media did not ameliorate this downregulation, suggesting that 
GABBR1 expression is unlikely to be specifically modulated by androgen 
signalling. In contrast, GABBR2 expression was significantly downregulated by 
AD and this effect was lessened when R1881 was present in the AD media, 
suggesting that GABBR2 may be somewhat modulated by androgen expression. 
These results were recapitulated when assessing after an initial 15 days of AD 
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instead of 5 days. GABBR1 expression was significantly downregulated after 15 
days of AD and the addition of R1881 actually suppressed the expression further, 
supporting the notion that GABBR1 is not mediated by androgen signalling. 
However, GABBR2 was downregulated by AD and vehicle in AD conditions, 
whilst addition of R1881 to AD conditions maintained GABBR2 at basal levels.  
 
During IAD, the expression of GABBR1 was slightly downregulated after 15 days 
of AD, but was significantly upregulated by the reintroduction of androgen to AD 
conditions, remaining at this level after a second period of AD. This result is 
contrary to the findings of the studies where R1881 was added at the start of AD, 
which appeared to show that GABBR1 was not modulated by androgen 
signalling. In the context of IAD, it would appear that AD cessation causes an 
upregulation in GABBR1 that is maintained through the second period of AD. 
GABBR2 expression also appeared to be androgen mediated during IAD, where 
it was downregulated by AD but significantly upregulated after reintroduction of 
androgen to AD conditions. After a second period of AD, the expression of 
GABBR2 was slightly suppressed compared to AD+R1881 but remained non-
significantly upregulated compared to control LNCaP cells. In the context of the 
present study, it is important to consider that the oligonucleotides used to detect 
GABBR1 and GABBR2 expression were designed to target transcript variant 1 of 
both genes and would not have detected additional splice variants. For GABBR1 
the GABBR1a splice variant is predominantly expressed in the developing brain, 
whereas GABBR1b becomes the more expressed variant in adulthood (Fritschy 
et al., 1999). Utilising additional primer sets to investigate GABABR splice variant 
expression could have facilitated increased characterisation of the NED PCa cells 
and given deeper insights into the potential GABA response of these cells. Having 
determined that GABABRs are present in PCa and NED PCa cells, investigating 
the splice variant expression would be an ideal future experiment. 
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5.3.7 Expression of genes involved in GABA synthesis and metabolism 
during IAD 
The expression of GABA transaminase (GABA-T), an enzyme, which 
metabolises GABA, was significantly lower in CRPC cell lines DU-145 and PC-3 
compared to LNCaP cells (Fig. 5.9). During AD, the expression of GABA-T was 
slightly increased at 5 and 15 days in LNCaP cells but not to a significant level. 
When R1881 was present in AD conditions, the expression of GABA-T was 
slightly suppressed compared to untreated LNCaP cells, suggesting that GABA-
T expression might be weakly modulated by androgen signalling. During IAD, 
GABA-T was slightly elevated after 15 days of AD and was downregulated during 
the reintroduction of androgen to AD conditions, becoming further suppressed 
after a second period of AD. This would suggest that successive cycles of AD 
causes a fundamental change in GABA metabolism in NED LNCaP cells (Ippolito 
et al., 2014).  Expression of GAD1 during IAD was slightly elevated after the first 
AD period, became significantly upregulated by the reintroduction of androgen to 
AD conditions and returned to the same levels as was observed after 1 AD cycle 
by the end of the second AD cycle. GAD2 expression was not affected by the 1st 
period of AD, was also significantly upregulated by the reintroduction of androgen 
to AD conditions and remained significantly elevated, but to a lesser degree, by 
the end of the second AD period. Not only would this suggest an increase in 
GABA synthesis, but coupled with the downregulation of GABA-T by the second 
AD cycle would also suggest that GABA levels within these cells is likely to be 
increasing. Furthermore, the GAD2 gene encodes isoform GAD65 which is 
predominantly found in nerve terminals and preferentially synthesises GABA for 
vesicular release, whereas GAD1 encodes GAD67 which is distributed 
throughout cells and synthesises mainly cytoplasmic GABA.  This would strongly 
hint at the possibility that NED LNCaP cells have the potential to secrete GABA 
in a paracrine manner, or more conservatively, are becoming more specialised 
towards that function  (Soghomonian & Martin, 1998).  
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5.3.8 The effect of muscimol and baclofen on a key panel of genes in AD 
LNCaP cells.  
Using selective GABAAR and GABABR agonists (muscimol and baclofen 
respectively) (Benarroch, 2012; Napoleone et al., 1990) allowed for the 
investigation of GABAergic signalling upon a key set of genes in NED LNCaP 
cells. Interestingly, although AR expression was not affected by either muscimol 
or baclofen, there were significant effects of GABAAR and GABABR agonism on 
the expression of PSA when compared to the vehicle control. All concentrations 
of muscimol significantly increased PSA expression compared to vehicle control, 
the lowest tested concentration (1 M) of muscimol increased PSA expression 
the most, an effect which was reduced in a stepwise manner at increasing 
concentrations. Conversely, only the highest concentration of baclofen (500 M) 
produced a statistically significant increase in PSA expression. 
 
A possible explanation for GABAergic signalling to increase PSA expression is 
that GABA has previously been shown to increase androgen production in rat 
testicular tissue (Ritta, Campos, & Calandra, 1987), which could potentially 
stimulate an increase in PSA expression under AD conditions. It is already 
established that prostate cancer tumours are capable of producing DHT under 
AD conditions from androgen precursors (Chang, Ercole, & Sharifi, 2014; Chang 
et al., 2011). The fact that this effect was observed through both GABAAR and 
GABABR signalling is particularly interesting and increased androgen synthesis 
in response to GABAergic signalling could be a potential mechanism of NED 
facilitating ADT resistance clinically. However, it is likely that this relationship 
would be best studied using in vivo xenografts, as it is unclear whether cell culture 
media with charcoal-stripped serum would contain representative levels of these 
androgen precursors.  
 
Furthermore, interesting links have previously been discovered between 
androgen availability and the excitatory nature of GABAARs. In neurons derived 
from female rats, multiple applications of muscimol result in an attenuated 
response in intracellular [Ca2+]I compared to the first application, whereas male 
derived neurons (and female derived neurons pre-treated with androgen) showed 
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no attenuation with multiple applications of muscimol (Nuñez & McCarthy, 2008). 
In the context of the present study, this would appear to suggest that GABAAR 
activity could be significantly altered by AD. Excitingly, this effect was also found 
to be inversely correlated to expression of the 2 subunit (Nuñez & McCarthy, 
2008) which was not detected in any of the PCa cells tested, including NED 
LNCaP cells throughout simulated IADT, suggesting that if this mechanism is 
present in PCa cells, it would be operating under optimal conditions. Expression 
of PTOV1, REST and NSE were not modulated by muscimol or baclofen 
treatments. However, expression of hASH1, which is a key driver of GABAergic 
neuronal development (Mazurier et al., 2014; Peltopuro et al., 2010; Yang et al., 
2017), was inhibited both by GABAAR and GABABR stimulation during AD. This 
would align with research demonstrating that GABA mediated activation of both 
GABAARs and GABABRs can inhibit neurogenesis in the developed brain 
(Giachino et al., 2014; Pallotto & Deprez, 2014).  
 
5.3.9 The effect of gabapentin on LNCaP cells 
An initial assessment of potential effects of gabapentin (GBP) on PCa cells was 
conducted on LNCaP cells which had not been subjected to AD. The most 
interesting finding of these experiments were that at concentrations of 20 M GBP 
key genes implicated in the NED pathway (PTOV1, hASH1 and NSE) were 
downregulated, although only NSE was significantly downregulated. In addition, 
GABA-T was downregulated in the presence of 2 and 20 M GBP and GAD2 was 
upregulated by 166 M GBP, indicating that GBP can potentially reduce GABA 
metabolism and increase GABA synthesis. Interestingly, this aligns with the 
proposed mechanism of action of gabapentin, where it is thought to increase 
concentrations GABA by increasing GABA synthesis (Cai et al., 2012). If this 
mechanism is active in these epithelial PCa cells, it could mean that increasing 
availability of GABA reinforces the epithelial phenotype and inhibits the proposed 
NED pathway. Interestingly, NED LNCaP cells treated with muscimol and 
baclofen did not exhibit this inhibitory effect of PTOV1, hASH1 and NSE 
expression, which could suggest that increasing GABA levels only inhibit the 
proposed NED pathway in epithelial phenotype LNCaP cells. 
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5.3.10 Future Functional GABAR experiments 
The results of muscimol and baclofen treatment experiments demonstrated that, 
within the scope of this study, agonism of the GABAAR and GABABR appeared 
to have very minimal effect upon the investigated NED pathway components in 
the AD LNCaP model. These results help to confirm and support a previous 
pharmacological and functional study, which also reported no effect in the LNCaP 
model and concluded that the effects of inhibiting GABA production were unlikely 
to be a direct consequence of inhibiting GABARs (Ippolito et al., 2006). A later 
paper from the same group proposes, after analysis using a novel fluorescence 
based functional assay, that it may be the metabolism of GABA that is responsible 
for increased PCa NED cell survival and growth via ALDH5A1 activity to supply 
the TCA cycle in these cells (Ippolito et al., 2014).  
 
Clearly, to further elucidate the activity of GABA in PCa NED cells, the next steps 
would be to employ more complex functional assays in order to properly assess 
and delineate the effects of GABA and GABA antagonist supplementation on 
GABAR dependent and GABAR independent pathways. In order to investigate 
the activity of GABAARs and CCCs, it is possible to visualise and measure the 
cellular chloride concentration using synthetic dyes such as SPQ, MQAE or MEQ. 
These dyes are fluorescent and are quenched when they come into contact with 
chloride ions, therefore cells with highest chloride concentrations will display the 
lowest fluorescence (Arosio & Ratto, 2014; Inglefield & Schwartz-Bloom, 1999). 
Using live cell confocal microscopy, it would likely be possible to visualise the 
effect of GABAAR agonists and antagonists on intracellular chloride ion 
concentrations, allowing for determination of likely GABAAR activity in AD LNCaP 
cells in real time. A second approach to a functional assay to assess GABAAR 
activity would be to take an electrophysiology approach and to measure directly 
the polarisation of AD LNCAP cells in response to GABAAR ligands (Ippolito et 
al, 2006).  
 
To investigate the presence of assembled GABABRs in the AD LNCaP model, a 
first step could be to use radio-labelled baclofen (Hill & Bowery, 1981), however 
additional assays would need to be performed to investigate whether agonism or 
antagonization of the GABABR had a functional effect upon the cell. A long 
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standing and well utilised method of measuring GABAB-specific activity in 
response to a specific agonist is measuring increases in inositol triphosphate 
using ion exchange chromatography (Komatsu, 1996; Brauner-Osborne & 
Krogsgaard-Larsen, 1999). This functional assay could be applied as a functional 
assay to investigate the activity of GABABRs in the AD LNCaP model. 
 
5.3.11 GABA results in relation to previous studies 
It is important to consider that in-depth characterisation of GABAR presence and 
functionality in non-neuronal tissues remains an emerging field and one where 
there are often conflicting reports. This is primarily due to the complexity of 
GABARs both in terms of multitude of different conformations of the GABAAR 
and the interdependence of both GABARs on CCCs for their functionality. 
Furthermore, when assessing whether present GABARs are functional, it is 
difficult to delineate whether effects of agonists and antagonists are directly 
mediated by the target GABAR or instead results of indirect activity such as 
increasing GABA concentrations. 
 
Although some studies have investigated the role of GABA and GABARs in NE 
cells of the prostate, it is already well established that PCa NED cells are more 
closely aligned to PCa epithelial cells, rather than direct expansion of the NE cell 
niche (Sauer et al., 2006). Therefore, studies investigating GABA activity in 
prostate NE cells are unlikely to be applicable to PCa NED cells (Solorzano et 
al., 2018).  
 
Furthermore, even fundamental questions such as the presence of functional 
GABAARs in LNCaP cells remains controversial. For example, a previous study 
concluded that LNCaP GABAARs were non-functional as they did not respond 
to GABA (Ippolito et al., 2006), however this has been refuted by several more 
recent publications which have shown growth modulatory effects of GABAAR 
specific agonists in LNCaP cells both in vitro, where isoguvacine increases 
proliferation of LNCaP cells and dihydroergotoxine decreased proliferation 
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 (Abdul, McCray & Hoosein, 2009). These findings have been confirmed by other 
investigators showing proliferation increases in LNCaP cells treated with 
isoguvacine can be blocked using picrotoxin (Wu et al., 2014).  
 
In relation to the previous literature, it is important to consider that 
characterisation of changes in cell proliferation were not conducted, instead this 
study focused on whether activation of the GABAAR or GABABR influenced the 
expression of genes thought to drive PCa NED. In the present study, there is little 
evidence to support that GABAAR agonism has any effect on the NED related 
genes that were assessed. Although a negative result, the effect of GABAAR 
agonism on the drivers of the NED process has not previously been assessed. In 
comparison, investigations into agonism of the GABABR revealed some changes 
in the proposed NED pathway, with PTOV1 being significantly upregulated by 
baclofen treatment, whilst MMP-9 was significantly downregulated by 500 M 
baclofen. In comparison to previous literature, the downregulation of MMP-9 is 
contrary to what has previously reported, with multiple studies linking GABABR 
agonism with increased MMP-9 expression in both rat hippocampal neurons (Car 
& Michaluk, 2012) and PCa NED (Azuma et al., 2003). In order to further assess 
whether GABARs are functional in the LNCaP NED model, more bespoke 
experiments and assays would need to be performed as described in section 
5.3.10.  
 
5.4 Conclusions of GABAR studies 
One of the fundamental findings of this comprehensive investigation of GABAR 
subunit expression in PCa cell lines, was that only LNCaP cells express  
subunits of the GABAAR. Therefore, although it is possible for functional GABA 
receptors to be present in DU-145 and PC-3 cells, they would be unable to bind 
the endogenous ligand GABA. This is an important discovery that illuminates a 
principle difference between androgen-sensitive PCa and CRPC.  
 
This initial assessment of GABAR subunit expression across LNCaP, PC-3 and 
DU-145 cells also facilitated the deduction that, as seen in a xenopus model 
(Ranaa et al., 2006), the  subunit is likely to be substituting for a lack of 2 and 
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3 subunit expression. Considering that the 1 and 2 subunits are the most 
expressed subunits in PC-3 CRPC cells, this could be an important finding with 
clinical relevance both as a drug target and as a biomarker. 
 
Overall this chapter presents evidence that NED LNCaP cells possess a 
phenotype more akin to developing neurons than mature neurons. This is 
evidenced by an absence of KCC2 expression (Li & Xu, 2008), high expression 
of the 3 subunit (Laurie et al., 1992; Liu et al., 2009), which increases further 
under AD conditions and significantly upregulated NKCC1 expression during the 
NED process (Li & Xu, 2008). Analysis of GAD2 revealed upregulation during 
IAD and suggests that increased GABA synthesis is likely to be for vesicular 
release (Montori et al., 2012; Soghomonian & Martin, 1998), hinting at the 
possibility of paracrine signalling.  However, the expression of GAD2 is at odds 
with the lack of KCC2 expression, as both are associated with well differentiated 
neurons, rather than during development. This could be further evidence of a 
hybrid/aberrant phenotype that does not conform to the stereotypes of canonical 
neutrons. The majority of the data would support that NED LNCaP neuronal-like 
cells are closer to developmental neurons than to mature neurons.  
 
Investigating the effects of AD and IAD on GABAR subunit expression also 
highlighted that during AD, expression of the 6 subunit increases significantly 
suggesting increased trafficking and anchoring of GABAARs to the cell surface 
after the NED process. Furthermore, the 3 subunit was progressively 
upregulated at each AD cycle and was downregulated during the intermediate 
AD cessation period is closely linked to the invasion and metastasis of breast 
cancer (Gumireddy et al., 2016). Whilst the interactions of estrogen signalling and 
GABAR activity and subunit expression are becoming well documented, there is 
a lack of research into the possibility that these mechanisms may also be present 
in androgen driven cancers such as PCa.  After IAD expression of 1 and 3 was 
enriched. These two subunits are known to be neuroprotective and could 
potentially be a facilitator of enhanced survival for NED LNCaP cells (Iwakiri et 
al., 2009). Considering that the 3, 1 and 3 subunits were significantly 
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upregulated by IAD, this could implicate the  subunit interface as a potentially 
interesting drug delivery target in NED PCa for anticancer drug conjugates. 
 
Also discovered was an enrichment of CCC expression progressively throughout 
IAD. CCC upregulation is well documented in cervical and ovarian cancer (Chen 
et al., 2009; Chiu et al., 2014; Zhang et al., 2009) and the data presented herein 
gives clear rationale to study CCC upregulation in androgen driven cancers such 
as PCa. Finally, the assessment of GABABR subunits revealed that the GABAB2 
subunit expression is modulated by the availability of androgen in the LNCaP 
cells, whereas GABAB1 appears to be expressed independent of androgen 
availability. Research in this chapter has helped to significantly elucidate the 
GABAR subunit expression profile across a range of PCa cell lines for the first 
time quantitatively and in the context of IAD. These findings have identified 
several intrinsic connections between androgen availability and GABAR subunits, 
CCCs and the proposed pathway of AD-induced NED in LNCaP cells which 
warrants further investigation. 
 
5.5 Limitations, weaknesses and future experiments 
Research in this chapter represents the first time that all subunits of the GABAAR 
and GABABR have been quantitatively assessed in a model of PCa NED. 
However, there are still substantial limitations of this studies and areas which 
could be greatly strengthened by additional experiments or the use of different 
methodology. For the assessment of GABAR subunits, it would have been 
preferable to use TaqMan probes for qPCR, which are much better suited to 
presence and absence studies, instead of SYBR-green detection chemistry 
(Bustin, 2000; Gangisetty & Reddy., 2009). Secondly, although the effects of 
GABAR agonists on the NED pathway were investigated, the effects upon 
proliferation or migration were not assessed. Since these have previously been 
reported as downstream effects of GABAR activation in PCa NED, not assessing 
these variables is a major weakness of this study and a clear opportunity for 
future experiments. In addition, functional assays could have been utilised, such 
as using radiolabelled baclofen (Hill & Bowery, 1981), measuring increases in 
inositol triphosphate using ion exchange chromatography (Komatsu, 1996; 
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Brauner-Osborne & Krogsgaard-Larsen, 1999) or electrophysiology experiments 
to determine whether GABAAR or GABABR agonists were affecting the cellular 
ion concentrations of these cells. Another weakness and limitation is that the 
expression of GABAR subunits were only assessed via qPCR and there was no 
investigation of whether there was detectable protein expression. As it is known 
that gene expression does not necessarily indicate expression at protein level, 
obtaining high quality antibodies targeting each subunit is clear and necessary 
next step in the process of characterising the GABARs in AD LNCaP cells. 
Finally, another clear limitation was that the effects of gabapentin were only 
assessed in normal LNCaP cells and not in AD LNCaP cells that possess the 
NED phenotype, this would be an important next step to determine if gabapentin 
could modulate PCa NED cells. 
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6. General Discussion and future directions 
6.1 Summary of findings 
The main findings of this investigation can be summarised as follows: 
 
6.1.1 hASH1 is a likely key driver of AD-induced NED in PCa 
Androgen deprivation (AD) of LNCaP induces a neuronal-like phenotype that is 
concomitant with a shift in localisation of transcription factor hASH1 into the nuclei 
of these cells. Although hASH1 has previously been suggested as a driver of AD-
induced neuroendocrine differentiation (NED) in PCa, this study is the first to 
assess hASH1 localisation during IAD and the first to propose a pathway that 
could facilitate hASH1 mediated NED. Recent investigations of small cell lung 
cancer (SCLC) have conclusively linked hASH1 as being essential to NED in 
SCLC (Borromeo et al., 2016; Meder et al., 2016). In this study, hASH1 
expression was found to be specifically modulated by AD, as were the proposed 
upstream components of this NED pathway (PTOV1 and REST). These findings 
suggest that hASH1 could be an interesting therapeutic target that warrants 
further validation. Although transcription factors like hASH1 are often considered 
intractable drug targets (Johnston & Carroll, 2015), gaining a better 
understanding of the potential upstream components of this pathway and direct 
interactors of hASH1 could identify mechanisms of indirect hASH1 targeting. 
Currently, there are no approved therapeutics which specifically target the 
process of PCa NED despite NED being a common mechanism of therapeutic 
resistance in patients (Borromeo et al., 2016). Very interestingly, 
Rovalpituzumab, one of the only NED targeting drugs currently in clinical trials for 
SCLC is a DLL3 targeted antibody-drug conjugate. Critically, DLL3 is both a 
known target gene of hASH1 and a key ligand of Notch (Rudin et al., 2017; Zhang 
et al., 2018), therefore the efficacy demonstrated thus far of rovalpituzumab in 
SCLC would strongly support the hypothesis presented herein that Notch 
signalling is an important component of the hASH1 driven NED pathway. As of 
June 2018, rovalpituzumab is currently under appraisal by the National Institute 
for Health and Care Excellence (NICE).  
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6.1.2 The molecular reversibility of AD-induced NED is established for the 
first time 
For the first time, the effects of intermittent AD on NED were investigated using 
an in vitro model, particularly in regard to the extent that NED could be reversed 
on a morphological and molecular level by cessation of AD. As previously 
reported using a cAMP induced NED model (Cox et al., 1999), the morphological 
changes associated with NED, including neurite-like extensions, were lost upon 
AD arrest, the first time that this has been assessed in an AD-induced NED 
model. However, most interesting were the molecular implications of AD 
cessation, which demonstrated that although NSE expression was 
downregulated and REST and PTOV1 expression were upregulated alongside 
restoration of PSA expression to basal levels, the expression of hASH1 remained 
elevated and was intensely retained within the nuclei of LNCaP cells. This is a 
fundamental finding that demonstrates for the first time that whilst the 
morphological aspects of NED appear to be reversible, the nuclear localisation of 
hASH1 is persistent and robust, which hints that these cells may be employing 
aspects of a neuronal-like transcriptional profile as part of a hybrid phenotype. An 
important consideration for this hybrid phenotype hypothesis is whether ADT 
could induce the expression of AR splice variants and whether these variants 
could be active under AD conditions. A limitation of this study is that an 
assessment of AR splice variant activity was not performed, thus it is not possible 
to ascertain whether aberrant AR signalling may play a role in the maintenance 
of the NED phenotype. The ability of LNCaP cells to differentiate into neuronal-
like cells which are highly therapeutic resistant (Deng et al., 2011; Hu et al., 2015; 
Yadav et al., 2017) and then back into an epithelial phenotype could also be a 
sophisticated mechanism of disease recurrence with high clinical relevance.  
 
6.1.3 The effects of intermittent AD on PCa NED were investigated for the 
first time 
Investigating the effects of a second AD period after AD cessation revealed that 
LNCaP cells can undergo NED a second time and that hASH1 remains enriched 
within the nucleus, further supporting the evidence that hASH1 is a likely key 
driver of AD-induced NED in PCa. Studying hASH1 localisation throughout IAD 
indicates that the robust exclusion of hASH1 from the nucleus is permanently 
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lost. This raises the question how what mechanisms are in place to exclude 
hASH1 from the nucleus and could there be a way to stabilise this effect under 
AD conditions. One such viable strategy to prevent hASH1 access to the 
chromatin is the application of bromodomain and extra-terminal motif inhibitors 
(iBETs) which can block the binding of transcription factors to acetylated histones 
(Garnier, Sharp, & Burns, 2014; Shi & Vakoc, 2014) and is discussed further in 
section 6.5.1. What is already known is that only cytoplasmic hASH1 is targeted 
by ubiquitin for degradation, a process which is reliant on Huwe1 E3 ligase 
(Gillotin et al., 2018). This would also support the findings within this study, that 
nuclear localisation of hASH1 is persistent and that clinically, this process is 
something which would be better avoided than attempted to reverse, the precise 
mechanism of how hASH1 is shuttled into the nucleus remains unknown at this 
stage (Gillotin et al., 2018). 
 
6.1.4 The first comprehensive assessment of GABAR subunit expression in 
PCa cell lines and the effect of IAD and GABAR agonists on their 
expression 
A comprehensive and quantitative assessment of GABAR subunit expression 
across LNCaP, DU-145 and PC-3 PCa cell lines was performed for the first time. 
This analysis revealed interesting differences between androgen-sensitive 
LNCaP cells and the CRPC cell lines, primarily that only LNCaP cells with the 
potential to produce GABAARs able to bind GABA. Furthermore, throughout IAD 
this study identified for the first time that the 3 subunit, which is associated with 
increased aggression of breast cancer, is also upregulated in LNCaP cells after 
IAD (Gumireddy et al., 2016). This studies analysis of GABAAR subunit 
expression also suggested, with the context of other studies (Ranna et al., 2006), 
that the  subunit is likely to be substituting for a lack of 2 or 3 expression in 
LNCaP and DU-145 cells. This is particularly relevant considering that the 2 
subunit is the most expressed subunit in the PC-3 CRPC cell line and one of the 
most prevalent subunits expressed in brain tissue. Analysis of CCCs revealed 
two particularly interesting findings, the first being that after AD-induced NED in 
LNCaP cells, there is no detected expression of KCC2, which is a specific 
biomarker of mature neurons. This supports the hypothesis that NED LNCaP 
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cells are only partially differentiated and could be simply exploiting selected 
aspects of the neurogenesis transcriptional profile to confer a survival and AD 
resistance advantage. Secondly, the upregulation of NKCC1, KCC1, KCC3 and 
KCC4 have previously been associated with tumorigenesis, increased 
proliferation, invasion and metastasis in cervical, ovarian and oesophageal 
cancers (Chen et al., 2009; Chiu et al., 2014; Hsu et al., 2007; Lu et al., 2007; 
Shiozaki et al., 2014; Shiozaki et al., 2014; Zhang et al., 2009). The data 
presented herein demonstrated that NKCC1, KCC1, KCC3 and KCC4 were 
progressively upregulated at each stage of IAD, with NKCC1, KCC3 and KCC4 
being significantly upregulated by the end of the AD cessation period and 
remained so by the end of the second AD period (Fig. 5.6). These findings 
suggest that CCC upregulation, as established in cervical and ovarian cancer 
progression, may also be a feature of PCa.  
 
Overall the findings of this investigation identify hASH1 as an interesting 
therapeutic target in NED PCa, provide the first molecular analysis of androgen-
sensitive PCa cells treated with simulated IADT and the first quantitative 
assessment of GABAAR and GABABR subunit expression, along with analysis of 
CCCs, across androgen-sensitive, CRPC and NED PCa in response to IAD. This 
study also required the development of a novel model of IAD, which is a useful 
contribution to the field and could facilitate further in vitro studies investigating 
IADT which is increasing in clinical interest. These findings have high translational 
relevance and provide a powerful rationale to further delineate the role of hASH1 
on NED and validate this transcription factor as a therapeutic target. This could 
be achieved using additional genomic and proteomic approaches such as ChIP-
Seq, RNA-Seq and RIME to identify both the target genes of hASH1 in the 
specific NED PCa context, it’s abilities to act as a pioneer factor (Iwafuchi-Doi & 
Zaret, 2014; Park et al., 2017; Wapinski et al., 2013, 2017) during IAD and NED 
as well as mapping the hASH1 interactome which could identify additional routes 
to hASH1 therapeutic targeting (Mohammed et al., 2016; Papachristou et al., 
2018). Furthermore, applying knowledge gained from the AD and IAD in vitro 
models to develop in vivo models, utilising LNCaP and patient derived xenografts 
will be critical to better understanding the role of hASH1, the impact of NED on 
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PCa tumours and to investigating whether IAD and methods of inhibiting hASH1 
activity increase survival or reduce metastasis and therapeutic resistance. 
 
6.2 hASH1 as a potential therapeutic target in NED PCa 
Although transcription and pioneer factors are notoriously difficult drug targets 
(Johnston & Carroll, 2015), previous evidence has shown that the BET inhibitor 
JQ1 can downregulate hASH1 expression by disrupting the binding of BRD4 to 
the hASH1 promoter in SCLC cells (Lenhart et al., 2015). This would provide a 
clear rationale to investigate the effects of JQ1 on hASH1 expression in NED PCa 
cells. Although JQ1 is not being pursued in clinical trials due to its short half-life 
(Wadhwa & Nicolaides, 2016), next generation BET inhibitors such as I-BET762 
from GlaxoSmithKline is currently in Phase I clinical trials for NUT midline 
carcinoma which is due to complete in December 2018 
(https://clinicaltrials.gov/ct2/show/NCT01587703). Interestingly, the inhibition of 
proliferation seen in SCLC cells treated with JQ1 was conserved when treated 
with I-BET762 (Lenhart et al., 2015). This next generation of BET inhibitors 
(iBETs) could potentially be applied in an adjuvant setting alongside ADT to 
alleviate or delay AD-induced NED. The most recent studies of BET inhibition in 
PCa have demonstrated that PCa can develop resistance to BET inhibition 
(Pawar et al., 2018), which would seem to advocate for a select and precise use 
of iBETs alongside existing treatments to specifically mitigate NED. Overall, it 
must be considered that NED is only one of many resistance mechanisms of PCa, 
in effect novel treatment strategies for PCa could effectively aim to close off these 
avenues of adaption, effectively forcing the tumour evolution into a ‘blind alley’, 
facilitating new options for synthetic lethality, a concept recently demonstrated by 
combining ADT with PARP inhibition in vivo (Asim et al., 2017). In the eventuality 
that direct or upstream targeting of hASH1 is not possible in PCa, a study of 
hASH1 activity in SCLC identified 24 hASH1 target genes that have existing 
targeted compounds (Augustyn et al., 2014). 
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6.3 Clinical implications of the effects of IAD on PCa NED 
Overall, the date presented herein would strongly support the EAU guidelines 
stating that ADT should be constant and not intermittent (Heidenreich et al., 2014; 
Mottet et al., 2011). Certainly, the future aims of PCa NED amelioration must be 
the initial prevention of NED and the prevailing dogma that NED is a completely 
reversible process (Cox et al., 1999) is made obsolete by our findings and the 
knowledge that nuclear, chromatin bound, hASH1 is many time more stable and 
degradation resistant than when in the cytoplasm. 
 
Our findings also support the hypothesis that NED PCa could function in tumour 
recurrence in a similar way to the cancer stem cell niche, i.e. utilising inherent 
radioresistance, chemoresistance and ADT-resistance to survive successive 
treatments whilst retaining the ability to transdifferentiate back into an epithelial 
phenotype and reseed the tumour or metastatic sites, for example 30-50% of high 
risk localised prostate cancer patients suffer disease recurrence within 5-years of 
receiving radiotherapy (Hu et al., 2015).   
 
6.4 Limitations and weaknesses of this study 
Before considering future experiments, it is important to acknowledge the 
weaknesses and limitations of the present study. These limitations can be broadly 
categorised as either limitations in scale and scope, limitations of the LNCaP and 
CS-FBS model of PCa NED and the limitations of the methodology employed to 
investigate said model. Perhaps the chief limitation of this study is that a 
hypothesis driven approach was taken, i.e. a proposed NED pathway 
synthesised from previous literature and the use of informatics tools such as the 
STRING database (Skzclarczyk et al., 2019; www.string-db.org) to guide this 
hypothesis. In comparison, an unbiased discovery-based approach would have 
been preferable, but would also have required the use of a much higher 
throughput ‘screening’ technique such as RNA-Seq or microarray to identify 
pathways activated and repressed by AD through a gene ontology approach in 
an unbiased manner. Clearly, the selection of a small panel of hypothesis driven 
genes has a high likelihood of not including genes that could be key to PCa NED, 
especially if those genes have not been widely studied or reported in the 
literature. However, there were some advantages to restricting the number of 
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targets assessed, for example this allowed for many different treatments and 
timepoints to be studied relatively inexpensively compared to using a large 
number of targets and a more restricted set of treatments and timepoints. Despite 
this, the number and frequency of time points assessed in this study were limited. 
It would perhaps have been valuable to include some much earlier timepoints 
such as 2, 4 and 6 h after AD or drug treatment to assess which molecular 
changes associated with NED are the first to occur.  
 
In terms of the AD LNCaP model used to study PCa NED, a key limitation is that 
these experiments were only performed in one cell line and only in vitro, which 
does not represent the high heterogeneity of patient tumours or the complexities 
of the tumour microenvironment. It is certainly possible that the neuronal-like 
phenotype observed in LNCaP cells after AD could simply be an artefact of this 
particular cell line and not applicable to clinical disease. Previous studies which 
have shown hASH1 expression to be enriched in patients treated with ADT would 
appear to support the observations made in the present study. However, a 
weakness of this study is that hASH1 activity and localisation was not assessed 
in patient material or in LNCaP xenografts which could have added greater 
credibility to the assertion that hASH1 is a potential therapeutic target. It must 
also be considered that whilst the use of CS-FBS to mimic ADT is widespread 
and a justified approach, there are inherent limitations of this approach. For 
example, the concentrations of androgens and other components in the FBS and 
CS-FBS are likely to fluctuate between lots and the hormone concentrations and 
GABA were not empirically determined by ELISA. In addition, the process of 
charcoal-stripping, as mentioned previously, is not androgen specific, which in 
addition to the lot to lot variability of supplied FBS and CS-FBS could contribute 
to increased variability between experiments. Although the specificity of changes 
observed in AD conditions was verified by using R1881 synthetic androgen as a 
control, it would have also been of great benefit to use enzalutamide (in non-
charcoal-stripped media) alongside the R1881 control to prove that changes in 
gene and protein expression were specifically mediated by changes in AR 
signalling.   
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Aside from the limitations of the model used, there are also substantial limitations 
arising the methodologies employed to study the model. For example, the AR 
antibody and qPCR oligonucleotides used in this study did not target the regions 
of the protein or gene conserved between the majority of AR splice variants. This 
severely limited the ability to consider the effects that AR splice variants might 
have on the NED process or their activity during AD. In addition, since this study 
focused on a relatively concise panel of NED related genes, it would likely have 
been preferable to use TaqMan probes for qPCR instead of SYBR-green 
detection chemistry. This would have allowed for increased sensitivity for targets 
with low expression and would have been better suited to determining presence 
and absence of the GABAR subunits. In addition, to robustly determine whether 
GABARs were functional in NED LNCaP cells, functional assays could have been 
utilised, such as using radiolabelled baclofen (Hill & Bowery, 1981), measuring 
increases in inositol triphosphate using ion exchange chromatography (Komatsu, 
1996; Brauner-Osborne & Krogsgaard-Larsen, 1999) or electrophysiology 
experiments to determine whether GABAAR or GABABR agonists were effecting 
the cellular ion concentrations of these cells. Another clear limitation was that the 
effects of gabapentin were only assessed in normal LNCaP cells and not in AD 
LNCaP cells that possess the NED phenotype, this would be an important next 
step to determine if gabapentin could modulate PCa NED cells. 
 
Finally, despite the evidence linking hASH1 nuclear localisation to the NED 
process, this study did not determine whether hASH1 was definitely 
mechanistically involved in PCa NED. On the strength of the data presented it is 
only possible to determine that hASH1 nuclear localisation in concomitant with 
NED. To more robustly evaluate hASH1 as a therapeutic target it would be 
necessary to determine whether overexpression or knock down of hASH1 was 
able to induce and prevent NED respectively. Furthermore, if hASH1 was 
determined to be an essential driver of NED, the use of ChIP-Seq or ChIP-qPCR 
experiments would reveal the target genes of hASH1 which could in itself 
highlight a more tractable drug target.  
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6.5 Future investigations 
The future work facilitated by this thesis is likely to follow three core strands, the 
first being the validation of hASH1 as a therapeutic target, the second being a 
deeper investigation of GABAR pharmacology, influence of CCCs and GABA 
metabolism in NED PCa, with the third being to assess the mechanisms by which 
NED PCa cells can support the survival, growth and metastasis of surrounding 
cells. It is likely that all three of these research niches will investigate these 
questions in the context of IAD and in the presence of adjuvant and neo-adjuvant 
treatments with docetaxel, which is becoming an increasingly popular clinical 
option (James et al., 2016; Vale et al., 2016). These important future 
investigations will utilise the data presented in this thesis to strive towards 
translational research outputs.  
 
6.4.1 Further investigations of hASH1 activity in PCa and validation as a 
therapeutic target  
In order to truly validate hASH1 as a therapeutic target, additional genomic and 
proteomic techniques must be applied, alongside the developments of in vivo 
models to study NED PCa in a more representative microenvironment. As already 
performed in SCLC samples (Borromeo et al., 2016), ChIP-Seq will be employed 
to both identify the direct target genes of hASH1 and to elucidate its ability to act 
as a pioneer factor. By mapping the location of histone marks that designate 
active regulatory sequences such as H3K27ac and active and poised enhancers 
such as H3Kme1 it will be possible (alongside hASH1 silencing experiments) to 
identify both the ‘when’ and ‘where’ that hASH1 acts as a pioneer factor 
(Activation et al., 2016; Creyghton et al., 2010; Rada-Iglesias et al., 2011).  
 
The next goal of this investigation will be to discover how and why hASH1 is able 
to directly drive PCa NED and function as a pioneer factor. This will be achieved 
using the mass spectrometry technique RIME (Mohammed et al., 2016) which 
will allow for the identification of the hASH1 interactome when bound to the 
chromatin. Gaining knowledge of the cofactors that either facilitate hASH1 
chromatin biding, or the factors recruited to the chromatin by hASH1, could 
elucidate alternative mechanisms by which hASH1 activity could be disrupted, for 
example by identifying highly prostate-specific interactors or interactors for which 
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existing drugs could be repurposed. Finally, by integrating the data from the afore 
mentioned experiments, RNA-Seq can be applied to validate and quantify which 
genes are likely to be specifically modulated in expression by hASH1 activity. 
This will provide substantial increases in the understanding of the minutiae of 
hASH1 activity and is likely to identify novel therapeutic targets for PCa NED, for 
which there is currently no specific targeted therapeutic.  
 
In addition to these in vitro experiments, LNCaP and androgen-sensitive patient 
derived xenografts (PDX) will be implanted into NSG mice (treated with 
enzalutamide, castrated or untreated). These in vivo experiments will be crucial 
to discovering the true impact of hASH1 activity upon the growth, invasion and 
metastasis of tumours, as well as allowing for the study of hASH1 in a more 
representative microenvironment (LNCaP and PDX) as well as studying NED 
PCa cells in their context as a subpopulation of cells in a PDX model with 
preserved tumour heterogeneity (Cassidy, Caldas, & Bruna, 2015). Recent 
advances have allowed for  this tumour tissue grown in vivo to also be subjected 
to the same ChIP-Seq and RIME analysis pipeline as in vitro experiments (Goetz 
et al., 2017; Papachristou et al., 2018) Critically, this analysis will also be 
performed on primary tumours and on the matched metastases grown in vivo 
after resection of the primary tumour. 
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6.4.2 Investigating the paracrine signalling potential of NED PCa cells 
To investigate the intracellular and paracrine signalling potential of NED PCa cells 
within tumours, in vitro experiments will be used to identify the active signalling 
pathways and the effects of these will be validated in vivo. The first series of 
experiments will be to apply the conditioned culture media from long term AD-
induced NED LNCaP cells to untreated LNCaP, DU-145 and PC-3 cells and using 
RNA-Seq to identify changes in gene expression when in the presence of any 
paracrine signalling molecules produced by NED LNCaP cells. ELISA assays will 
also be used to quantify the concentration of molecules thought to have paracrine 
signalling potential in PCa and NED PCa, including GABA, cAMP and IL-6 
(Deeble et al., 2001; Deng et al., 2011; Ippolito et al., 2014; Shen et al., 1997a; 
Tawadros et al., 2013; Wang et al., 2018; Wu et al., 2014b; Zhu et al., 2014).  
 
Next, transwell invasion assays will be used to investigate whether co-culture with 
NED LNCaP cells increases the invasive potential of LNCaP, DU-145 and PC-3 
cells. Harvesting the non-invading cells from the top layer and the invasive cells 
in the bottom layer of the transwell plate with allow RNA-Seq analysis to compare 
the gene expression enrichment and depletion of both populations of cells and 
will allow for the identification of genes specifically upregulated by co-culture with 
NED LNCaP cells. Furthermore, identifying these genes will allow for 
bioinformatics analysis to infer which signalling pathways may be implicated. It 
may also be possible to employ a whole genome CRISPR screen approach, 
which combined with the co-culture invasion assays would identify which genes 
are likely to be essential for producing pro-invasive signalling molecules and 
which are essential for responding to them, which can be ascertained through 
sequencing and identifying which gRNAs are enriched or depleted in the invading 
and non-invading population (Prolo et al., 2017).  
 
Finally, the knowledge gained from the in vitro experiments will be used to 
investigate paracrine signalling potential in vivo. This will be achieved by 
implanting NED LNCaP and either prostate cancer cell lines or dissociated PDX 
material in co-cultures into NSG mice treated with ADT. By transfecting these 
cells with imaging markers such as RFP or luciferase it will be possible to track 
the invasion and metastasis of tumours (Sflomos et al., 2016) in the presence or 
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absence of NED LNCaP cells. If this in vivo model can be established and well 
characterised, it will be used as a test bed for potential hASH1 and NED PCa 
targeted therapeutics. 
 
6.4.3 Investigating the role of GABARs and CCCs in NED PCa 
Data presented in chapter 5 demonstrated that IAD triggers an upregulation in 
CCCs, a phenomenon that has previously been seen during the progression of 
many cancer types, particularly estrogen driven cancers such as breast and 
cervical cancer (Chiu et al., 2014; Hsu et al., 2007; Shiozaki et al., 2014; Zhang 
et al., 2009). The first steps in future work would be to comprehensively validate 
the qRT-PCR data obtained thus far using a complete panel of NKCC and KCC 
antibodies and assess expression throughout IAD via immunoblot. Next, the 
same validation could be performed for the GABAAR and GABABR subunits. In 
order to begin to determine the GABAAR subunit composition, co-
immunoprecipitation could be used to identify which subunits are assembled with 
each other (Klausberger et al., 2001). A particularly interesting future experiment 
would be to use siRNA to knock down expression of the  subunit, which is 
thought to substitute for a lack of 2 and 3 subunit expression. The expression 
of the  subunit exclusively in PCa cells that did not express either or both of the 
2 and 3 subunits would suggest that the properties of the 2 and 3 subunits 
are important to PCa cells and that disrupting expression of the  subunit could 
potentially have an anti-cancer effect. 
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APPENDIX 
8.1 Investigation of androgen receptor splice variants induced by AD 
LNCaP cells which were maintained in AD conditions (AD and V) showed robust 
expression of a lower molecular weight band in the AR immunoblot, this is 
approximately 95 kDa (Fig. 4.4). Differentiated LNCaP cells which had 1 nM 
R1881 re-introduced to their culture conditions lost expression of this additional 
band (Fig. 4.4).  
 
This prompted investigation of possible AR splice variants that may have been 
targeted by the AR antibody SC-815. The antibody used in this study was 
confirmed by the manufacturer (Santa Cruz Biotechnology, USA) to target amino 
acids in the region 869-919 at the C-Terminus of human androgen receptor 
(accession: P10275) which encodes exons 5-8 of the full-length AR protein, 
comprising the ligand binding domain. The manufacturer was not willing to give 
the precise peptide sequence of the immunogen. Consulting the literature and 
the Ensembl genome browser 91, identified 18 known AR splice variants (Fig. 
8.1), of which AR-45 and AR-23 retain exons 5-8 and therefore could be targeted 
by the SC-815 antibody. However, only AR-45 is truncated (at the N-terminus) 
and therefore a lower molecular weight than the full-length AR protein. However, 
AR-45 is reported to be 45 kDa (Lu & Luo, 2013), whereas the additional 
immunoblot band identified in this study is approximately 95 kDa. A previous 
study has demonstrated that AR-23 is of a higher molecular weight than the 
endogenous LNCaP AR protein, thereby ruling out the possibility that the 
additional band is AR-23 (Jagla et al., 2007). This analysis would suggest that 
the additional bands observed in the immunoblot are likely to be protein 
degradation products, rather than an AR splice variant. Ideally, an antibody 
targeting the highly conserved N-terminus of AR (such as sc-816, widely used in 
the literature (He et al., 2018)) could be used to better investigate the potential 
induction of AR splice variants by AD and their likely identity, however this was 
not completed during this project.  
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Figure 8.1. Diagram displaying known androgen receptor splice variants 
and their exon composition adapted from Lu and Luo, 2013.  
 
  
